请选择 进入手机版 | 继续访问电脑版

查看: 1091|回复: 0










Rank: 9Rank: 9Rank: 9

发表于 2019-9-3 13:57:02 | 显示全部楼层 |阅读模式
High-dose vitamin therapy stimulates variant enzymes with decreased coenzyme binding affinity (increased Km): relevance to genetic disease and polymorphisms1–3
Bruce N Ames, Ilan Elson-Schwab, and Eli A Silver
As many as one-third of mutations in a gene result in the corresponding enzyme having an increased Michaelis constant, or Km, (decreased binding affinity) for a coenzyme, resulting in a lower rate of reaction. About 50 human genetic diseases due to defective enzymes can be remedied or ameliorated by the administration of high doses of the vitamin component of the corresponding coenzyme, which at least partially restores enzymatic activity. Several single-nucleotide polymorphisms, in which the variant amino acid reduces coenzyme binding and thus enzymatic activity, are likely to be remediable by raising cellular concentrations of the cofactor through high-dose vitamin therapy. Some examples include the alanine-to-valine substitution at codon 222 (Ala222→Val) [DNA: C-to-T substitution at nucleo-tide 677 (677C→T)] in methylenetetrahydrofolate reductase (NADPH) and the cofactor FAD (in relation to cardiovascular disease, migraines, and rages), the Pro 187→Ser (DNA: 609C→T) mutation in NAD(P):quinone oxidoreductase 1 [NAD(P)H dehy-drogenase (quinone)] and FAD (in relation to cancer), the Ala44→Gly (DNA: 131C→G) mutation in glucose-6-phosphate 1-dehydrogenase and NADP (in relation to favism and hemolytic anemia), and the Glu487→Lys mutation (present in one-half of Asians) in aldehyde dehydrogenase (NAD+) and NAD (in relation to alcohol intolerance, Alzheimer disease, and cancer). Am J Clin Nutr 2002;75:616–58.

多达三分之一的基因突变导致相应酶的米氏常数增加,或KM,(降低结合亲和力)对辅酶,导致反应速率降低。大约50种由酶缺陷引起的人类遗传病可以通过使用相应辅酶的高剂量维生素组分来补救或改善,至少部分恢复了酶的活性。几个单核苷酸多态性,其中变异的氨基酸减少辅酶结合,从而降低酶活性,可以通过高剂量维生素治疗来提高细胞内辅助性因子的浓度。一些例子包括基码222丙氨酸对戊酸盐取代(Ala222→Val)[DNA: C-to-T substitution at 核苷酸 677 (677C T)C被T的替代],在亚甲基四氢叶酸还原酶(NADPH)和辅助因子FAD中,(这与心血管疾病、偏头痛和狂怒症),NAD(P)醌氧化还原酶1187位点脯氨酸→色氨酸(DNA:609C→T)基因突变,Ala44→Gly(dna:131c→G)突变于葡萄糖-6-磷酸脱氢酶和NADP(与嗜好和溶血性贫血有关),以及Glu487→Lys突变(存在于一半亚洲人)中的醛脱氢酶(NAD)和NAD(与酒精不耐受、阿尔茨海默病和癌症有关)。

KEY WORDS Genetic disease, therapeutic vitamin use, binding defect, favism, alcohol intolerance, autism, migraine headaches, single nucleotide polymorphisms, enzyme mutations, review


High doses of vitamins are used to treat many inheritable human diseases. The molecular basis of disease arising from as many as one-third of the mutations in a gene is an increased Michaelis constant, or Km, (decreased binding affinity) of an enzyme for the vitamin-derived coenzyme or substrate, which in turn lowers the rate of the reaction. The Km is a measure of the binding affinity of an enzyme for its ligand (substrate or coenzyme) and is defined as the concentration of ligand required to fill one-half of the ligand binding sites. It is likely that therapeu-tic vitamin regimens increase intracellular ligand (cofactor) con-centrations, thus activating a defective enzyme; this alleviates the primary defect and remediates the disease. We show in this review that 50 human genetic diseases involving defective enzymes can be remedied by high concentrations of the vitamin component of the coenzyme, and that this therapeutic technique can be applied in several other cases, including polymorphisms associated with disease risks, for which molecular evidence suggests that a mutation affects a coenzyme binding site.

The nutrients discussed in this review are pyridoxine (page 618); thiamine (page 625); riboflavin (page 627); niacin (page 632); biotin (page 637); cobalamin (page 638); folic acid (page 641); vitamin K (page 643); calciferol (page 645); tocopherol (page 645); tetrahydrobiopterin (page 646); S-adenosylmethion-ine (page 646); pantothenic acid (page 646); lipoic acid (page 647); carnitine (page 647); hormones, amino acids, and metals (page 648); and maxi B vitamins (page 649).


The proportion of mutations in a disease gene that is responsive to high concentrations of a vitamin or substrate may be one-third or greater (1–3). Determining the true percentage from the literature is difficult because exact response rates in patients are not always reported and much of the literature deals only with individual case reports. The true percentages depend on several factors, such as the nature of the enzyme, the degree of enzyme loss that results in a particular phenotype, how much a small conformational change disrupts the binding site of the particular enzyme, whether the binding site is a hot spot for mutations, and whether dietary administration of the biochemical raises its concentration in the cell. From what is known of enzyme structure, it seems plausible that, in addition to direct changes in the amino acids at the coenzyme binding site, some mutations affect the conformation of the protein, thus causing an indirect change in the binding site.


Potentially vitamin-responsive polymorphisms1 潜在的对维生素治疗有反应的多态性

Enzyme and EC no.酶和EC号
Cofactor 辅因子
Nucleotide 核苷酸
Amino acid
Polymorphic frequency
Region wherevariant is found 发现的区域

Methylenetetrahydrofolate reductase (NADPH)(
TT = 10–20
Human enzyme shows decreased affinity for FAD

NAD(P):quinone oxidoreductase 1

TT = 4–20
FAD affinity is lowered

Short-chain acyl-CoA dehydrogenase
AA + AG = 35
Control population of an SCAD study
Mutation may affect FAD interaction

Aldehyde dehydrogenase
醛脱氢酶(NAD+) (
KK + EK = 50
Asians worldwide
Km (NAD) is increased 150-fold

Glucose-6-phosphate 1-dehydrogenase
G = 112
Rural south India
Km (NADP) is increased 5-fold

Methionine synthase
AdoCbl 腺苷钴胺素
G = 152
Control population of an MS study
Mutation is in the AdoCbl binding site

Folylpoly-γ-glutamate carboxypeptidase (
Folylpoly--glutamates (dietary
HY = 7.7 YY = 0.2
Control populationof a dementia study
Enzyme activity is lowered 53%

1 AdoCbl, adenosylcobalamin; E, glutamate; H, histidine; K, lysine; K
m, Michaelis constant; MS, methionine synthase; SCAD, short-chain acyl-CoA dehy-
drogenase; Y, tyrosine.
2 Allelic frequencies.

An alternate form of a gene present in > 1% of the population is called a polymorphism. Some polymorphisms that are associated with a phenotype have been shown to alter cofactor binding and affect a large percentage of the population (see Table 1 for a list of the allelic frequencies of the polymorphisms dis-cussed in this review). Our analysis of metabolic disease that affects cofactor binding, particularly as a result of polymorphic mutations, may present a novel rationale for high-dose vitamin therapy, perhaps hundreds of times the normal dietary reference intake (DRI) in some cases. This area should interest the entire health community because of the considerable percentage of the population affected by polymorphisms, many of which may have outlived their genetic usefulness. The setting of a DRI may become more complicated if a sizable percentage of the popula-tion in fact has a higher B-vitamin requirement because of a polymorphism. It seems likely that the examples listed in Table 1 will represent the beginning of a much longer list as genomics advances and awareness of remediable Km mutants increases.


It also seems plausible that for each example of a genetic disease or polymorphism clearly involving derangement of metabolism, multiple forms of the disease exist that reflect slight increases in the enzyme Km but that are not commonly thought of as genetic diseases. It seems likely that, as the generality of this phenomenon is appreciated, this approach will be found to be effective on a wider scale and with a larger variety of enzyme substrates and cofactors. The administration of high doses of vitamins may reverse, at least partially, many more genetic dis-eases than those described here [see Online Mendelian Inheri-tance in Man (OMIM) (4) for extensive, referenced reports on human genetic diseases]. To facilitate the collection and organi-zation of similar data, we have created a forum on the Internet (www.KmMutants.org; 5) that will house dialogues on the data and ideas brought forth in this review; investigators in relevant disciplines are encouraged to correct or add to these discussions.

似乎也有道理,对于每一个明显涉及新陈代谢紊乱的遗传病或多态,这种疾病的多种形式反映了酶Km的轻微增加,但它们通常不被认为是遗传病。很有可能,由于这一现象的普遍性受到赞赏,这种方法将在更广泛的范围内被发现是有效的并且含有更多的酶底物和辅助因子。服用高剂量维生素可能会逆转,至少在一定程度上,更多的遗传疾病比这里描述的要简单得多。[关于人类遗传疾病的广泛参考报告,请参阅在线Mendelian Inheri-in Man(OMIM)(4)]。为方便收集和组织类似数据,我们在因特网上建立了一个论坛(www.KmMutants.org;5)这将包括关于本次审查中提出的数据和想法的对话;鼓励相关学科的调查人员纠正或补充这些讨论。

There are 40 000 human genes. Of the 3870 enzymes catalogued in the ENZYME database (6), 860 (22%) use a cofactor. Any cofactor used by many enzymes is of particular interest, such as the 8 vitamin-derived coenzymes discussed in this review. Although high-dose vitamin remediation seems to be routinely tried for diseases involving enzymes dependent on pyridoxal-P (PLP) and thiamine pyrophosphate (TPP), some of the vitamins, such as riboflavin, pantothenate, folate, and niacin, deserve more attention. Thus, www.KmMutants.org is also intended for the input of physicians, who may examine the benefits of high-dose multivitamin treatment (see the section on maxi B vitamins) for mental or metabolic disorders of unknown cause or report side effects of vitamin treatment. Provided safe dosages are used (Table 2), there is potentially much benefit and possibly little harm in trying high-dose nutrient therapy because of the nominal cost, ease of applica-tion, and low level of risk. Most of the vitamins discussed here appear safe in relatively high doses because the body can discard excess.


Therapeutic remediation is contingent on increasing intracellular vitamin and cofactor concentrations; therefore, we present some data on plasma and tissue concentrations of coenzymes after the feeding of various amounts of vitamins (such informa-tion is sparse for some vitamins, especially at high doses). Data on plasma concentrations of amino acids after the administration of these metabolites would be desirable as well. Metals such as Mg2+, Ca2+, Zn2+, Fe2+, and K+ are used by many enzymes, but the increases in concentration obtainable may be small because of toxicity limitations and physiologic regulation. For example, zinc is a cofactor for > 300 proteins, but the human Zn2+ requirement is 10 mg/d and symptoms of toxicity can appear at 100 mg/d (10). Ascorbate concentrations are tightly regulated in young men and women and there is an upper limit on steady state plasma ascorbate concentrations of 80 mol/L (11, 12). At the end of each vitamin section, we discuss the toxicity of the vitamin as well as data on raising tissue concentrations. Note that some reports discussed below did not ascertain the minimal necessary therapeutic level of treatment, but instead used high doses that were thought would produce the desired effect. This treat-ment strategy is obviously not feasible with all nutrients (because of possible toxicity). Additionally, it is likely that not all administered vitamin is absorbed at very high doses (see the discussion of tissue concentrations and toxicity in the section on riboflavin). In an ideal situation, the lowest adequate therapeutic dosage would be elucidated and used.

治疗补救取决于增加细胞内维生素和辅助因子的浓度;因此,我们给出了一些数据,说明摄入不同量维生素后血浆和组织中辅酶的浓度(这种信息对于某些维生素来说是稀疏的),特别是在高剂量时)。服用这些代谢物后血浆中氨基酸浓度的数据也是可取的。诸如Mg2,Ca2,Zn2,Fe2,K等金属被许多酶所使用,但由于毒性限制和生理调节,可获得的浓度增加可能较小。例如,锌是超过300个蛋白质的辅助因子,但人体锌的需要量为10毫克/天,毒性症状可在100毫克/天(10)出现。抗坏血酸的浓度在年轻的男性和女性中受到严格的调节,稳态血浆抗坏血酸浓度的上限为80 mol/L。在每个维生素部分的末尾,我们讨论维生素的毒性以及提高组织浓度的数据。请注意,下面讨论的一些报告没有确定治疗的最低必要治疗水平,而是使用了被认为会产生预期效果的高剂量。这种治疗策略显然是不可行的,所有的营养(因为可能的毒性)。此外,并非所有服用的维生素都是在很高剂量下被吸收的(见关于核黄素一节中关于组织浓度和毒性的讨论)。在理想的情况下离子,最低的适当治疗剂量将被阐明和使用。

Dietary reference intakes (DRIs), tolerable upper intake levels (ULs), and mega-doses of nutrients discussed in this review


DRI  1
UL  2
Mega-dose   大剂量 3
Pyridoxine (vitamin B-6)
1.3 mg
100 mg
1000 mg
Thiamine (vitamin B-1)
1.1 mg
1000 mg
Riboflavin (vitamin B-2)
1.1 mg
400 mg
Niacin (vitamin B-3)
14 mg
35 mg
2000 mg
Biotin (vitamin B-7)
30 [size=9.0000pt]μ[size=9.0000pt]g
100 000 [size=9.0000pt]μ[size=9.0000pt]g
Cobalamin (vitamin B-12)
2.4 [size=9.0000pt]μ[size=9.0000pt]g
1000 [size=9.0000pt]μg
Folic acid
400 [size=9.0000pt]μ[size=9.0000pt]g
1000 [size=9.0000pt]μ[size=9.0000pt]g
40 000 [size=9.0000pt]μ[size=9.0000pt]g
Vitamin K
90 [size=9.0000pt]μ[size=9.0000pt]g
45 000 [size=9.0000pt]μg
Calciferol (vitamin D)
5 [size=9.0000pt]μ[size=9.0000pt]g
50 [size=9.0000pt]μ[size=9.0000pt]g
5000 [size=9.0000pt]μg
Tocopherol (vitamin E)
15 mg
1000 mg
800 mg
40 mg
800 mg
Pantothenic acid 泛酸
5 mg
150 m
Lipoic acid
300 mg
Carnitine 左旋肉碱
Thyroid hormone 甲状腺激素
1.75 mg
500 mg · kg1 · d1
200 mg · kg1 · d1
8 mg
40 mg
2000 mg
1 Daily values for female adults; values for males are similar. From ref-erences 7–9.女性成年人的日常价值观;男性的价值观相似。参考文献
2 The maximum daily nutrient intake that is likely to pose no risk of[size=9.0000pt] adverse effects. If no value is listed, either not enough data are available to establish a UL or no data are available.
3 Upper doses used clinically as found in the literature; side effects were[size=9.0000pt] of less concern because of the disease severity but may accompany these mega-doses.

Nutritional interventions to improve health are likely to be a major benefit of the genomics era. Many coenzyme binding motifs have been characterized, and essential residues for binding have been elucidated. Structural data can be found at the beginning of many sections. It will soon be possible to identify the complete set of genes having cofactor binding sites and the polymorphisms that fall into these regions, with an end goal of using vitamins, and possibly amino acids, hormones, and minerals, to effect a metabolic “tune-up.”


Support for some of the views discussed here can be found in the literature. It is clear that many individual researchers have recognized that high-dose vitamin treatment is effective in par-ticular diseases because a mutation affects the affinity of an enzyme for its coenzyme. In particular, Linus Pauling (13) hypothesized in his review entitled Orthomolecular Psychiatry that much mental disease may be due to insufficient concentrations of particular biochemicals in the brain as the result of an inadequate intake of particular micronutrients and that some brain dysfunction may be due to mutations that affect the Km of enzymes: “The still greater disadvantage of low reaction rate for a mutated enzyme with K[m] only 0.01 could be overcome by a 200-fold increase in substrate concentration to [S] = 400. This mechanism of action of gene mutation is only one of several that lead to disadvantageous manifestations that could be overcome by an increase, perhaps a great increase, in the concentration of a vital substance in the body. These considerations obviously suggest a rationale for megavitamin therapy.” More recently, high-dose pyridoxine therapy has been suggested as a treatment for improving dysphoric psychological states (eg, loneliness, anxiety, hostility, and depression) by stimulating the production of 2 pyridoxine-dependent neurotransmitters, serotonin and -aminobutyric acid (14).

对这里讨论的一些观点的支持可以在文献中找到。很明显,许多研究人员已经认识到,高剂量的维生素治疗对于寻常性疾病是有效的,因为突变会影响酶对辅酶的亲和力。尤其是Linus Pauling,他在题为“正分子精神病学”的评论中假设,许多精神疾病可能是由于大脑中特定生物化学物质浓度不足造成的。摄入特定微量营养素某些脑功能障碍可能是由于影响酶Km的突变:“K[m]突变酶的低反应率更大的缺点是只能克服0.01。底物浓度增加200倍,达到[S]=400.这种基因突变的作用机制只是导致不利表现的几种机制之一,这些不利的表现可以通过增加,也许是大幅度增加的浓度来克服。人体中的重要物质。这些考虑显然表明高剂量营养治疗的理论,最近,大剂量维生素B6被认为是一种改善焦虑症心理状态的治疗方法。(例如,孤独、焦虑、敌意和抑郁)通过刺激2种吡啶依赖性神经递质,5-羟色胺和GABA-氨基丁酸。

Although he does not discuss binding defects, Roger Williams (15), another pioneer in the field of biochemical nutrition, also recognized that higher doses of vitamins may be necessary to accommodate for what he calls biochemical individuality: “Indi-viduality in nutritional needs is the basis for the genetotrophic approach and for the belief that nutrition applied with due con-cern for individual genetic variations, which may be large, offers the solution to many baffling health problems. This certainly is close to the heart of applied biochemistry.” [Human genetic vari-ation appears greater than previously thought (16).] Williams’ conclusions suggest that genetic and thus biochemical individu-ality necessitates much nutritional individuality. This is especially relevant in the dawning age of genomics, in which it will someday become routine to screen individuals for polymorphisms and thus treat persons more efficaciously by genotype, rather than just by phenotype.


It also appears that, during aging, oxidation deforms many proteins, thereby decreasing their affinity for their substrates or coenzymes (17). Mechanisms of protein deformation include direct protein oxidation, adduction of aldehydes from lipid per-oxidation, and, in the case of membrane proteins, decreases in fluidity of oxidized membranes. This oxidative decay is particu-larly acute in mitochondria (18–20). Thus, feeding high amounts of several mitochondrial biochemicals may reverse some of the decay of aging (17, 21–26). Fourteen genetic diseases due to defective mitochondrial proteins are discussed in this review.


The impetus for this review arose while teaching an undergraduate laboratory course in which the students isolated bacterial mutants that grew on a complex medium but not on a minimal medium and characterized the defective gene and pathway. An appreciable percentage of mutant phenotypes could be explained by an increased Km (decreased affinity) of an enzyme, which could then be remedied by higher concentrations of the coenzyme or substrate (27).



The DRI for vitamin B-6 is 1.3 mg/d for adults (7). In the liver, pyridoxine and pyridoxal (an oxidized form of pyridoxine) are phosphorylated by pyridoxal kinase to form pyridoxine-P and PLP, the active cofactor form. Pyridoxine-P is oxidized to PLP by pyridoxine oxidase (7). PLP is utilized by 112 (3%) of the 3870 enzymes catalogued in the ENZYME database (6). The cofactor forms a covalent linkage (Schiff base) with a lysyl residue in the enzyme. This internal aldimine (enzyme-PLP) is converted to an external aldimine (substrate-PLP) when PLP is attacked by a substrate amino group. The PLP binding site has been elucidated for some enzymes (28) and may be useful for probing genomic sequences for homology. The PLP-requiring enzymes discussed in this section are summarized in Table 3.

维生素B-6的DRI为成年人1.3mg/d。在肝脏中,吡多星和吡多沙尔(嘧啶的氧化形式)被吡啶醛激酶磷酸化生成吡多辛-P以及PLP,活性辅助因子形式。吡啶多辛-P被吡啶多辛氧化酶氧化为PLP。在酶数据库中编目的3870种酶中,有112种(3%)使用了PLP。辅助因子形成共价键(Schiff base)在酶中残留了一种赖氨酸。这种内部醛亚胺(酶-PLP)被转化为外部胺 (substrate-PLP)当PLP被底物氨基攻击时。一些酶的PLP结合位点已经被阐明。可能有助于研究基因组序列的同源性。本节讨论的需要PLP的酶概述在表3中。

Ornithine aminotransferase: gyrate atrophy of the choroid and retina 鸟氨酸转氨酶:脉络膜和视网膜的旋转萎缩

Ornithine aminotransferase (OAT; ornithine–oxo-acid transam-inase) is a PLP-dependent mitochondrial matrix protein that catalyzes the breakdown of ornithine to -pyrroline-5-carboxylic acid, which is then converted into proline. Defects in OAT lead to gyrate atrophy of the choroid and retina, an autosomal recessive disease that affects persons of all ages (see OMIM 258870). The disease is characterized by slowly progressive chorioretinal degeneration leading to blindness. Ornithine accumulates 10- to 15-fold when the enzyme is defective and appears to be responsi-ble for much of the pathology of gyrate atrophy (29). In the pyridoxine responsive forms of the disease, for which doses ranged from 10 to 750 mg/d, it appears that the defective enzyme has a Km defect for PLP; ornithine accumulation is decreased when patients are given high doses of pyridoxine.

鸟氨酸转氨酶(OAT;鸟氨酸-氧-酸转运酶)是一种依赖plp的线粒体基质蛋白,催化鸟氨酸分解成吡咯啉-5-羧酸,然后转化成脯氨酸。OAT的缺陷导致脉络膜和视网膜的旋转萎缩,一种常染色体隐性疾病,影响所有年龄的人(见OMIM 258870)。这种疾病的特点是缓慢进展的脉络膜视网膜退化导致失明。鸟氨酸在酶有缺陷时会累积10至15倍,似乎对许多回转体萎缩的病理都有反应。这种疾病的吡多辛反应形式,其剂量范围为10至750毫克/天,该缺陷酶对PLP有KM缺陷,当给予大剂量吡多星时,鸟氨酸积累减少。

The OAT activity in fibroblast extracts of a pyridoxine-respon-sive patient with the alanine-to-valine substitution at codon 222 (Ala226→Val) increased from 9 to 44 nmol product · mg1 · h1 when the concentration of PLP in the assay was increased to 600 mol/L. The Km from the cell line of a second patient with the same Ala226→Val mutation was 122 mol/L (control Km: 6 mol/L). Similar to cells from the second patient, Chinese hamster cells expressing an OAT complementary DNA (cDNA) producing the Ala226→Val protein also exhibited increased OAT activity with the addition of pyridoxine (30).

Vitamin B-6–responsive and -nonresponsive patients with gyrate atrophy were shown to have different point mutations resulting in single amino acid changes in the mature enzyme (31). After incubation with 40 mol PLP/L, OAT activity increased substantially more in fibroblasts from carriers of the pyridoxine-responsive variant than in fibroblasts from control subjects and nonresponsive patients (32). These investigators concluded that “the greater increases in activity seen in pyridoxine-responsive cells when PLP was added to the assay suggest both that the holoenzyme content in these cells is decreased owing to low affinity and that PLP binding to the apoenzyme occurs at a higher concentration.”

In another study, 3 patients responded to oral vitamin B-6 (600–750 mg/d) with a decrease in serum ornithine and a return to normal of reduced concentrations of serum lysine. Lower doses of vitamin B-6 (18–30 mg/d) appeared to work just as well as the high doses (33).

In another study of 9 patients with gyrate atrophy (34), 4 patients responded to pyridoxine, which lowered serum ornithine by ≥50% in 3 cases. The Km (of OAT for PLP) was 23 mol/L in the con-trol subjects, 23 mol/L in the pyridoxine-nonresponsive patients, and 168 mol/L in the pyridoxine-responsive patients. This higher Km for pyridoxine-responsive patients could be explained by mutations in the binding site that severely reduce coenzyme affinity, whereas nonresponsive patients may harbor more severe mutations that affect a different area of the enzyme.

In a study of Japanese patients in which 1 of 7 patients (all with different mutations) responded to vitamin B-6, the pyridoxine-responsive mutation was found to be Thr181→Met, but the affin-ity for PLP was not measured (35). In another Japanese study, one patient (of 3) responded to vitamin B-6 (300–600 mg/d) with a 60% reduction in serum ornithine concentrations. OAT activity in the fibroblasts from this patient increased up to 25% of normal levels in the presence of 2000 mol PLP/L, although no signifi-cant improvement was observed in acuity or visual field. Thus, vitamin B-6 responsiveness may be due to a mutation in OAT that results in a high Km for PLP (36, 37). A Glu318→Lys muta-tion of the OAT gene was found in 3 heterozygous patients and 1 homozygous patient, all of whom were vitamin B-6-responsive according to previous in vivo and in vitro studies. Dose-dependent effects of the Glu318→Lys allele were observed in the homozy-gotes and heterozygotes in 1) OAT activity, 2) increase of OAT activity in the presence of PLP, and 3) apparent Km for PLP with these values approximately doubled in the homozygous individual compared with the heterozygotes. Thus, the highest residual level of OAT activity and mildness of clinical disease correlated directly with the higher number of the mutant Glu318→Lys allele found in the homozygous patient (38).

Many case reports of gyrate atrophy exist; as of 1995, pyri-doxine-responsiveness had been observed in 7 of the 150 total documented cases (7/150 = 5%) (39). Whether pyridoxine treat-ment was actually attempted in each of these cases is unclear. Thus the true response rate may be higher or lower than 5%.

Cystathionine -synthase: homocystinuria 胱硫醚合成酶:高胱氨酸尿

Cystathionine -synthase (CBS) of the transsulfuration pathway catalyzes the PLP-dependent condensation of homocysteine and serine to form cystathionine. Individuals carrying a defective form of this enzyme (see OMIM 236200) accumulate homocys-teine in the blood and urine and display a wide range of symp-toms that appear to be due to homocysteine toxicity, including mental retardation, vascular and skeletal problems, and optic lens dislocation. Barber and Spaeth (40) were the first to report pyridoxine-responsiveness with a complete return to normal of the patient’s methionine and homocysteine concentrations in plasma and urine. They speculated that “if the deficient enzymatic activity were due to decreased affinity of a defective apoenzyme for its cofactor, activity might be restored by increas-ng the intracellular concentration of pyridoxal phosphate” (40).

转硫途径的胱硫醚合成酶(Cbs)催化同型半胱氨酸与丝氨酸的PLP依赖缩合形成胱硫醚.携带有缺陷的这种酶的个体(见OMIM 236200)在血液和尿液中积累同型半胱氨酸,展示了大量的同型半胱氨酸毒性物质,包括智力迟钝,血管和骨骼问题,以及光学晶状体脱位。Barber和Spaeth(40岁)第一次报告了吡多星的反应性,患者血浆和尿液中的蛋氨酸和同型半胱氨酸浓度完全恢复到正常水平。他们推测“如果酶活性不足是由于有缺陷的载脂蛋白酶对其辅助因子的亲和力降低,可通过增加磷酸吡啶的胞内浓度来恢复细胞活性。

Kim and Rosenberg (41) showed that CBS activity was 5% of that of control subjects in pyridoxine-responsive homocystinuric patients, who had markedly elevated plasma and urinary concen-trations of methionine and homocystine. The mutant synthases had a 20-fold lower affinity for PLP. A 2- to 3-fold increase in the Km for homocysteine and serine was found in one vitamin B-6-responsive patient, although the Km for PLP was not meas-ured. The maximum reaction rate (Vmax) was also reduced. It was suggested that pharmacologic doses of pyridoxine led to increased cellular concentrations of PLP and increased enzymatic activity (41).


One group showed cell lines from pyridoxine-responsive patients to have higher Km values for PLP (155, 145, 195, and 200 mol/L) than control values (52, 52, and 85 mol/L), whereas nonresponsive patients had the highest values (990 and 4000 mol/L). It was noted that, in general, about one-half of CBS-deficient patients respond to pyridoxine with a lowering of homocysteine and serine concentrations to normal (42). A 21-y-old pyridoxine-responsive individual had a 3- to 4-fold elevated apparent Km of CBS for PLP as measured in fibroblast extracts (43). An Ala114→Val substitution was present in this indi-vidual, which is only 5 residues away from the lysine residue, Lys119, that binds PLP. These investigators concluded that in vivo responsiveness in individuals with some residual CBS activity is related both to the affinity of the mutant aposynthase for PLP and to the capacity of cells to accumulate PLP (43).

有一组患者的细胞株对吡多辛酸有较高的km值。(155、145、195和200 mol/L)超过对照值(52、52和85 mol/L),而无反应的病人有最高值(990和4000 mol/L)。据指出,一般而言,大约一半cbs缺乏的患者对吡多辛有反应,同型半胱氨酸和丝氨酸浓度降低到正常水平。以成纤维细胞提取液测量,21岁的吡多星敏感个体的cbs表观km为成纤维细胞提取物的3至4倍。在此标记中存在Ala114→Val取代,该碱基距赖氨酸残基Lys 119只有5个残基,而赖氨酸残基与PLP结合。这些调查人员得出结论,在体内,具有某些cbs活性的个体的反应性与突变的PLP合酶的亲和力有关,也与细胞累积PLP的能力有关系

In one report (44), a G-to-A substitution at nucleotide 797 (797G→A; amino acid substitution: Arg266→Lys) was found in most pyridoxine-responsive patients. Seven of 12 patients were responsive to pyridoxine (40–900 mg/d), which greatly decreased total plasma homocysteine. Pyridoxine (50–1000 mg/d) markedly reduced homocysteine excretion in a group of pyridoxine-responsive patients: patient 1, 867 to 10 mol/d; patient 2, 1021 to 79 mol/d; patient 3, 15 mol/L (blood concentration) to undetectable concentrations; and patient 4, plasma amino acids reverted to normal (45). It appears that a missense mutation (Ile278→Thr) is common (41%) in pyridoxine-responsive patients and that patients who are responsive to pyridoxine usually have a milder clinical pheno-type than do nonresponsive patients.

在一份报告中,核苷酸797的G到A替换(797G A; 氨基酸置换:精氨酸266 -赖氨酸)在大多数对吡多星有反应的病人中被发现。12例患者中有7例对吡多辛有反应。(40-900毫克/日),这大大降低了血浆总同型半胱氨酸。吡啶多辛(50-1000 mg/d)明显减少了一组对吡多星有反应的患者的同型半胱氨酸排泄:病人1,867至10 mol/d;病人2,1021至79 mol/d;病人3,15 mol/L(血液浓度)无法检测到的浓度;病人4血浆氨基酸恢复正常,似乎是一种错误的突变(Ile278-苏氨酸)很常见(41%),对吡多辛有反应的患者和对吡多辛有反应的患者,其临床症状类型通常比无反应的患者要轻。

The idea that pyridoxine-responsive patients have an increased Km was supported in a review of the mechanism of pyridoxine-responsive disorders (46). A review of the CBS deficiencies (2) found 629 patients in the literature: 231 (37%) were vitamin B-6–responsive, 231 (37%) were vitamin B-6–nonresponsive, 67 (11%) were intermediate in response, and 100 (16%) had not been classified. A decade later, the field was reviewed again and it was suggested that dosages of pyridoxine of 500 mg/d for 2 y appear to be safe, but that 1000 mg/d should not be exceeded (47).

吡多星反应患者Km增加的观点在一项对吡多星反应障碍的机制的综述中得到了支持。对CBS缺陷的回顾(2)在文献中发现629名患者:231(37%)维生素B-6敏感,231(37%)维生素B-6-无反应,67(11%)为中间反应,100例(16%)未分类。十年后,人们再次回顾了这一领域,并认为500 mg/d的吡多辛剂量2y似乎是安全的,但不应超过1000毫克/日。

A database of mutations in CBS (48) lists and maps >100 patho-genic mutations (including >70 missense mutations) that span all 7 exons of the CBS gene. Although the Schiff-base forming lysine has been assigned to nucleotide 119 in exon 3, it is difficult to say which domains are responsible for PLP binding. Serine should be tested clinically in addition to pyridoxine for treating patients, with the use of homocysteine concentrations as a measure of efficacy, because the Km of CBS for serine was shown to be increased in several cases (41). Oral serine administration (500 mg·kg1 ·d1) raises serine concentrations in plasma and cerebrospinal fluid (49), although very high doses (1400 mg·kg1 ·d1) can result in adverse effects (50).

CBS基因突变数据库列出和地图>100个致病突变(包括>70个错义突变),跨越CBS基因的所有7个外显子。虽然形成赖氨酸的席夫碱被指定为外显子3中的核苷酸119,很难说哪些域负责PLP绑定。丝氨酸除了用于治疗病人外,还应进行临床试验,用同型半胱氨酸浓度作为疗效的衡量标准,因为CBS对丝氨酸的Km在一些情况下被证明是增加的(41,)口服丝氨酸(500 mg·Kg1·D1)提高血浆和脑脊液中丝氨酸浓度,虽然很高的剂量(1400毫克·千克·d1)会产生副作用

Vitamin B-6-therapy may be valuable in more than just severe homozygous CBS-deficient cases: heterozygous parents of CBS-deficient patients also have significantly increased homocysteine concentrations (51). Increased homocysteine is a risk factor for cardiovascular disease (52). Heterozygosity for CBS deficiency may be present in 1% or 2% of the population.


Enzymes that use a pyridoxal-P (PLP) cofactor 1使用吡啶-P(PLP)辅助因子1的酶

Defective enzyme and EC no. 酶缺陷和EC号。
Localization 位置
Reaction catalyzed 反应催化
Disease or condition
OMIM no.
Ornithine aminotransferase (
Ornithine + -ketoglutarate → △-pyrroline-5-carboxylate + glutamate
Gyrate atrophy of choroid and retina,degrading sight to eventual blindness
Autosomal recessive
Cystathionine β-synthase (
Homocysteine + serine → cystathionine
Homocystinuria, opticlens dislocation,osteoporosis, skeletal abnormalities, and mental retardation
Autosomal recessive
Erythroid specific -aminolevulinic acid synthase (
Glycine + succinyl-CoA → δ-aminolevulinicacid + CoA + CO2   
X-linked sideroblastic anemia
X-linked recessive
Kynureninase (
(Hydroxy-)kynurenine + H2O → (hydroxy-) anthranilic acid + alanine
Mental retardation
Autosomal recessive
Glutamic acid decarboxylase (
Glutamic acid → GABA
Infantile seizures unresponsive to typical anticonvulsants
Autosomal recessive
γ-Cystathionase (
Cystathionine → cysteine + α-ketobutyrate
Mental retardation, convulsions, thrombocytopenia, nephrogenic diabetes
insipidus, and diabetes mellitus
Autosomal recessive
Alanine–glyoxylate aminotransferase (
Alanine + glyoxylate → pyruvate + glycine
Hyperoxaluria, kidney (calcium oxalate) deposits, and renal failure
Aromatic-L-amino-acid decarboxylase (
L-DOPA → dopamine + CO2;5-hydroxytryptophan → serotonin + CO2
Serotonin and dopamine deficiency,developmental delay, hypotonia,
Autosomal recessive
Housekeeping -aminolevulinic acid synthase (
Glycine + succinyl-CoA → δ-aminolevulinic
acid + CoA + CO2
Sideroblastic anemia
Autosomal recessive
β-Alanine--ketoglutarate transaminase (
β-Alanine → malonic semialdehyde
Cohen syndrome, hypotonia, midchildhood obesity, mental deficiency, and facial,
Autosomal recessive
Enzyme involved with neurotransmittermetabolism (?)  
1 DOPA, dihydroxyphenylalanine; GABA, -aminobutyric acid; OMIM, Online Mendelian Inheritance in Man (4).

Erythroid specific δ-aminolevulinic acid synthase: X-linked sideroblastic anemia 红系特异性,δ-氨基乙酰丙酸合酶:X-连锁铁粒母细胞贫血

Erythroid specific -aminolevulinic acid synthase (ALAS2; 5-aminolevulinate synthase), with its PLP cofactor, is located in the mitochondria of animal cells and catalyzes the condensation of glycine and succinyl-CoA to form -aminolevulinic acid, the first and rate-limiting step in the series of reactions that makes heme for incorporation into hemoglobin. Defects in ALAS2 are responsible for the most common inherited form of sideroblastic anemia, which is X-linked (see OMIM 301300). Because iron is transported to the mitochondria whether or not it is combined with heme, deficiencies in heme lead to iron deposits in erythroblast mitochondria and increased ringed sideroblasts in the marrow (53). About one-third of patients with sideroblastic anemia respond to pyridoxine (1), with doses ranging from 50 to 600 mg/d.

红系特异性氨基乙酰丙酸合酶(ALAS2;5-氨基乙酰丙酸合酶),它的PLP辅因子位于动物细胞的线粒体中,催化甘氨酸与琥珀酰辅酶A缩合生成氨基乙酰丙酸,血红素进入血红蛋白的一系列反应中的第一步和限速步骤。ALAS 2的缺陷是最常见的遗传性铁质母细胞贫血的原因,它是X链接的(参见OMIM 301300)。因为铁被转运到线粒体,不管它是否与血红素结合,血红素缺乏症导致红细胞线粒体铁沉积,骨髓成铁细胞增多。大约三分之一的铁质再生障碍性贫血患者对吡多辛(1)有反应,剂量范围为50至600毫克/天。

Three generations in a family originally described by Cooley in 1945 were found to have an ALAS2 gene with an A-to-C point mutation that results in an ALAS2 variant with reduced activation by PLP. The specific activity of the mutant enzyme was 26% of normal in the presence of 5 mol PLP/L. The PLP cofactor activated or stabilized the purified mutant enzyme in vitro, consistent with the pyridoxine-responsive anemia in affected patients. It was hypothesized that the mutation alters the local secondary struc-ture and possibly perturbs the overall conformation, thus decreas-ing stability, reducing the affinity for PLP, or both (54).

在1945年Cooley最初描述的一个家族中,有三代人被发现有一个带有A到C点突变的ALAS 2基因,导致ALAS 2变异体被PLP激活降低。在5 mol PLP/L的情况下,突变酶的活性是正常酶的活性的26%。PLP辅助因子激活或者在体外稳定纯化的突变酶,与受影响患者的吡多星反应性贫血相一致。据推测,突变改变了局部次级结构,可能扰乱了整体构象,从而降低了稳定性,降低了对plp的亲和力,或者两者兼而有之。

A point mutation (663G→A) in the ALAS2 gene of an 8-mo-old Japanese male led to pyridoxine-responsive sideroblastic anemia. The activity of the mutant enzyme (Arg204→Gln) expressed in vitro was 15% of that of the control; with the addition of PLP, the activity of the mutant enzyme increased to 35% (55).

一位8岁的日本男性ALAS 2基因的点突变(663G→A)导致了吡多星反应性铁质形成性贫血。在体外表达的突变酶arg 204→Gln的活性为对照的15%;随着pplp的加入,突变酶的活性提高到35%。

Among 6 other cases (1 patient and 5 kindreds), 4 had an amino acid substitution at a PLP binding site of ALAS2 that reduced the affinity of ALAS2 for its coenzyme (1, 54, 56–58). One of the ALAS2 mutations, Gly291→Ser, reduced enzyme activity to 10% of normal; enzymatic activity was increased with the addition of PLP in vitro (57). In another mutation, Thr388→Ser, activity was decreased to 50% of wild-type but was raised by pyridoxine sup-plementation (1). A mutation found in a highly conserved region of exon 9, Ile471→Asn, was found in a 30-y-old Chinese man with the pyridoxine-responsive form of XLSA (56). Prokaryotic expression of the normal and mutant cDNAs showed that the mutant construct had lower enzymatic activity than did the normal enzyme and required higher concentrations of PLP to achieve maximal activation. The amino acid substitution occurred in the exon containing the putative PLP binding site, which may account for the reduced ability of the enzyme to catalyze the formation of -aminolevulinic acid. Another study showed that a large number of probands have mutations in exon 9, the exon containing the PLP binding site (59). Furuyama et al (60) reported an ALAS2 mutation that results in 12% of normal ALAS activity, which increases to 25% in the presence of PLP.

其他6例(1例成人和5例儿童),4例在alas 2的plp结合位点上有一个氨基酸替换,从而降低了alas 2对其辅酶的亲和力。ALAS 2突变之一Gly 291→Ser使酶活性降至正常水平的10%;ALAS 2突变之一Gly 291→Ser使酶活性降至正常水平的10%;体外添加PLP可提高酶活性。在另一种突变中,Thr 388→Ser的活性下降到野生型的50%,但因吡多辛的补充而升高。在第9外显子ile 471→asn高度保守的区域发现了一个突变,该突变发生在一名30岁的中国人身上。正常和突变体cdna的原核表达表明,突变体的酶活性低于正常酶,需要较高浓度的plp才能达到最大酶活性。氨基酸替换发生在含有推测的PLP结合位点的外显子中,这可能是该酶催化生成-氨基乙酰丙酸的能力降低的原因之一。另一项研究表明,大量的先证者在外显子9上有突变,该外显子含有plp结合位点。Furuyama等人报道了一个ALAS 2突变,导致12%的正常AlAs活性,在PLP存在的情况下增加到25%。

A novel missense mutation in the ALAS2 gene, 1754A→G, in a patient with 53% ALAS activity had 20% activity when expressed in bacteria but 32% in the presence of PLP. Although the mutation, which results in the substitution of glycine for serine, lies outside of exon 9, it is possible that it induces a conformational change that may alter PLP binding to the protein (61). Other mutations located outside exon 9 have also been reported to influence PLP binding (53).

ALAS 2基因中一个新的错义突变,1754A→G在53%AlAs活性的患者中在细菌中表达时活性为20%,在PLP存在时为32%。虽然导致甘氨酸取代丝氨酸的突变,位于外显子9之外,它可能会引起构象改变,从而改变PLP与蛋白质的结合。外显子9外显子外的其他突变也被报道会影响plp的结合。

Two cases that appeared late in life have also been analyzed (58). A 77-y-old man and an 81-y-old woman with initial diagnoses of refractory anemia with ringed sideroblasts (which is typi-cally unresponsive to pyridoxine) were found to respond very well to pyridoxine (100 mg/d in the man and 600 mg/d in the woman); hemoglobin concentrations increased in both patients after treatment. The mutations Lys299→Gln and Ala172→Thr were found in the man and woman, respectively. The Ala172→Thr mutation resulted in decreased in vitro stability of bone marrow ALAS2 activity. ALAS2 from both patients showed marked thermolability. Addition of PLP in vitro stabi-lized the mutant enzymes, which is consistent with the observed in vivo response to pyridoxine. This late-onset form can be dis-tinguished from refractory anemia and ringed sideroblasts by microcytosis, pyridoxine responsiveness, and ALAS2 muta-tions. These findings emphasize the need to consider all elderly patients with microcytic sideroblastic anemia as candidates for ALAS2 defects, especially if pyridoxine-responsiveness is demonstrated. These investigators concluded, “A decline in PLP availability or metabolism may have precipitated the late onset of XLSA in these patients. An age-related decline in pyridoxine metabolism in combination with a reduced vitamin intake has been described in elderly populations” (58).

我们还分析了两例晚年出现的病例(58).一名77岁的男子和一名81岁的妇女,最初诊断为顽固性贫血伴铁质网。(这是典型的对吡多辛没有反应)对吡多辛有很好的反应(男性为100 mg/d,女性为600 mg/d);两位患者治疗后血红蛋白浓度均升高。在男性和女性中分别发现Lys 299→Gln突变和Ala172→Thr突变。Ala172THR突变导致骨髓ALAS 2活性在体外稳定性下降。两位患者的ALAS 2均表现出明显的热溶作用。PLP在体外稳定突变酶,与观察到的体内对吡多星的反应是一致的。这种晚发型可通过微细胞增生症、吡多辛反应性和ALAS 2的变化,从难治性贫血和铁质形成细胞中获得。这些发现强调,需要考虑所有老年患者的微细胞铁质母细胞贫血作为ALAS 2缺陷的候选,特别是在证明了吡多星反应性的情况下。这些调查人员得出结论,“PLP的有效性或新陈代谢的下降可能导致这些患者的XLSA的晚发。与年龄有关的吡多辛酸代谢下降与减少的维生素摄入已在老年人口中被描述为“

It appears that supplementation with glycine, as well as pyridoxine, may be beneficial in new patients and that supplementation with glycine may be beneficial in patients who do not respond to pyridoxine, because the Km for glycine may be affected in some ALAS mutations. For example, the Gly142→Cys con-structed mutant has a 4-fold increased Km for glycine (62). If a patient had such a mutation, increased plasma glycine concen-trations might increase ALAS activity. One report showed an increase in plasma and cerebrospinal fluid glycine after the administration of 200 mg · kg1 · d1 (49).

似乎补充了甘氨酸,与吡啶多辛一样,对新病人也有好处,而补充甘氨酸对那些对吡多辛没有反应的病人也可能是有益的,因为甘氨酸的Km可能在某些AlAs突变中受到影响。例如,gly 142→cys结构突变体对甘氨酸的作用增加了4倍。如果病人有这样的突变,血浆甘氨酸浓度的增加可能会增加AlAs的活性.一份报告显示注射200 mg·kg1·d1(49)后血浆和脑脊液甘氨酸含量增加。

Kynureninase: xanthurenic aciduria and mental retardation  犬尿酸酶:黄嘌呤酸尿与智力低下

Kynureninase, a PLP-requiring enzyme involved in tryptophan degradation, catalyzes the conversion of kynurenine and 3-hydroxykynurenine to anthranilic acid and 3-hydroxyanthranilic acid, respectively (see OMIM 236800). Mutations in the kynureninase gene cause mental retardation in children and an excessive urinary output of 3-hydroxykynurenine and kynurenine (and their metabolites, xanthurenic and kynurenic acids). The condition was normalized in 2 children with pyridoxine doses of ≤ 30 mg/d. Significantly decreased kynureninase activity in a liver biopsy sample was markedly increased with the addition of PLP, suggesting that a mutation caused a modification in the binding site of the coenzyme (63). A follow-up study confirmed that the defective enzyme was a Km mutant (64).(See the discussion of autism in this section.)

犬尿氨酸,一种需要PLP的酶参与色氨酸的降解,催化犬尿氨酸和3-羟基犬尿氨酸转化为氨基苯甲酸和3-羟基-2-基苯甲酸。犬尿氨酸酶基因变异导致儿童智力低下和3-羟基犬尿氨酸尿和犬尿氨酸尿症(和其他的代谢产物,黄尿酸尿,犬尿喹啉酸)。2例≤剂量为30 mg/d的患儿恢复正常。肝活检标本中尿激酶活性显著降低随PLP的加入而显著增加,表明一个突变导致辅酶结合位点的改变。一项后续研究证实,该缺陷酶是km突变体。

Glutamic acid decarboxylase: seizures in newborns and intelligence quotient deficits 谷氨酸脱羧酶:新生儿癫痫发作与智商缺陷

Glutamic acid decarboxylase (GAD; glutamate decarboxylase), a PLP enzyme, converts glutamic acid, an excitatory amino acid, to γ-aminobutyric acid, the most important inhibitory neurotransmitter in the central nervous system (up to one-third of synapses in the brain use γ-aminobutyric acid as an inhibitory signal). Defects in GAD result in seizures in newborns (see OMIM 266100), but it is not clear whether the seizures are due to too little γ-aminobutyric acid or too much glutamic acid (65). Intravenous injection of 100–200 mg pyridoxine generally stops the seizures (66). One infant with pyridoxine-dependent seizures was shown to have decreased γ-aminobutyric acid production; the seizures stopped within 5 min of the administration of 100 mg pyridoxine. More than 50 cases of pyridoxine-dependent seizures have been reported since 1954 (67).

谷氨酸脱羧酶(GAD),一种可将转谷氨酸,一种兴奋性氨基酸,转化为GABA,中枢神经系统中最重要的抑制性神经递质,的PLP酶,(多达三分之一的突触在大脑中使用,γ-氨基丁酸作为抑制信号)。GAD对新生儿癫痫发作的影响,但尚不清楚癫痫是由于γ-氨基丁酸过少还是谷氨酸过多所致。静脉注射100-200毫克吡多辛一般能阻止癫痫发作。一名婴儿因吡啶依赖发作而被证明减少了γ-氨基丁酸的产生。100 mg吡多辛给药后5 min,癫痫发作停止。自1954年以来,已报告50多例依赖于吡多辛的癫痫。

In one study of 28 infants with seizures, 3 infants had the pyri-doxine-responsive phenotype (68). In a study of 120 infants with documented repeated and intractable seizures, only 2 infants responded to pyridoxine administration, suggesting that either only a small percentage of seizures are responsive or that there are many other causes of seizures that are not due to mutations in this vitamin B-6 enzyme (69). There appear to be other enzyme defects that can lower PLP and cause pyridoxine-dependent seizures: one patient had decreased -aminobutyric acid and increased glutamic acid in the brain, but no significant difference in GAD activity was found between the patient and control sub-jects, and PLP concentrations were markedly reduced (70).


In a cell line from an infant with pyridoxine-dependent seizures, GAD activity was increased when the enzyme was incubated with high PLP. The investigators speculated that the metabolic abnormality in this disorder may be a binding abnor-mality between GAD apoenzyme and PLP (71).


A 13-y-old child who died with seizures in progress had ele-vated glutamic acid and decreased -aminobutyric acid concen-trations in the frontal and occipital cortices but not in the spinal cord; concentrations of all other amino acids, except for cystathionine, were normal. PLP was reduced in the frontal cortex, and GAD activity comparable to that of control subjects was detected when the PLP concentration was > 50 mol/L (70). Response rates from 2 reports give a cumulative pyridoxine-responsiveness of 3%, although seizures may be due to many dif-ferent defective genes (68, 69).

一名13岁儿童在发作过程中死亡,其额叶和枕叶皮质谷氨酸含量下降,而脊髓中无;所有其他氨基酸的浓度,除胱硫醚外,都是正常的。PLP在额叶皮质降低,当PLP浓度>50 mol/L时,GAD活性与对照组相当。2份报告的应答率为3%,尽管癫痫发作可能是由于许多不同的缺陷基因所致。

Intelligence quotients are decreased in pyridoxine-dependent GAD patients, suggesting that the amount of pyridoxine administered should be adjusted to optimally retain intellec-tual capacity, and not just to stop seizures. A prospective open study found that an increased dose of pyridoxine was associ-ated with an improvement in intelligence quotient. It was sug-gested that pyridoxine dependency has a wider range of clinical features than classic neonatal seizures and causes specific impairments of higher function, some of which may be reversible by vitamin B-6 therapy (72).


A treatment of asthma, theophylline, depresses PLP concentrations, and may cause seizures by decreasing -aminobutyric acid production. Pyridoxine treatment reduces theophylline-induced seizures in both mice and rabbits (73).

A linkage analysis study of 2 families argued that pyridoxine-dependent seizures are not due to a Km mutation because the base pair substitutions found in the patients’ enzymes were also found in control subjects, and different maternal alleles were passed on to 2 affected children in one family (74). However, some forms of pyridoxine-dependent seizures, which are likely a disease of multiple etiologies, are probably due to Km defects affecting PLP binding by GAD (75).


γ-Cystathionase: cystathioninuria, mental retardation, and diabetes γ-胱硫脲酶:膀胱硫氨酸尿、智力低下和糖尿病

After the formation of cystathionine by CBS, another PLP enzyme in the transsulfuration pathway, -cystathionase (cystathionine -lyase), converts cystathionine into cysteine and -ketobutyrate, completing the transfer of sulfur from homocys-teine to cysteine. Enzymatic defects (see OMIM 219500) result in cystathionine accumulation in the urine and tissues. The clin-ical features can include mental retardation, convulsions, throm-bocytopenia, nephrogenic diabetes insipidus, and diabetes mellitus. High-dose pyridoxine therapy can markedly reduce concentra-tions of cystathionine in the urine and blood of deficient patients; it was suggested that vitamin B-6 responsiveness “can best be explained by a structural alteration of the apoenzyme, resulting in failure to combine normally with the coenzyme” (76). This binding theory is supported by others: “The B-6-responsive form results from the synthesis of an aberrant enzyme protein exhibit-ing altered interaction with the coenzyme, thereby resulting in an inherited increase in the requirement for vitamin B-6” (77). A high percentage of the cases can be ameliorated by supplemen-tation with pyridoxine, which is associated with a reactivation of the defective enzyme and a major decrease in urinary cysta-thionine excretion; 33 of 37 cases (89%) were found to be pyri-doxine-responsive (47). This high percentage is puzzling; one possible explanation is that more severe mutant genes cause lethality and that most of the remaining genes code for a protein with a partial activity and increased Km.


Alanine–glyoxylate aminotransferase: hyperoxaluria and renal failure  丙氨酸-乙醛酸转氨酶:高草酸尿和肾功能衰竭

Alanine–glyoxylate aminotransferase is a liver-specific enzyme that uses a PLP cofactor to transfer the amino group from alanine to glyoxylate, forming serine and pyruvate. A primary hyperoxaluria (see OMIM 259900) caused by a functional deficiency of the peroxisomal alanine–glyoxylate aminotransferase results in an accumulation of glyoxylate that is converted to oxalate, resulting in renal deposits of calcium oxalate and renal failure. In one study, large doses of pyridoxine reduced urinary oxalate excretion in 2 of 3 patients with primary hyperoxaluria (78). Posttreatment oxalate concentrations were between pretreatment and control concentrations, and the effect of pyridoxine was maintained for 6 mo.

丙氨酸-乙醛酸转氨酶是一种肝脏特异性酶,它使用PLP辅助因子将氨基从丙氨酸转移到乙醛酸盐,形成丝氨酸和丙酮酸。原发性高草酸尿(见OMIM 259900),由于过氧化物酶体丙氨酸-乙醛酸转氨酶功能缺乏,导致乙醛酸盐转化为草酸,导致肾积草酸钙和肾功能衰竭。在一项研究中,大剂量吡多辛,在3例原发性高草酸尿中的2例尿草酸排泄减少。处理后草酸盐浓度介于预处理浓度和对照浓度之间,吡柔嗪的作用维持6mo。

A review of hyperoxaluria indicates that pharmacologic doses of pyridoxine are of benefit and that a Km mutant may be respon-sible. Pyridoxine treatment may overcome the effects of muta-tions in the gene encoding alanine–glyoxylate aminotransferase that might interfere with cofactor binding (79). It is suggested that as many as 30% of patients with type I primary hyperoxaluria respond to pyridoxine (80). A review of pyridoxine treatment, which discussed 2 recent reports including 18 patients, stated that 50% of patients are unresponsive to pyridoxine, whereas oxaluria is normalized in 20% of patients and somewhat reduced (but not to normal concentrations) in the remaining 30% (81).

Physicians may consider treating with alanine in addition to pyridoxine to determine the optimum cocktail for minimizing oxalate accumulation. We have not seen any reports in which plasma alanine concentrations were measured after the adminis-tration of high doses.


Aromatic-L-amino-acid decarboxylase: developmental delay  芳香-L-氨基酸脱羧酶:精神错乱

Aromatic-L-amino acid decarboxylase (AAD; see OMIM 107930)is a homodimeric PLP-containing enzyme synthesizing 2 impor-tant neurotransmitters: dopamine and serotonin (82). After the hydroxylation of tyrosine to form dihydroxyphenylalanine, cat-alyzed by tyrosine hydroxylase, AAD decarboxylates dihydrox-yphenylalanine to form dopamine. Dopamine is sequentially broken down to dihydroxyphenylacetaldehyde by monoamine oxi-dase B [amine oxidase (flavin-containing)], to dihydroxypheny-lacetic acid by aldehyde dehydrogenase, and finally to homovanillic acid by catechol O-methyltransferase. Tryptophan 5-monooxygenase produces 5-hydroxytryptophan, which is also decarboxylated by AAD to give rise to serotonin. Serotonin is broken down to 5-hydroxyindoleacetic acid. AAD deficiency is an autosomal recessive inborn metabolic disorder characterized by combined serotonin and dopamine deficiency.

芳香-L-氨基酸脱羧酶(AAD;见OMIM 107930)是一种合成2种重要神经递质多巴胺和5-羟色胺,的高二聚体的含plp酶,酪氨酸羟化形成二羟基苯丙氨酸后,通过酪氨酸羟化酶进行分析, 芳香-L-氨基酸脱羧酶将二氢-亚苯丙氨酸脱羧基,形成多巴胺.多巴胺被单胺氧化酶B分解成二羟基苯乙醛。[胺氧化酶(含黄素)],通过醛脱氢酶将二羟基苯-1-乙酸加入到二羟基苯-1-乙酸中,最后用邻苯二酚O-甲基转移酶合成高香草酸。色氨酸5-单加氧酶产生5-羟色胺,它也被AAD脱羧而产生血清素。5-羟色胺分解为5-羟基吲哚乙酸.AAD缺乏症是一种以5-羟色胺和多巴胺缺乏为特征的常染色体隐性先天代谢紊乱。

The first reported cases of AAD deficiency were monozygotic twins with extreme hypotonia and oculogyric crises (83). AAD activity was severely reduced and concentrations of dihy-droxyphenylalanine and 5-hydroxytryptophan were elevated in cerebrospinal fluid, plasma, and urine. Pyridoxine (100 mg/d) lowered dihydroxyphenylalanine concentrations in cere-brospinal fluid, but treatment with either bromocriptine or tranylcypromine was required for clinical improvement. Another AAD-deficient patient, with similar presentation, also had greatly reduced activity of AAD in plasma (84). Similar to the first reported cases, combined treatment with pyridoxine,bromocriptine, and tranylcypromine produced some clinical improvement. Several other cases of AAD deficiency have appar-ently benefited from high-dose pyridoxine treatment (85).
首次报告的AAD缺乏症病例为同卵双生子,伴有极度低张力和眼震性危象。AAD活性严重下降,二羟基苯丙氨酸浓度降低而脑脊液、血浆、尿中5-羟色胺升高。B6(100 mg/d)可降低脑脊液中二羟基苯丙氨酸的浓度,但临床上仍需用溴隐亭或三聚氰胺治疗。另一例aad缺陷患者,具有类似的表现,也大大降低了血浆中aad的活性。与第一次报告的病例相似,联合使用吡柔嗪、溴隐亭和三聚氰丙胺可使临床有所改善。其他几例AAD缺乏症患者已从大剂量吡多星治疗中获益惊人。

Housekeeping -aminolevulinic acid synthase: sideroblastic anemia 铁粒幼细胞贫血

The mapping of a second -aminolevulinic acid synthase (5-aminolevulinate synthase) gene, ALAS1, to an autosome, chro-mosome 3, rules it out as the site of the primary defect in X-linked sideroblastic anemia. It was concluded that this gene is a house-keeping form of ALAS (see OMIM 125290) because it is expressed in all cell types including erythroid cells; thus, the gene is designated ALAS1 to distinguish it from the red cell–specific form, ALAS2 (86).

第二氨基乙酰丙酸合酶的定位基因(5-氨基酮戊酸合酶),ALAS 1,常染色体,Chro-mosome 3,排除它为X-连锁铁粒母细胞性贫血的原发缺陷部位。由此得出结论,这种基因是一种令人不快的家常便饭(见Omim125290)。因为它在包括红系细胞在内的所有细胞类型中都有表达;因此,该基因被命名为ALA1,以将其与红色细胞区分-特异性形式,ALAS2(86)。

In a study of 20 patients with sideroblastic anemia, 3 patients showed low ALAS activity that was corrected by PLP in vitro, and 2 other patients were found to be responsive to pyridoxine (20 mg/d) (87). When 1 of these 2 patients was taken off pyridoxine, ALAS activity, as measured in bone marrow, fell markedly unless PLP was added in vitro. Additionally, the Km of the enzyme for PLP was substantially greater (2.5 times) than that of a control sample. However, it is unclear whether these are ALAS1 or ALAS2 defects.

对20例铁质母细胞性贫血患者的研究,3例患者经体外PLP校正后,出现较低的AlAs活性;另外两名病人对吡多辛(20毫克/天)有反应。当这2名病人中有1名被摘除吡多辛时,AlAs活性,在骨髓中,除非在体外加入PLP,否则骨髓中PLP的含量明显下降。此外,PLP酶的Km远大于对照样品的2.5倍。但是,尚不清楚这些缺陷是ALAS 1还是ALAS 2缺陷。

A 70-y-old who exhibited an attack of polymorphic, hypochronic anemia, with increased serum iron and numerous ringed sider-oblasts in the bone marrow, was determined to have pyridoxine-responsive primary acquired sideroblastic anemia (88). Administration of pyridoxine (initially 200 mg/d, then 600 mg/d) caused a complete remission of all hematologic abnormalities. ALAS activity was increased to 50% of control with 600 mg pyridoxine/d. The activity could be further increased to 100% of control in vitro with 1000 mol/L PLP. This defect could also be in ALAS1 or ALAS2.

一个70岁的老人表现出,多态性,慢性贫血,随着血清铁含量的增加和骨髓中许多环状成纤维细胞的增加,确定具有维生素B6应答的原代培养的侧粒幼细胞贫血。服用吡多辛(最初200毫克/天,然后600毫克/天)可使所有血液异常完全缓解。用600 mg吡多辛/d,可使LAS活性提高到对照的50%。1000 mol/L PLP可使体外活性进一步提高到100%。此缺陷也可能出现在ALAS 1或ALAS 2中。

β-Alanine -ketoglutarate transaminase: Cohen syndrome β-丙氨酸酮戊二酸转氨酶:科恩综合征

β-Alanine -ketoglutarate transaminase (AKT; 4-aminobutyrate aminotransferase) is involved in the formation of malonic semi-aldehyde from -alanine. Children with AKT deficiency have Cohen syndrome (see OMIM 216550), which involves hypoto-nia, midchildhood obesity, mental deficiency, and facial, oral, ocular, and limb anomalies. A case report of a girl with features of the syndrome reported a response to 100 mg pyridoxine/d for 1 mo, with a normalization of electroencephalogram and a sub-siding of lethargy. The girl was hospitalized once when she missed a week of pyridoxine treatment, but reinstatement of the treatment resulted in more improvement. Cultured skin fibro-blasts from the girl showed a toxic response to -alanine with a 50% reduction in growth. The addition of 100 mol pyridoxine/L to the cells abolished the toxic effects and increased AKT activ-ity more than 2-fold (89).

β-丙氨酸酮戊二酸转氨酶(AKT;4-氨基丁酸氨基转移酶)与丙氨酸形成丙二醛有关。AKT缺乏症儿童Cohen综合征(见OMIM 216550),它涉及睡眠不足,儿童中期肥胖,精神缺陷,以及面部,口腔,眼睛和肢体异常.一例以该综合征为特征的女孩报告了100毫克吡多星/日的疗效,疗程为1mo,有正常的脑电图和昏睡症状。这名女孩因错过一周的吡多辛治疗而住院一次,但恢复治疗后情况有了更大改善。从女孩培养的皮肤成纤维细胞显示了对丙氨酸的毒性反应,生长下降了50%。100 mol吡多辛/L可消除细胞毒性作用,使AKT活性提高2倍以上。

Autism 孤独症
Autism (a developmental disorder that involves impaired social interactions and deviant behavior) and its associated behaviors are thought to affect 5 in 10 000 individuals [and as many as 1 in 300 in some US communities (90)]. Autism may be due to defects in a PLP-requiring enzyme or enzymes involved in the metabolism of serotonin and dopamine, although a genetic link to a vitamin B-6–requiring enzyme has not been established. The most replicated clinical sign of autism is an elevation of whole-blood serotonin (5-hydroxytryptamine), which is found in > 30% of patients (91). Increased concentrations of homovanillic acid, a breakdown product of dopamine, have also been found in several autistic patients. Pyridoxine therapy has been reported to be successful in autism, raising the possibility that a PLP-requiring enzyme might be defective in those patients responsive to vitamin B6. (PLP is a coenzyme that forms a Schiff base with an amino group in its catalytic action, so that enzymes with PLP metabolize amino acids or other amines, such as dopamine and serotonin.) The only PLP-requiring enzyme directly involved with the synthesis or degradation of dopamine and serotonin is AAD (ie, dihydroxyphenylalanine decarboxylase). The finding in some vitamin B-6–responsive patients, namely elevated homovanillic acid that is at least partially reversible with pyri-doxine therapy (92), does not suggest a defect in this enzyme. Additionally, cases of AAD deficiency have been reported in the literature (see the discussion of AAD above) and result only in a very severe inborn metabolic disorder involving deficient con-centrations of dopamine and serotonin.


It remains to be seen whether other enzymes in the metabolic pathways of these neurotransmitters may be responsible for the various forms of autism that involve altered neurotransmitter metabolism. Autism is diagnosed by clinical, not biochemical, indexes. Thus, if different autistic patients harbor mutations in dif-ferent metabolic enzymes, it may be possible to reverse the effects of autism by targeting a treatment to each individual patient. In addition to PLP, the coenzymes FAD, NAD, S-adenosylmethion-ine, tetrahydrobiopterin, and ascorbate are used by enzymes in serotonin and dopamine metabolism.


Because so little is known about the biochemical basis of this condition, it is difficult to associate a treatment response with a particular biochemical or physiologic pathway; however, there have been many reports of successful treatment of autism with pyridoxine. In a survey involving 4000 questionnaires completed by parents of autistic children, high-dose vitamin B-6 and mag-nesium treatment (n = 318) elicited the best response; for every parent reporting behavioral worsening with the treatment, 8.5 parents reported behavioral improvement. The next best results were with the acetylcholine precursor, deanol (n = 121); 1.8 parents reported a favorable response for every 1 patient who reported worsening (93).


Sixteen autistic patients previously shown to respond to vitmin B6 treatment were reassessed and given vitamin B6 or a placebo in a double-blind study (94). Behavior deteriorated significantly during B6 withdrawal, and 11 of 15 children behaved better when given 300 mg vitamin B-6/d. The authors speculated that vitamin B-6 therapy may correct, or partially correct, a tryptophanrelated metabolic error because of a marked increase in serotonin efflux from platelets of autistic children and because large doses of vitamin B-6 elevate serotonin con-centrations (95).


A double-blind trial involving 60 autistic children found that vitamin B-6 (30 mg pyridoxine hydrochloride · kg-1 · d-1 up to 1 g/d) and magnesium (10–15 mg · kg-1 · d-1) were more helpful than either supplement alone in ameliorating the various effects of autism. Patients receiving the combined treatment showed a significant (P < 0.02) decrease in homovanillic acid excretion (from 6.6 to 4.4 mol/mmol creatine) and significant clinical improvement (96).

一项涉及60名自闭症儿童的双盲试验发现,维生素B-6(30毫克盐酸吡多辛·kg-1·d-1至1g/d)和镁(10-15毫克·kg-1·d-1)比各自单独补充更有帮助。接受综合治疗的患者有显着性差异(P < 0.02),高香草酸排泄量减少(从6.6到4.4mol/mmol肌酸)和显著的临床改善

Tryptophan metabolism was studied in 19 children with various forms of psychosis including autism. Four children (includ-ing at least one who was autistic) who had abnormal tryptophanmetabolite ratios were treated with 30 mg pyridoxine/d, where-upon biochemical features normalized (97). It was thought that these children had kynureninase defects because the kynureninase reaction required greater than normal amounts of PLP to proceed normally (see the discussion of kynureninase above).


More than a dozen other reports (with up to 190 participants) since 1965 and a review of controlled trials (98) have reported improvements in autistic patients with vitamin B-6 and often magnesium supplementation (99–102), although the conclusion that pyridoxine is an effective treatment of autism has been challenged: “interpretation of these positive findings needs to be tempered because of methodological shortcomings inherent in many of the studies” (92). A rebuttal (103) to this critique leaves the matter somewhat unresolved. Evidence supporting the hypothesis that defects in enzymes involved in neurotransmitter biosynthesis may be responsible for some forms of autism comes from a study showing that tetrahydrobiopterin, the cofactor for tyrosine and tryptophan hydroxylases, elicited behavioral improve-ments in 6 children with autism (104).


Tardive dyskinesia 迟发性运动障碍

The long-term use of neuroleptic drugs for the attenuation of psychotic disorders such as schizophrenia can lead to tardive dyskinesia, a neurologic movement disorder characterized by rapid, repetitive, uncontrolled movements. There may be > 1 mil-lion cases of tardive dyskinesia in the United States today and there is some speculation that deranged metabolism of amino acid–derived neurotransmitters is responsible for the disease. The involvement of PLP in dopamine, serotonin, and -aminobutyric acid metabolism may be the reason for the first clinical applica-tions of pyridoxine in the treatment of tardive dyskinesia; pyri-doxine-responsiveness has been reported.


A double-blind, placebo-controlled crossover study found high doses of pyridoxine (≤400 mg/d) to be effective in reducing symp-toms of tardive dyskinesia in patients with schizophrenia (105). Pyridoxine or placebo was added to the normal neuroleptic treatment of all 15 patients in the study for 4 wk at a time, split by a 1-wk washout period. Pyridoxine treatment invoked improvements in both the dyskinetic movement and Parkinsonian subscales with returns to baseline with removal from pyridoxine. An earlier pilot study by the same group showed significant clinical improvement in 4 of 5 tardive dyskinesia patients given 100 mg pyridoxine/d on top of their normal treatment (106). Three of the responders also showed significant improvement on the brief psychiatric rating scale.

一项双盲安慰剂对照研究发现大剂量吡多星(≤400 mg/d)治疗精神分裂症迟发性运动障碍的疗效观察。将吡多辛或安慰剂加入到所有15名患者的正常抗精神病药物治疗中,每次4wk,分裂为1 wk冲洗期。吡多星治疗在运动障碍和帕金森氏次级量表上都有改善,从吡多辛中移除后恢复到基线水平。同一组早期的一项初步研究显示,5例迟发性运动障碍患者中有4例在正常治疗的基础上服用100 mg吡多辛/d,临床有明显改善。其中三名反应者在简短的精神病评定量表上也有明显的改善。

The relation between tardive dyskinesia susceptibility and polymorphisms in dopamine and serotonin receptor genes has been a focus of exploration. Homozygosity for the Ser9→Gly polymorphism in the dopamine D3 receptor was higher in schizophrenics with tardive dyskinesia (22%) than without (4%), suggesting that the glycine allele may be a risk factor for developing tardive dyskinesia (107). A similar study supports the involvement of Ser9→Gly in tardive dyskinesia risk, although the presence of tardive dyskinesia was higher in heterozygotes than in either homozygous group (108). The Thr102→Cys polymorphism in the serotonin type 2A receptor gene has also been investigated, although contradictory results leave the matter unresolved as to which allele may be associ-ated with schizophrenia, tardive dyskinesia, or both. A poly-morphism might code for a receptor that has a decreased neurotransmitter binding and the capacity to be stimulated by a pyridoxine-induced increase of neurotransmitter level (95), but before any such hypothesis is taken seriously more detailed biochemical evidence is necessary.

迟发性运动障碍易感性与多巴胺和5-羟色胺受体基因多态性的关系一直是研究的热点。多巴胺D3受体9→Gly多态性在迟发性运动障碍精神分裂症患者中的纯合性较高(22%)与无(4%)相比,甘氨酸等位基因可能是迟发性运动障碍的危险因素。一项类似的研究支持Ser9→Gly参与迟发性运动障碍的风险,虽然杂合子中迟发性运动障碍的存在高于纯合子组。本文还对5-羟色胺2A受体基因Thr 102→Cys多态性进行了研究。虽然有矛盾的结果,但对于哪种等位基因可能与精神分裂症、迟发性运动障碍或两者兼而有之,这一问题仍未解决。多态性可能意味着受体的神经递质结合减少,并且被吡多辛诱导的神经递质水平的增加所刺激的能力。但在认真对待任何这样的假设之前,更详细的生化证据是必要的。

Tissue concentrations and toxicity 组织浓度和毒性

Pyridoxine’s active role in ameliorating many cases of genetic disease involving enzymes that require a PLP cofactor is clear. Plasma PLP concentrations correlate well with tissue PLP concentra-tions in rats (109), and thus serve as a good indicator of vitamin B-6 status. There is a linear relation between vitamin B-6 intake and plasma concentrations of PLP (up to an intake of 3 mg/d in humans, which correlates with a plasma concentration of 60 nmol/L) (7). This proportional relation has been shown to hold even at 25 mg/d, resulting in a plasma PLP concentration of 200 nmol/L (110). A double-blind study investigating high-dose vitamin B-6 treat-ment of tardive dyskinesia showed that baseline plasma PLP (49 nmol/L) could be raised >14 times (690 nmol/L) safely with 400 mg/d pyridoxine (105). A rat study referenced in the DRI pub-lication showed that extremely large doses are well absorbed (7).

吡多星在改善许多需要PLP辅助因子的酶的遗传病中的积极作用是显而易见的。血浆PLP浓度与大鼠组织PLP浓度相关性良好。从而作为维生素B-6状态的一个很好的指标.维生素B-6摄入量与血浆PLP浓度呈线性关系。(人体摄入3mg/d,与血浆浓度60 nmol/L相关。这一比例关系被证明即使在25毫克/天时也保持不变,从而使血浆plp浓度达到200 nmol/L。对大剂量维生素B-6治疗迟发性运动障碍的双盲研究表明,400 mg/d吡啶可使基础血浆plp(49 nmol/L)安全升高14倍(690 nmol/L)。DRI公开引用的一项大鼠研究表明,极大剂量的药物被很好地吸收。

The higher concentrations of PLP likely facilitate apoenzyme-coenzyme interaction, and hence higher enzymatic activity, although it should be noted that numerical discrepancies do exist in the literature. Normal serum PLP concentrations appear to be 60 nmol/L, whereas control Km concentrations have been described in the mol/L range for some enzymes (eg, OAT and CBS).

较高浓度的PLP可能会促进酶与辅酶的相互作用,因此,更高的酶活性,虽然应该指出,数量上的差异确实存在的文献。正常血清PLP浓度似乎为60 nmol/L,而对照Km浓度则被描述为某些酶的浓度在mol/L范围内。(如OAT和CBS)。

An upper limit exists as to pyridoxine administration. Although dosages in the hundreds of milligrams have been safely applied, reports exist of neurotoxic effects with very high vitamin B-6 usage. One review advises avoiding doses >1000 mg pyridoxine/d (47). The tolerable upper intake level (UL) of pyri-doxine for normal use is 100 mg/d (7); however, the severity of some genetic diseases has reasonably prompted physicians to prescribe higher doses.



The DRIs for thiamine for men and women are 1.2 and 1.1 mg/d,respectively (7). Thiamine is phosphorylated to form TPP, the cofactor used by many enzymes. The crystal structure of at least one of these enzymes has been solved (111) and critical residues in the TPP binding site have been identified. The thi-amine-dependent enzymes discussed in this section are sum-marized in Table 4.


Branched-chain -ketoacid dehydrogenase: maple syrup urine disease (ketoacidosis, mental retardation, and ataxia)


The branched-chain -ketoacid dehydrogenase (BCKAD) multienzyme mitochondrial complex is composed of 3 subunits: an E1 component (TPP-dependent decarboxylase) containing and  subunits, an E2 component (lipoate-containing acyl-transferase), and an E3 component (FAD- and NAD-containing dihydrolipoyl dehydrogenase), the latter of which is also a component of pyruvate and -ketoglutarate dehydrogenases. BCKAD is responsible for the oxidative decarboxylation of -ketoacids of the 3 branched-chain amino acids valine, leucine, and isoleucine. Genetic defects in the complex cause maple syrup urine disease (see OMIM 248600), which involves ketoacidosis, mental retardation, ataxia, and sometimes blind-ness as a result of the accumulation of -keto acids.

支链酮酸脱氢酶(BCKAD)多酶线粒体复合体由3个亚基组成:E1组(TPP依赖性脱羧酶)包含和亚基,和E2组(含脂酰基转移酶)及E3组(含FAD和NAD的二氢硫辛醇脱氢酶),后者也是丙酮酸和α-酮戊二酸脱氢酶的组成部分。BCKAD负责3种支链氨基酸-酮酸的氧化脱羧,缬氨酸、亮氨酸和异亮氨酸。复杂原因枫糖浆尿病的遗传缺陷(见OMIM 248600),这包括酮症酸中毒,智力迟钝,共济失调,有时由于-酮酸的积累而导致失明。

In 1985, thiamine responsiveness was reported in 12 patients who were fed thiamine in doses ranging from 10 to 1000 mg/d (112). The accumulation of ketoacids was shown to return to normal  after thiamine feeding (113). In one thiamine-responsive maple syrup urine disease cell line (WG-34) the Km for TPP (as meas-ured via BCKAD decarboxylation activity) was found to be 16 times higher than normal (114). The sequence of the WG-34 mutant has been determined and unexpectedly, the dihy-drolipoamide acyltransferase component of the complex was found to be altered. It is possible that the presence of a normal E2 is essential for the efficient binding of TPP to E1 (115). Other genes from thiamine-responsive patients have been sequenced and the E2 subunit was found to be altered in ≥ 2 other patients (116–118). It appears that mutations in E2 are responsible for the thiamine-responsive versions of maple syrup urine disease and it has been suggested that this E2 defect impairs the E1-E2 interaction where the TPP molecule must bind, thus increasing the cell’s requirement for thiamine and TPP (116).


The crystal structure of the TPP binding portion of the BCKAD complex has been determined as well as the effects of various maple syrup urine disease mutations on the enzyme. One mutation (E1 N222S) increased the Km for TPP in a nonrespon-sive patient. The other 3 mutations, which are described as affecting cofactor binding, all resulted in nonresponsive maple syrup urine disease. Another residue, E1 N126, which is altered in some patients with maple syrup urine disease, affects interface interaction in the complex and may be involved with subunit association and K+ binding (111). (See the discussion of potas-sium in the section on hormones, amino acids, and metals.) It remains to be seen whether some of the other mutations, specifically in the intermediate or thiamine-responsive patients, also result in an increased Km for TPP.

In 9 thiamine-dependent cases, the decarboxylation activity (which is a measurement of overall BCKAD activity) ranged from 3% to 40% of normal (119). In one case, the mutant enzyme was shown to be heat labile and stabilized by increased TPP (120). No adequate reports of the percentage of cases that are remediable by thiamine are available. Although the enzyme complex also uses NAD, FAD, and dihydrolipoic acid as cofac-tors in addition to the Mg2+ salt of TPP, it appears that the thera-peutic application of niacin, riboflavin, and lipoic acid has not been attempted. NAD, CoA, and Mg2+ were tried in cell culture but were ineffective (121).

测定了BCKAD复合物TPP结合部分的晶体结构,以及各种枫糖浆尿病突变对酶的影响。一个突变(E1,N222S)增加了非反应性患者TPP的Km。其他3种突变,这些都被描述为影响辅助因子结合,所有的结果都没有反应的枫树糖浆尿病。另一种残留,E1,N 126,在一些枫树糖浆尿病患者中有改变。,影响复杂环境中的界面交互作用,可能与亚基关联和K结合有关。(参见激素、氨基酸和金属一节中对铯的讨论。)其他一些突变,特别是中间或硫胺素反应中的突变,还有待观察。我的患者也会导致TPP的KM增加。

In one case, supplementation with oral thiamine reversed the blindness that sometimes accompanies the disease (122). Another noteworthy thiamine-responsive case involved a compound heterozygote with a large deletion and a 1002G→A transition at an exon 8 splice site that resulted in exon skipping and the tran-scription of different length mRNAs (117). The mechanism for this thiamine response remains to be explained.


The data suggest that combination therapy with thiamine, lipoic acid, riboflavin, nicotinamide, and adequate potassium [for which the recommended dietary allowance intake is 2000 mg/d (9)] may be optimal for the initial treatment of patients with maple syrup urine disease. Potassium might be beneficial because K+ is required for the stabilization of E1 by TPP. The stabilizing effect of K+ on BCKAD was shown in the rat liver BCKAD enzyme (123) as well as in the human E1 protein (124). Both groups observed a depen-dence of enzyme activity on the concentration of potassium salts.

数据表明硫胺素联合治疗,硫辛酸、核黄素、烟碱和足够的钾[推荐摄入量为2000 mg/d(9)]可能是治疗枫糖浆尿病的最佳方法。钾可能是有益的,因为K是稳定E1的TPP所必需的。K对大鼠肝脏BCKAD的稳定作用以及人的E1蛋白。两组均观察到酶活性对钾盐浓度的依赖关系。

Pyruvate decarboxylase: Leigh disease (lactic acidosis, ataxia, and mental retardation) 丙酮酸脱羧酶::利病(乳酸酸中毒、共济失调和智力迟钝)

Pyruvate decarboxylase is part of the pyruvate dehydrogenase multienzyme mitochondrial complex (PDHC) that uses TPP, lipoic acid, CoA, FAD, and NADH coenzymes to catalyze the conversion of pyruvate to acetyl-CoA (see OMIM 312170). The gene encoding the E1 peptide of the E1 subunit (pyruvate decar-boxylase), which binds TPP, is located on the X chromosome. Genetic defects in the complex can lead to lethal lactic acidosis, psychomotor retardation, central nervous system damage, ataxia, muscle fiber atrophy, and developmental delay (125).

丙酮酸脱羧酶是丙酮酸脱氢酶多酶线粒体复合物(PDHC)的一部分,它使用TPP,硫辛酸、辅酶A、脂肪酸和NADH辅酶催化丙酮酸合成乙酰辅酶(见OMIM 312170)。编码与TPP结合的E1亚单位(丙酮酸脱氢酶-BOXYLase)的E1肽的基因位于X染色体上。该复合体的遗传缺陷可导致致死性乳酸酸中毒、精神运动迟缓、中枢神经系统损害、共济失调、肌纤维萎缩和发育延迟(125)。

X-linked genetic defects in PDHC cause pyruvate and lac-tate accumulation and encephalomyelopathy. Twenty-six patients responded to high intakes of thiamine, ranging from 20 to 3000 mg/d. In 2 sisters (126), lipoic acid (100 mg/d) plus thiamine (3000 mg/d) were found to give the best remediation. In several cases, the mutation was shown to increase the Km of the E1 subunit for TPP and reduce the Vmax (127, 128). In several cases in which lactate was measured, thiamine lowered lactate concentrations significantly (127, 129, 130).

PDHC的X-连锁遗传缺陷可引起丙酮酸和乳酸盐的积聚和脑脊髓病.26例患者对大量摄入硫胺素(20~3000 mg/d)有反应.在2个姐妹(126)中,硫辛酸(100 mg/d)和硫胺素(3000 mg/d)的修复效果最好。在一些情况下,突变会增加tpp的e1亚基的km并降低vmax。在测定乳酸的几个病例中,硫胺素显著降低了乳酸的浓度。
In a study of 13 thiamine-responsive PDHC-deficient patients, some had a decreased affinity of PDHC for TPP that was respon-sive to TPP, whereas the PDHC activity of others increased at high TPP concentrations with no statement about enzyme affinity (131). Another group of patients with lactic acidemia and muscle fiber atrophy had TPP-responsive PDHC enzymes (1.82 and 2.63 nmol · min1 · mg protein1 with 400 mol/L TPP com-pared with 0.28 and 0.02 nmol · min1 · mg protein1, respec-tively, with 0.1 mol/L TPP) (132).


A female infant with West syndrome (a unique epileptic syn-drome with frequently poor prognosis and spasms associated with elevated blood and cerebrospinal fluid lactate concentra-tions) had thiamine-responsive PDHC deficiency (133). Lactate concentrations were lowered and symptoms disappeared when the infant was administered dichloroacetate and high doses of thiamine (500 mg/d). The patient carried the mutation Gly89→Ser in exon 3 of her PDHC E1 gene, resulting in a decreased affin-ity for TPP. PDHC activity was activated in vitro with the addition of TPP. Gly89→Ser, along with 4 other mutations in thiamine-responsive PDHC-deficient patients (His44→Arg, Arg88→Ser, Arg263→Gly, and Val389→fs) are in regions outside the TPP binding site in exon 6 (133). However, these mutations may affect overall protein conformation and indirectly decrease cofactor binding affinity. Pyridoxine was shown to be effective in several cases of West syndrome (134).

一名West综合征女婴(一种独特的癫痫综合征,预后差,痉挛与血和脑脊液乳酸浓度升高有关)硫胺素应答型PDHC缺乏症。婴儿服用二氯乙酸和大剂量硫胺素(500 mg/d)后,乳酸浓度降低,症状消失。患者携带PDHCE1基因第3外显子的Gly89基因,从而降低TPP的亲和力。在体外加入TPP后,PDHC活性被激活。Gly 89→Ser和其他4个硫胺应答型PDHC缺乏症患者(His 44→Arg、Arg 88→Ser、Arg 263→Gly和Val389→fs)在第6(133)外显子中位于TPP结合位点以外的区域。然而,这些突变可能会影响蛋白质的整体构象,间接降低辅因子结合亲和力。吡多辛对几例West综合征有效。

Three point mutations in E1-deficient patients were recreated in vitro. One mutation, Met181→Val, exhibited a 250-fold increased Km for TPP and, in addition to another studied mutation (Pro188→Leu) is involved with TPP binding. It was mentioned that an aspartate and an asparagine residue form H-bonds with and coordinate the divalent cation (Mg2+ or Ca2+). This cation interacts with the oxygen groups of the pyrophosphate portion of TPP (135). Thus, encouraging adequate intake of magnesium and calcium in PDHC-deficient patients by physicians seems reasonable. The Met181→Val mutation also raised the Km for pyruvate 3-fold (135). Physicians might consider treating PDHC-deficient patients with precursors to all of the cofactors used by the enzyme complex: thiamine, lipoic acid, pantothenate, riboflavin, and niacin.


Thiamine transporter, thiamine pyrophosphokinase, and -ketoglutarate dehydrogenase: thiamine-responsive megaloblastic anemia


Thiamine-responsive megaloblastic anemia (see OMIM 249270) can be caused by defects in a putative thiamine transporter, thi-amine pyrophosphokinase (TPK), and -ketoglutarate dehydro-genase [KGDH; oxoglutarate dehydrogenase (lipoamide)]. The putative thiamine transporter, encoded by SLC19A2, is homolo-gous to reduced folate carrier proteins and may bring thiamine into cells. TPK is responsible for the phosphorylation of thiamine to TPP cofactor. KGDH is one of the thiamine-dependent dehydroge-nases that binds TPP by an E1 carboxylase (see also the discussions of BCKAD and PDHC above).

硫胺反应性巨幼细胞性贫血(见OMIM 249270)可能是由推定的硫胺素转运蛋白、Th1-胺焦磷酸激酶(TPK)和-酮戊二酸脱氢酶中的缺陷引起的,[KGDH; oxoglutarate dehydrogenase 酮戊二酸脱氢酶(2-氧(代)异戊酸脱氢酶)]。SLC19A2编码的硫胺素转运体与叶酸载体蛋白具有同源性,可将硫胺引入细胞。Tpk负责硫胺素磷酸化为TPP辅助因子。KGDH是由E1羟甲基纤维素结合TPP的硫胺素依赖性脱氢基酶之一。(另见上文BCKAD和PDHC的讨论)。
Mutations in SLC19A2 (136, 137) and defects in TPK (138, 139) and KGDH (140, 141) have all been found in patients with thiamine-responsive megaloblastic anemia. Thiamine-responsive megaloblastic anemia, first described by Rogers et al (142) in 1969, is an autosomal recessive condition with an early onset and is characterized by the triad of megaloblastic anemia, dia-betes mellitus, and sensorineural deafness.


Mutations in the gene for the putative thiamine transporter, SLC19A2 (see OMIM 603941), were found in all affected individuals in 6 families with thiamine-responsive megaloblastic anemia (136). Another study found similar results and supports the putative role of SLC19A2 in some forms of thiamine-responsive megaloblastic anemia (137). There is evidence that there is a low-affinity thiamine transporter and that this transporter is responsi-ble for the clinical thiamine-responsiveness, partially correcting for the decreased intracellular thiamine concentrations that result from the defective high-affinity transporter, SLC19A2 (143). The low-affinity version may be the recently identified thiamine transporter SLC19A3 (144). Such a bypass would not involve overcoming a Km defect. Both thiamine transport and TPK were thought to be the enzymes affected in a group of 7 patients with thiamine-responsive megaloblastic anemia (143).

被认为是硫胺转运体的基因突变,SLC19A2(见OMIM 603941),在6个硫胺素应答性巨幼细胞性贫血家系的所有患者中均有发现。另一项研究发现了类似的结果,并支持SLC19A2在某些形式的硫胺素反应的巨幼细胞性贫血中的作用。有证据表明存在一种低亲和力的硫胺素转运体,并且这种转运体对临床硫胺素的反应性是有效的,部分校正了减少的内标物(Intracel)。由缺陷的高亲和力转运体SLC19A2引起的环状硫胺浓度。低亲和力版本可能是最近发现的硫胺转运体SLC19A3。这样的绕行将不涉及克服KM缺陷。7例硫胺素反应性巨幼细胞性贫血患者中,硫胺素转运和tpk均被认为是受影响的酶。

TPK activity was reduced in a patient with thiamine-responsive megaloblastic anemia in whom 60 d of thiamine therapy (50 mg/d) normalized concentrations of free and phosphorylated thiamine (139). Thiamine responsiveness was found in 2 similar cases of thiamine-responsive megaloblastic anemia with defi-cient TPK activity (138). After thiamine ingestion (75 mg/d), which raised erythrocyte TPP concentrations 1.5- and 2-fold in the patients, hematologic findings returned to normal and insulin requirements decreased by 66%. (See OMIM 606370.)

硫胺素应答性巨幼细胞性贫血患者Tpk活性下降,其中硫氨治疗60d(50 mg/d),游离和磷酸化硫胺素(139)正常浓度。在2例tpk活性低下的硫胺素应答型巨幼细胞性贫血患者中发现了硫胺素反应性。硫胺素摄入(75mg/d)后,患者红细胞TPP浓度升高1.5倍和2倍,血液学发现恢复正常,胰岛素需求下降66%(见OMIM 606370。)

Deficient KGDH activity (see OMIM 203740) in one patient with thiamine-responsive megaloblastic anemia was stimulated by TPP titration. Near normal activity was reached with 0.75 mol TPP/L, whereas control subjects were not responsive (140). The KGDH activity in another patient was 2% of that of a control sub-ject, and a defect in binding of TPP to the KGDH complex was suggested (141). Because the KGDH complex uses other coen-zymes including lipoic acid, CoA, FAD, and NAD, patients may benefit initially from a high-dose mixture of thiamine, lipoic acid, pantothenate, riboflavin, and niacin, but controlled clinical inves-tigations are needed to validate or reject this hypothesis.

缺乏KGDH活性(见OMIM 203740)在1例患者中,通过TPP滴定刺激了硫胺素响应的巨幼细胞贫血。0.75mol TPP/L,活性接近正常。而对照组则没有反应。另一例患者的kgdh活性为对照组的2%,提示tpp与kgdh复合物的结合存在缺陷。由于kgDH复合物使用其他coen-酶,包括硫辛酸、coA、fad和nod,患者最初可能受益于高剂量的硫胺素混合物,硫辛酸,泛酸,核黄素和烟酸,但控制的临床入侵,需要验证或拒绝这一假设。

Oxidation of -ketoglutarate, pyruvate + malate, and malate + palmitate: lactic acidosis and cardiomyopathy

Cardiomyopathy and lactic acid accumulation in a neonate was remedied by feeding thiamine (50 mg/d), carnitine (2 g/d), and riboflavin (50 mg/d), which reversed the high blood lac-tate concentrations and other symptoms. The patient showed a deficiency in the oxidation of all substrates tested: pyruvate, -ketoglutarate, and palmitate. After freezing and thawing and addition of essential cofactors (TPP, CoA-SH, NAD), the activi-ties of the ketoacid dehydrogenases became normal. The appar-ent deficiency may have been caused by a primary deficiency in one of the cofactors or by a defect at the level of thiamine. Although the precise metabolic defect was not assessed, it was concluded that the patient was responsive to thiamine (145). A similar case (146) was also reversed by thiamine (50 mg/d).

用硫胺(50 mg/d)、肉碱(2g/d)和核黄素(50 mg/d)治疗新生儿心肌病和乳酸积累。从而逆转了血乳酸含量过高等症状。病人显示所有被测底物的氧化缺乏:丙酮酸,戊二酸酮,棕榈酸酯。冻融后添加必需的辅助因子(TPP、CoA-SH、NAD),酮酸脱氢酶活性正常。可怕的缺乏症可能是由一个辅助性因素中的一个初级缺乏症引起的,或者是由于硫胺素水平的缺陷造成的。虽然没有对确切的代谢缺陷进行评估,但结论是病人对硫胺素(145)有反应。类似的病例(146)也被硫胺素(50 mg/d)逆转。

Tissue concentrations and toxicity 组织浓度和毒性

The effectiveness of thiamine administration in these diseases involving several mutant genes seems clear. It has been shown that a 10-mg dose of thiamine raised serum thiamine concentrations to 24 nmol/L; concentrations returned to baseline (17 nmol/L) 6 h later (147). With higher pharmacologic doses, namely, repetitive 250-mg amounts taken orally and 500 mg/d given intramuscularly, nearly 1 wk was required for steady state plasma concentrations to be reached (148). It seems apparent that thiamine administration raises both TPP and thiamine concentrations in serum, but we have not found documentation of this.

硫胺素给药在涉及几个突变基因的这些疾病中的有效性似乎是清楚的。已经显示,10mg剂量的硫胺素升高血清硫胺素浓度为24nmol/L;浓度在6小时后恢复到基线(17 nmol/L)。随着较高的药量,即重复的250毫克口服和500毫克/天肌肉注射,需要近1周才能达到稳态血浆浓度。很明显,硫胺素的使用会提高血清中的TPP和硫胺素的浓度,但我们还没有发现这方面的文献。

There is no defined UL for thiamine because of its relative safety. Adverse effects of thiamine have been documented, although they appear to be rare. For example, in a study of 989 patients, 100 mg thiamine hydrochloride/d given intra-venously resulted in a burning effect at the injection site in 11 patients and pruritus in 1 (149).



The DRI for riboflavin is 1.3 mg/d for men and 1.1 mg/d for women (7). Riboflavin kinase synthesizes flavin mononu-cleotide (FMN) from ATP and riboflavin. Flavin adenine dinucleotide (FAD) is synthesized by the subsequent adenylation of FMN by FAD synthetase. A flavin-containing cofactor, FAD or FMN, is utilized by 151 (4%) of the 3870 enzymes catalogued in the ENZYME database (6). In addition to the identification of protein motifs (eg, Rossmann folds) involved with nonadenine binding of adenylate-containing cofactors (including FAD and NAD), a common adenine moiety binding motif was recently found in a large group of FAD binding proteins (150). The pyrophosphate moiety may be most important for FAD recognition because of a strongly conserved pyrophosphate binding motif found in FAD binding protein families (151). The following enzymes requiring flavin coenzymes are summarized in Table 5.

对于男性而言,核黄素的DRI为1.3mg/d,女性为1.1mg/d。 核黄素激酶合成黄素核苷酸 (FMN) 自ATP和核黄素,核黄素腺嘌呤二核苷酸FAD是由fmn的后续腺苷化反应合成的通过FAD合成酶,一种含Flavin的辅助性因子,FAD或FMN,在酶数据库中编目的3870种酶中,有151种(4%)被利用。除了蛋白质基序的鉴定之外,(如Rossmann折叠),与非腺嘌呤结合的含腺苷酸辅因子(包括FAD和NAD),最近在一大群FAD结合蛋白中发现了一个常见的腺嘌呤结合基序。由于fad结合蛋白家族中存在一个高度保守的焦磷酸结合基序,焦磷酸基元可能是fad识别中最重要的。表5概述了下列需要Flavin辅酶的酶。

Methylenetetrahydrofolate reductase (NADPH): homocysteinemia, cardiovascular disease, migraine,neural tube defects, Down syndrome, diabetic nephropathy, congenital cardiac malformations, dementia, and male infertility


Human MTHFR (also discussed in the section on folic acid) uses both NADP and FAD cofactors to catalyze the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate (see OMIM 236250). The latter is the predominant circulatory form of folate and the main carbon donor for the remethylation of homocysteine to methionine. The 677C→T (Ala222→Val) polymorphism (TT genotype occurring in 10–20% of the population) in the human MTHFR gene results in a thermolabile enzyme with reduced activity (152). Individuals with the polymorphism have a larger pool of 5,10-methylenetetrahydrofolate and are at a lower risk of developing chromosome breaks and cancer (153) and sperm dysfunction (154) when folic acid intake is marginal. The variant enzyme, however, results in a smaller pool of 5-methyltetrahydrofolate and an accumulation of homocys-teine (155), which has been associated with an elevated risk of cardiovascular disease (51, 52). A higher frequency of the 677C→T polymorphism has been associated with cardiovascular dis-ease (156), neural tube defects (NTDs) (157), Down syndrome (158), migraine (159), diabetic nephropathy (160), congenital cardiac malformations (161), dementia (162), male infertility (163), and other conditions.

人MTHFR(在叶酸一节中也有讨论)使用NADP和FAD辅助因子催化5,10-亚甲基四氢叶酸转化为5-亚甲基四氢叶酸。(见OMIM 236250)。后者是叶酸的主要循环形式,是同型半胱氨酸再甲基化为蛋氨酸的主要碳供体。677c→T(Ala222→Val)多态性(TT基因型出现在10-20%的人群中)在人MTHFR基因中,产生一种活性降低的热摩尔酶。当叶酸摄入量是边际时。,多态个体有较大的5,10-亚甲基四氢叶酸库而且发生染色体断裂、癌症、精子功,能障碍的风险较低。然而,这种变异酶会导致较小的5-甲基四氢叶酸库和同型半胱氨酸的积累。这与心血管疾病的风险增加有关,较高频率的677 c→T多态性与心血管疾病、神经管缺陷、唐氏综合征、偏头痛、糖尿病肾病、先天性心脏畸形、痴呆、男性不孕及其他疾病易感有关。

Although individuals with the polymorphism and many of the associated conditions have typically been treated with folic acid, the precursor to the MTHFR substrate, riboflavin, the FAD precursor vitamin, may prove to be of additional benefit because the primary defect in the 677C→T mutated enzyme is altered FAD binding. The human 677C→T mutation (164) and its Escherichia coli homologue (165) were found to alter the struc-ture of MTHFR and lower the binding affinity for the FAD cofactor, while not affecting the Km for folate. It was also found that the addition of FAD to crude extracts of human lymphocytes and of recombinant human MTHFR expressed in E. coli protects both wild-type and mutant enzymes, and that the protection is more dramatic with the mutant enzyme (165). The reduced ability to bind FAD was abolished under very high concentrations (mol/L) of folate (normal serum range is nmol/L), and this mechanism was offered as the basis for the effectiveness of folic acid therapy in lowering homocysteine in those with the poly-morphism. This suggests that feeding high doses of riboflavin to raise the concentrations of FAD might be of additional benefit to folic acid in lowering homocysteine concentrations in persons homozygous for the 677C→T mutation.


The maintenance of adequate riboflavin status is likely important for homocysteine and methylation metabolism, as suggested by the results of a rat study that showed MTHFR to be sensitive to both severe and moderate riboflavin deficiency (166). The 677C→T variant may be even more sensitive. Additionally, plasma riboflavin was found to be inversely related to plasma total homocysteine in a recent study in Norway of 423 healthy blood donors with adequate B-vitamin intake (167). Plasma total homocysteine, serum folate, serum cobalamin, serum creatinine, and MTHFR 677C→T genotype were measured, as well as both FMN and FAD. Riboflavin was found to be an independent determinant of total homocysteine status: total homocysteine was 1.4 mol/L higher in the lowest than in the highest riboflavin quartile (P = 0.008). The riboflavin–total homocysteine relation was modified by genotype (P = 0.004) and was essentially confined to subjects with the 677C→T polymorphism in the MTHFR gene. Those with the CC genotype did not show the correlation, whereas those heterozygous and homozygous for this common polymorphism (in this study, 9% were TT and 43% were CT) did show a riboflavin determinacy of homocysteine status. It was suggested that subjects with the T allele may require higher concentrations of FAD for maximal catalytic activity. The altered interaction between FAD and MTHFR sug-gests that high-dose riboflavin treatment should be studied in TT individuals, even those who have normal vitamin intakes, who might benefit by lowered homocysteine concentrations in the blood via the stimulation of MTHFR and thus a lowered risk of cardiovascular and other diseases. Another study showed an inverse correlation between the intake of several B vitamins, including riboflavin, and plasma homocysteine in atherosclerotic patients and control subjects (168). MTHFR genotype was not considered in this study.

维持足够的核黄素状态可能对同型半胱氨酸和甲基化代谢很重要,正如一项表明MTHFR对严重和中度核黄素缺乏都敏感的大鼠研究结果所表明的那样。677c→T变异体可能更敏感。此外,在挪威对423名健康献血者进行的一项研究发现,血浆核黄素与血浆总同型半胱氨酸呈负相关。测定血浆总同型半胱氨酸、血清叶酸、血清钴胺、血清肌酐、MTHFR677c→T基因型,并进行fmn和fad检测。核黄素是决定总同型半胱氨酸状态的独立决定因素:总同型半胱氨酸最低比最高的核黄素四分位高1.4mol/L(P=0.008)。核黄素-总同型半胱氨酸关系受基因型的影响(P=0.004),主要局限于基因677 c→T多态性的人群。CC基因型的人没有表现出相关性,而那些杂合子和纯合子导致了这种常见的多态性(在本研究中,9%为TT,43%为CT)表现出核黄素测定同型半胱氨酸的状态相关性。提示T等位基因的受试者可能需要较高浓度的FAD以达到最大的催化活性。FAD与MTHFR相互作用的变化表明应在TT个体中研究大剂量核黄素治疗,即使是那些维生素摄入正常的人,他们也可能受益于通过MTHFR刺激血液中同型半胱氨酸浓度的降低,从而降低患心血管疾病和其他疾病的风险。另一项研究显示,几种维生素B的摄入量成反比关系,包括核黄素,血浆同型半胱氨酸在动脉粥样硬化患者和对照组(168)。本研究未考虑MTHFR基因型。

A positive correlation was found between the 677C→T polymorphism and migraine (159), which was shown to be responsive to high-dose riboflavin treatment (400 mg/d), with a significant reduction in attack frequency (169). Those homozygous for the T allele were at a considerably greater risk of migraine than were control subjects, suggesting that homocysteine, an excitatory amino acid, is a risk factor for migraine. Seventy-four patients with migraine were compared with 261 healthy control subjects. The frequency of the TT genotype among the control subjects (9.6%) was significantly lower than in the migraine patients with aura (9/22, or 40.9%; P < 0.0001). No significant difference was found between the control subjects and the patients with migraine without aura or with tension-type headaches (159). In a randomized controlled study of 55 patients, more patients taking 400 mg riboflavin/d improved by ≥50% than did those taking a placebo: 59% of the riboflavin group responded to treatment with fewer migraine days compared with 15% for the placebo group (P = 0.002), 56% of patients in the riboflavin group responded to treatment with a decrease in attack frequency compared with 19% for the placebo group (P = 0.01), and 41% of the riboflavin patients improved on the migraine index compared with 8% for the placebo group (P = 0.01) (169). The patients with aura made up 22% of the group but were not differentiated in the analysis. This confirmed a previous open study.


Riboflavin and -blockers were similarly tested for the pre-vention of headaches (170). Intensity dependence of auditory evoked cortical potentials, a measurement of cortical informa-tion processing, was found to be decreased after treatment with -blockers. Riboflavin had a clinical efficacy similar to that of -blockers in the patients, but it did not change cortical infor-mation processing. Headache frequency decreased significantly in both patient groups (P < 0.05). Eight of 15 patients responded to riboflavin (meaning a reduction in attack frequency by > 50%). It would be of interest to compare MTHFR genotype with riboflavin responsiveness in these migraine patients, although such a study has not been done (J Schoenen, personal communication, 2001).

核黄素和阻滞剂也同样用于预防头痛,听觉诱发皮层电位的强度依赖性是大脑皮层信息处理的一种测量,经-阻滞剂治疗后,听觉诱发皮层电位的强度依赖性降低。核黄素的临床疗效与受体阻滞剂相似,但不改变皮质信息处理。两组患者头痛发生率均明显降低(P<0.05)。15例患者中有8例对核黄素有反应(这意味着攻击频率减少了50%以上)。在这些偏头痛患者中比较MTHFR基因型和核黄素反应是有意义的,尽管还没有做过这样的研究 (J Schoenen, personal communication, 2001).

NTDs, which are among the most common genetic malformations, have traditionally been prevented with periconceptional folic acid supplementation. It is estimated that the fraction of NTDs due to the TT genotype in Ireland is 11.4% (157). Homocysteinemia has been implicated in NTDs, and although some studies (171) found no correlation between 677C→T and NTDs, another study (157) of 271 NTD cases and 242 controls, found a higher prevalence of the TT genotype in the cases (18.8%) than in the controls (8.3%; P = 0.0005). These findings suggest that raising MTHFR activity through riboflavin administration may complement the action of periconceptional folic acid, especially because most women carrying affected embryos have plasma and red blood cell folate concentrations well above the clinically deficient range (172). Supporting evidence for this hypothesis may come from 2 Hungarian studies that showed a multivitamin (containing 800 g folate) was more efficient than was folate alone (6 mg) in preventing the first occurrence of an NTD (173).

NTDs是最常见的遗传畸形之一,传统上是通过补充叶酸来预防的。据估计,爱尔兰TT基因型所致NTDs的比例为11.4%。同型半胱氨酸血症与NTDs有关,尽管有一些研究发现677 c→T与NTDs无相关性,另一项研究在271例NTD病例和242例对照中,发现TT基因型在病例中的患病率(18.8%)高于对照组(8.3%;p=0.0005)。这些发现提示,通过核黄素的应用来提高MTHFR的活性可能是对叶酸的补充作用,特别是因为大多数携带受感染胚胎的妇女血浆和红细胞叶酸的浓度远远高于临床缺乏的范围。支持这一假说的证据可能来自匈牙利的两项研究这表明复合维生素(含800克叶酸)比叶酸单独(6毫克)预防首次发生NTD更有效。

A positive relation between elevated homocysteine and cardiovascular disease risk has been clearly established. However, most of the > 20 studies looking at the relation of the 677C→T polymorphism to cardiovascular disease risk failed to find a positive correlation. This failure has been attributed to a lack of statistical power to detect the added risk due to the mild homo-cysteine elevation associated with the TT genotype (174). A positive correlation of cardiovascular disease with the TT geno-type was found in patients with end-stage renal disease (175),familial hypercholesterolemia (176), and cardiovascular disease alone (156, 177, 178).


Two studies, involving 57 and 157 cases, respectively, showed the 677C→T mutation to be more prevalent among mothers of children with Down Syndrome than among control mothers (with odds ratios of 2.6 and 1.9, respectively) (158, 179). Trisomy 21 is due to maternal nondisjunction 93% of the time, and it is possible that the maternal polymorphism leads to altered folate metabolism, DNA hypomethylation, and abnormal chro-mosomal segregation. In fact, a positive correlation between the 677C→T genotype and DNA hypomethylation was been found in leukocytes of individuals with the polymorphism (180). DNA methylation was directly and significantly related to red blood cell folate concentrations in persons with the TT genotype, but not in those with wild-type MTHFR.


The 677C→T polymorphism and concomitant hyperhomocys-teinemia are also associated with diabetic nephropathy in patients with serum folate concentrations <15.4 nmol/L (P = 0.02) (160). Congenital cardiac malformations may be connected with the 677C→T polymorphism as well: 26 pregnancies compli-cated by fetal cardiac defects had higher amniotic homocys-teine concentrations and a higher incidence of the 677C→T polymorphism than found in 116 normal pregnancies (161). TT homozygosity is more common in infants with congenital heart disease than in control infants (181). Additionally, a higher incidence of TT was found in patients with dementia (25%) than in control subjects (12%) (162). When only study participants with hyperhomocysteinemia (concentrations ≥15 mol/L) were considered, the percentage of TT in the dementia group rose to 43% (compared with 14% in the control group), suggesting that 677C→T and homocysteine are risk factors for dementia.


Other mutations in MTHFR also seem to affect FAD binding and may be remedied with high-dose riboflavin treatment. The E. coli homologue of the human mutation, Arg157→Gln, displays defective flavin binding (165). Two other mutations in MTHFR, 985C→T and 1015C→T, identified in 2 patients may also decrease the binding of the FAD cofactor (182). Rosenblatt and Erbe previously studied these 2 patients and found that reductase activity was much less stable at elevated temperatures in the absence of added FAD than with the addition of 72 mol FAD/L (183). They concluded that, “There is a mutationally induced structural defect in the aporeductase as the basis for the observed alteration in thermostability, presumably reflecting reduced ability to bind the FAD cofactor” (183).

MTHFR的其他突变似乎也会影响FAD结合,并可通过大剂量核黄素治疗加以补救。人突变Arg 157→Gln的大肠杆菌同源性显示Flavin结合有缺陷。Rosenblatt和Erbe先前对这2例患者进行了研究,发现在没有添加FAD的情况下,还原酶活性在升高的温度下 比在而添加72 mol FAD/L的环境下更不稳定。他们的结论是,作为观察到的热稳定性变化的基础,脱还原酶存在突变性结构缺陷,可能反映了结合fad辅助因子的能力降低

The TT genotype has been associated with increased homo-cysteine concentrations (especially in persons with low plasma folate) (184, 185). Clinical trials of the interventions of folate, vitamins B-6 and B-12, and high-dose riboflavin treatment would be of interest in patients with the 677C→T polymorphism or any of the accompanying conditions including migraine and diabetic nephropathy.

TT基因型与同型半胱氨酸浓度升高有关(尤其是在血浆叶酸水平较低的人群中,)叶酸、维生素B-6和B-12的干预措施以及大剂量核黄素治疗的临床试验将对677 c→T多态性患者或任何伴随的cond患者感兴趣。偏头痛和糖尿病肾病。

NAD(P):quinone oxidoreductase 1: urothelial tumor risk, leukemia risk, benzene-induced hematoxicity risk
NAD(P):醌氧化还原酶1 :尿路上皮肿瘤的风险,白血病风险,苯诱导造血风险

NAD(P):quinone oxidoreductase 1 [NQO1; NAD(P)H dehy-drogenase (quinone)] utilizes NAD and FAD cofactors to catalyze the 2-electron reduction of quinones and quinonoid compounds to hydroquinones (see OMIM 125860). Normal NQO1 activity is involved in both detoxification and chemoprotection as well as in the bioactivation of some compounds, including cytotoxic antitumor agents. A polymorphic mutation in NQO1, 609C→T(TT frequency: 4–20%), which results in a Pro187→Ser amino acid substitution, has been associated with an increased risk of urothelial tumors, therapy-related acute myeloid leukemia, cuta-neous basal cell carcinomas, pediatric leukemias, and the devel-opment of benzene-induced hematoxicity in exposed workers (186).

NAD(P):醌氧化还原酶1[NQO1; NAD(P)H 脱氧核糖核酸酶(醌)】利用NAD和FAD辅助因子催化醌类和醌类化合物的2-电子还原制氢醌(see OMIM 125860). 正常的NQO 1活性参与解毒和化学保护以及某些化合物的生物活性,包括细胞毒性抗肿瘤药物。NQO 1,609 C→T的多态性突变(TT频率:4~20%),其导致PRO187或Ser氨基酸取代,会增加患尿路上皮肿瘤的风险,治疗相关的急性髓系白血病,基底细胞癌,儿童白血病,和苯对接触工人血液毒性的影响。

The data concerning an association between lung cancer risk and NQO1 genotype are contradictory. Some studies found the wild-type allele (C609) to be overrepresented in lung cancer cases relative to control subjects (187, 188), suggesting a chemo-protective role of the polymorphism (T609). In contrast, other studies found either the opposite to be true (189, 190) or that no correlation exists (191). The latter study was the largest of the NQO1 genotype and lung cancer risk studies to date, comprising 814 lung cancer patients and 1123 control subjects.

关于肺癌风险与NQO1基因型之间的关联的数据是矛盾的。一些研究发现,与对照组相比,肺癌病例中野生型等位基因(C 609)的表达过高。提示多态具有化学保护作用。相反,其他的研究发现两者都是相反的或者说不存在相关性。后一项研究是迄今为止最大的NQO 1基因型和肺癌风险研究,包括814名肺癌患者和1123名对照者。

The polymorphism results in reduced amounts of the NQO1 protein, possibly as the result of to an accelerated degradation via the ubiquitin pathway. The mutant expressed in E. coli has between 2% and 4% of the activity of the wild-type enzyme (186). The cause of both of these observations is likely to be an aber-rant binding of FAD by the mutant enzyme. The Pro187→Ser mutation disturbs the structure of the central parallel -sheet (192), resulting in a reduction in binding affinity for the FAD cofactor (193). Others found that NQO1 activity can be measured only in the presence of increased concentrations of FAD, confirming that the impairment of activity in the Pro187→Ser enzyme is due to lowered FAD affinity (Ivonne Rietjens, unpub-lished observations, 2001).
这种多态性导致NQO 1蛋白的数量减少,可能是通过泛素途径加速降解的结果。在大肠杆菌中表达的突变体具有2%~4%的野生型酶活性。这两种观察的原因很可能是突变酶对FAD的快速结合。Pro187→Ser突变干扰了中心并行片的结构。导致与FAD辅助因子结合的亲和力降低,另一些人认为,只有在FAD浓度增加的情况下才能测量NQO 1的活性,证实Pro187→Ser酶活性受损是由于FAD亲和力降低所致(Ivonne Rietjens, unpub-lished observations, 2001).

These data suggest that individuals with the NQO1 polymor-phism might benefit from high-dose riboflavin treatment by reductions in cancer risk. Further studies should be done to verify or reject this theory.

这些数据表明,具有NQO 1多聚物的个体可能通过降低癌症风险而受益于大剂量核黄素治疗。应该做进一步的研究来验证或否定这一理论。

Protoporphyrinogen oxidase: variegate porphyria and motor neuropathy

Protoporphyrinogen oxidase, a mitochondrial flavoprotein, catalyzes the oxygen-dependent oxidation of protoporphyrinogen IX to protoporphyrin IX, the penultimate step in the heme biosynthetic pathway. Protoporphyrinogen oxidase deficiency results in variegate porphyria (see OMIM 176200), which involves various neuropsychiatric symptoms, including bulbar paralysis, quadriplegia, and motor neuropathy. Protoporphyrinogen oxidase shares significant homologies with several oxidases (eg, monoamine oxidases) that contain an FAD binding motif at the amino terminus (194). The Arg59→Trp mutation, one of fewer than a dozen mutations reported in the gene encoding pro-toporphyrinogen oxidase to date and common in South Africa [because of to a 17th century Dutch immigrant founder effect (195)], affects the FAD binding motif and is suspected to alter the FAD binding affinity of protoporphyrinogen oxidase. A sim-ilarity is postulated to X-linked sideroblastic anemia, which has been successfully treated with pyridoxine (see the discussion of ALAS2 in the section on pyridoxine). A similar approach with riboflavin supplementation may be useful in the treatment of persons with variegate porphyria whose mutations affect the FAD binding region of protoporphyrinogen oxidase (194).

原卟啉原氧化酶,一种线粒体核黄素蛋白,催化氧依赖氧化原卟啉原Ⅸ至原卟啉Ⅸ,血红素生物合成途径的倒数第二步.原卟啉原氧化酶缺乏导致杂色卟啉症(见OMIM 176200),涉及各种神经精神症状,包括球麻痹、四肢瘫痪和运动神经病变。原卟啉原氧化酶与几种氧化酶有显著的同源性(如单胺氧化酶),含有一个FAD结合基序,在氨基端,Arg59是TRP突变,目前为止,在南非发现的编码前拓扑卟啉原氧化酶的基因中,有一种突变是常见的[由于17世纪荷兰移民的创立者效应],影响FAD结合基序,可能改变原卟啉原氧化酶的FAD结合亲和力。X-连锁铁粒细胞性贫血被认为是一种相似的缺乏症,这种贫血已经被成功地用吡多辛治疗了(见关于吡多辛一节中对ALAS 2的讨论)。一种类似的核黄素补充方法可能有助于治疗那些突变影响原卟啉原氧化酶fad结合区的杂色卟啉病患者。

Electron-transferring-flavoprotein and electron-transferring-flavoprotein ubiquinone oxidoreductase: glutaric aciduria type II and myopathy


Electron-transferring-flavoprotein [ETF; which contains an  (see OMIM 231680) and a  βsubunit (see OMIM 130410)] and electron-transferring-flavoprotein ubiquinone oxidoreductase (ETF-QO, see OMIM 231675) are 2 mitochondrial proteins that use FAD coenzymes. The enzymes mediate the transfer of electrons from mitochondrial flavoprotein dehydrogenases (see the discussion of short-chain, medium-chain, and long-chain acyl-CoA dehydrogenases below) to ubiquinone. Metabolic diseases characterized by defects in the mitochondrial oxidation of acyl-CoA esters involved in the metabolism of fatty acids and branched-chain amino acids are often ameliorated by feeding high riboflavin.

电子传递黄素蛋白[ETF;其中包含(见OMIM 231680)β亚组】和电子传递黄素蛋白泛醌氧化还原酶(etf-qo,见omim 231675)是使用FAD辅酶的2种线粒体蛋白。这些酶介导线粒体黄蛋白脱氢酶电子的转移至泛醌(见下文对短链、中链和长链酰基辅酶的讨论)。以酰基辅酶A线粒体氧化缺陷为特征的代谢性疾病参与脂肪酸和支链氨基酸代谢的酯类通常通过喂食高核黄素而得到改善。

Glutaric aciduria II is characterized clinically by hypoglycemia, metabolic acidosis, myopathy, and stridor and biochemically by the accumulation of metabolites, such as glutaric acid. Electron transfer from 9 primary flavoprotein dehydrogenases to the main respiratory chain is impaired in this disease. In most cases, the disorder is due to a deficiency of either ETF or ETF-QO; treatment with oral riboflavin (100–300 mg/d) has been particu-larly effective in a few patients. It has been suggested that increased FAD concentrations might help some patients over-come a defect in coenzyme binding by ETF or ETF-QO (196).

戊二酸尿的临床特征是低血糖,代谢性酸中毒,肌病,以及代谢产物的积累,例如戊二酸。呼吸链上电子传递 的9种主要的黄素蛋白脱氢酶是受损的,在大多数情况下,这种紊乱是由于缺乏ETF或ETF-QO;口服核黄素治疗(100至300毫克/日)在少数患者中特别有效。研究表明,fad浓度的增加可能有助于一些患者克服etf或etf-qo在辅酶结合方面的缺陷。

The crystal structure of human ETF was solved to study 2 mutations seen in patients with glutaric aciduria II:

Thr266→Met and  Gly116→Arg, the former being the most common in ETF-deficient patients (197). The structure shows  Thr266 to be within hydrogen-bonding distance of the N-5 of the FAD cofactor; the C-4 carbonyl oxygen of FAD resides in similar proximity to the amide nitrogen of  Thr266 (198). The  Thr266→Met mutant alters the flavin environment. Salazar et al (197) concluded, “The loss of the hydrogen bond at N(5) of the flavin and the altered flavin binding increase the thermodynamic stability of the flavin semiquinone by 10-fold relative to the semiquinone of wild-type ETF.…However, kcat/Km [a measure of catalytic activity] of ETF-QO in a coupled acyl-CoA:ubiquinone reductase assay with oxidized [Thr266→Met] ETF as substrate is reduced 33-fold.”

苏氨酸 266→Met和甘氨酸 116→精氨酸,前者是etf缺乏患者中最常见的。结构显示FAD辅助因子苏氨酸266,与N-5距离氢键结合,FAD的C-4羰基氧,与Thr 266的酰胺氮相似。苏氨酸266→Met突变,在黄素环境下。Salazar 等人得出结论,Flavin在N(5)处氢键的丢失和Flavin结合的改变使Flavin半醌的热力学稳定性提高了10倍相对于野生型ETF的半醌类……然而,以氧化的[Thr 266→Met]ETF为底物的ET-QO在偶联酰基辅酶A中的kcat/kM[催化活性]降低了33倍。

A 29-y-old woman with aciduria who suffered from head-aches, depression, and seizures responded markedly to riboflavin (100 mg/d) (199). Cultured fibroblasts collected before treatment showed residual oxidation of palmitate of between 66% and 52% of control fibroblasts. These investigators concluded, “The biochemical response to riboflavin we observed is consistent with the stabilization of a defective ETF or ETF-QO by increased levels of intramitochondrial FAD” (199). Five ETF-QO mutations identified in four patients with glutaric aciduria II were rare and resulted in a total lack of enzyme activity (200).


Cell lines from patients with glutaric aciduria II showed significantly lower mitochondrial oxidation of glutarate and ETF activity (201). The addition of FAD increased ETF activity from 4% to 21% of control in a cell line from one patient. The increase in ETF activity in this cell line may have resulted from FAD binding to an ETF apoenzyme with a lowered affinity for the cofactor, thus partially restoring enzymatic activity.


A child with brain damage induced by glutaric aciduria II responded to riboflavin therapy at the age of 4 y with consistent and rapid improvement (202). Several other cases of aciduria that responded to riboflavin have been reported in the literature, though the exact enzymatic defect is not always clear (203, 204).


Glutaric aciduria II was assessed through clinical follow-ups in 7 patients, 2 with the neonatal-onset form with congenital anomalies, 3 with the neonatal-onset form without congenital anomalies, and 2 with the late-onset form (205). The neonatal form frequently results in rapid death. All 7 patients received a diet low in fat and protein in addition to oral riboflavin and car-nitine. The results were promising for the late-onset disease, because the 2 children appeared to be growing normally and experiencing complications only with the consumption of food rich in fat or protein. One of the patients with the neonatal-onset form without congenital anomalies responded clinically and bio-chemically to intravenous carnitine (200–300 mg · kg1 · d1) and oral riboflavin (100 mg · kg1 · d1).

对7例戊二酸尿进行了临床随访,2新生儿发病形式伴先天性异常,3新生儿发病形式,无先天性异常,和2例晚发形式,新生儿形态常常导致快速死亡。除口服核黄素和卡尼汀外,所有7例患者均接受低脂低蛋白饮食。结果对于晚发性疾病是有希望的,因为2名儿童似乎在正常生长只有食用富含脂肪或蛋白质的食物才会出现并发症。1例无先天性异常的新生儿起病患者临床上有反应以生物化学方法静脉注射卡尼汀(200~300 mg·kg1·d1)和口服核黄素(100 mg·kg1·d1)。

A 470T→G transversion was identified in the subunit of a patient’s ETF whose cultured cells showed ETF deficiency (206). Reduced ETF was found in the cells despite its being synthe-sized at a normal rate. It was suggested that ETF confers stability on ETF when they bond and that the instability of the mutant ETF could be attributed to its inability to bind with ETF because of drastic conformational changes. In another study, a defect in ETF biosynthesis in a patient with glutaric aciduria II was revealed by pulse labeling techniques (207).

A 470T→G转换在病人的ETF的亚单位中被发现,其培养细胞显示ETF缺乏症。减少的ETF被发现在细胞中,尽管它是同步大小的正常速率。有人认为,etf在与etf结合时会给etf带来稳定性,而变体etf的不稳定性可能是由于其无法与etf结合所致,因为巨大的构象变化。在另一项研究中,用脉冲标记技术揭示了一例戊二酸尿患者ETF生物合成的缺陷。

Peroxisomal glutaryl-CoA oxidase: glutaric aciduria type III Investigation of cultured skin fibroblasts showed that the defect in a girl who responded to riboflavin was in peroxisomal glutaryl-CoA oxidase (see OMIM 231690) and not in ETF or ETF-QO, as in most patients with glutaric aciduria. Glutaric aciduria III in this patient was caused by a peroxisomal rather than by a mitochondr-ial dysfunction (208).

过氧化物酶戊二酰辅酶A:戊二酸尿Ⅲ型培养皮肤成纤维细胞的研究发现,一名对核黄素有反应的女孩的缺陷是过氧化物酶体戊二酰辅酶(见OMIM 231690)而不是ETF或ETF-QO,与大多数戊二酸尿患者一样。戊二酸尿Ⅲ型是由过氧化物酶体引起,而非有丝分裂功能障碍所致。

Short-chain, medium-chain, and long-chain acyl-CoA dehydrogenases: multiple acyl-CoA dehydrogenase deficiency, seizures, and neuromuscular disorders Short-chain (SCAD; butyryl-CoA dehydrogenase), medium-chain (MCAD; acyl-CoA dehydrogenase), and long-chain acyl-CoA dehydrogenases (see OMIM 201470, 201450, and 201460) use FAD to catalyze the first steps in the -oxidation of acyl-CoA substrates, which result in the transfer of electrons to ETF. Defects in the 3 acyl-CoA dehydrogenases, in addition to ETF and ETF-QO defects, have been implicated in multiple acyl-CoA dehydrogenase deficiency. All 5 are mitochondrial proteins. The resulting urinary accumulation of ethylmalonate, methylsucci-nate, and butyrylglycine is associated with neuromuscular dys-function and seizures.

短链、中链和长链酰基辅酶A脱氢酶:多种酰基-辅酶A脱氢酶缺乏、癫痫发作和神经肌肉疾病短链(SCAD;丁酰-CoA脱氢酶),中链(mcad;酰基-coa脱氢酶)和长链酰基-coA脱氢酶(见OMIM 201470、201450和201460)利用FAD催化酰基-CoA底物氧化的第一步,导致电子向ETF转移。3-酰基-CoA脱氢酶中的缺陷,除ETF和ETF-QO缺陷外,涉及多个acyl-CoA脱氢酶缺乏。所有5种都是线粒体蛋白。由此产生的尿路积乙丙二酸、丁二酸甲酯和丁酸甘氨酸与神经肌肉功能障碍和癫痫发作有关。

Epileptic seizures were reported in a child carrying a Gly209→Ser mutant SCAD, resulting from the DNA mutation 625G→A (209). This SCAD polymorphism has been postulated to lower FAD affinity and occurs in 35% of individuals (AA = 4% of control population, AG = 31% of control popula-tion). The symptoms disappeared, with rapid and permanent improvement of the child’s condition, with the administration of 25 mg riboflavin/kg, later lowered to 10 mg · kg1 · d1. The authors speculated that the amino acid change affects the folding efficiency of the variant SCAD or influences the interaction of SCAD with its FAD cofactor.

据报道,一名携带Gly 209→Ser突变体的儿童癫痫发作,由625 g→A突变引起的。这种SCAD多态性被认为降低了fad亲和力,并在35%的个体中发生。(AA=对照种群的4%,AG=对照种群的31%。)随着儿童病情的迅速和永久改善,症状消失,注射核黄素25 mg/kg,随后降至10 mg·kg1·d1。推测氨基酸的变化影响变异体SCAD的折叠效率,或影响SCAD与FAD辅助因子的相互作用。
In another case report, SCAD and MCAD activities were 35% of normal in a 12-y-old girl (210). Western blot analysis showed the absence of SCAD and decreased MCAD but normal amounts of ETF. Although unresponsive to carnitine, the patient showed a marked improvement with 100 mg riboflavin/d with a concomitant normalization of SCAD activity and a reappearance of SCAD protein in Western blots. MCAD activity and protein amounts remained low. It is possible that a mutation decreased the stability and that riboflavin increased enzyme stability. Although it is also possible that the patient had an altered riboflavin metabolism resulting in lower mitochondrial FAD concentrations, the authors speculated that “the different effects of riboflavin deficiency on SCAD, MCAD, and possibly ETF and [ETF-QO] could be explained by the different affinities of FAD for the flavoprotein apoenzymes” (210). An FAD-related acyl-CoA dehydrogenation defect was also suspected in a patient with MCAD and SCAD deficiency who responded to 3   100 mg riboflavin/d (211).


An 11-mo-old boy with a mild variant of multiple acyl-CoA dehydrogenase deficiency (ethylmalonic-adipic aciduria) received 200 mg riboflavin/d, leading to dramatic clinical improvement with a restoration of normal respiration and an increase in muscu-lar tone within 2 mo (212). Riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency was confirmed in cultured fibroblasts, which showed increased enzymatic activity in the presence of 1 g riboflavin/L (265 nmol/L).

一名11岁男孩患有轻度的酰基-辅酶A脱氢酶缺陷(乙基丙二酸尿),每天服用200毫克核黄素,在2mo内恢复正常呼吸和增加肌肉张力,使临床有了显著的改善。培养成纤维细胞核黄素反应多酰基辅酶A脱氢酶缺陷,当核黄素浓度为1 g/L(265 nmol/L)时,酶活性增强。

Another case report described a male infant diagnosed with multiple acyl-CoA dehydrogenase deficiency who exhibited marked improvement through the administration of riboflavin (100 mg/d) and Lcarnitine (1000 mg/d) (213). The child showed normal development (up to the age of 10 y) and was suspected of harboring an ETF-QO deficiency, although defects in SCAD, MCAD, and long-chain acyl-CoA dehydrogenase could also be responsible.


TABLE 4 Enzymes that use a thiamine pyrophosphate (TPP) cofactor1
Defective enzyme and EC no.
Reaction catalyzed
Disease or condition
OMIM no.
Branched-chain _x0007_-ketoacid dehydrogenase
Mitochondrial matrix
_x0007_α-Keto acids → acyl-CoA + CO2
Maple syrup urine disease (branched-chain ketoaciduria) and buildup of BCAAs (leucine, isoleucine, and valine) in blood and urine
Autosomal recessive
Pyruvate decarboxylase (
Mitochondrial matrix
Pyruvate → acetyl-CoA + CO2
Leigh disease and lactate and pyruvate buildup in serum
Thiamine transporter SLC19A2
Integral membrane protein
Megaloblastic anemia, diabetes mellitus, and sensorineural deafness
Autosomal recessive
Thiamine pyrophosphokinase (
ATP + thiamine → AMP + TPP
Megaloblastic anemia, diabetes mellitus, and sensorineural deafness
Autosomal recessive
_x0007_α-Ketoglutarate dehydrogenase
Mitochondrial matrix
_x0007_α-Ketoglutarate + CoA + NAD →succinyl-CoA + CO2 + NADH
Megaloblastic anemia, diabetes mellitus, and sensorineural deafness
Autosomal recessive
1 BCAA, branched-chain amino acid; OMIM, Online Medelian Inheritance in Man (4).

TABLE 5 Enzymes that use an FAD or FMN (riboflavin) cofactor1 使用fad或FMN(核黄素)cofactor 1的酶
Defective enzyme and EC no.
Reaction catalyzed
Disease or condition
OMIM no.
Methylenetetrahydrofolate reductase
5,10-Methylene-THF + NADPH → 5-methyl-THF + NADP
Homocystinemia, 高胱氨酸血,cardiovascular disease,migraine, diabetic nephropathy,and congenital cardiac malformations
Autosomal recessive
NAD(P):quinone oxidoreductase 1 (
Reduction of quinones and quinonoid compounds to hydroquinones
Risk of leukemia and urothelial tumor
Autosomal recessive常染色体隐性
Protoporphyrinogen oxidase
Bound to inner mitochondrial membrane
Protoporphyrinogen IX + O2 →protoporphyrin IX + H2O2
Variegate porphyria and neuropsychiatric complications, including motor neuropathy
Autosomal dominant
Electron-transferring-flavoprotein and electron-transferring-flavoprotein ubiquinone oxidoreductase (
Inner mitochondrial membrane (ETF-QO)
Electron flow: reduced acyl-CoAdehydrogenases → ETF → ETF-QO
Glutaric aciduria type II, myopathy, metabolic acidosis, and hypoglycemia
Autosomal recessive
Peroxisomal glutaryl-CoA oxidase
Glutaric aciduria type III
Autosomal recessive
Short-chain, 短链,medium-chain,中链, and long-chain long-chain
acyl-CoA dehydrogenases
Mitochondrial matrix
Acyl-CoA + ETF → 2,3-dehydroacyl-CoA + reduced
Multiple acyl-CoA dehydrogenase deficiency,seizures, failure to thrive, metabolic acidosis,and neuromuscular disorders
201470,201450, 201460
Autosomal recessive
Mitochondrial complex I (
Mitochondrial membrane
Electron transport enzyme
Complex I deficiency and myopathy
Autosomal recessive
Complex I (mitochondrial transfer RNA Leu mutations)
复合体I(线粒体转移RNA 亮氨酸突变 )
Mitochondrial membrane
Electron transport enzyme
Complex I deficiency and MELAS
1 ETF, electron-transferring-flavoprotein dehydrogenase; ETF-QO, electron-transferring-flavoprotein ubiquinone oxidoreductase; MELAS, mitochondrial encephalomyopathy, lactic acidosis, and stroke-
like episodes; OMIM, Online Mendelian Inheritance in Man (4); THF, tetrahydrofolate.

Mitochondrial complex I: myopathy Defects in mitochondrial complex I [NADH dehydrogenase (ubiquinone)] cause myopathies (see OMIM 252010). Decreased affinity for the FMN cofactor may explain the cases of riboflavin responsiveness.


In 5 patients with a mitochondrial myopathy associated with a complex I deficiency, riboflavin (35–60 mg/d) was effective in 3 patients, with a normalization of enzymatic activity (214). In cultured fibroblasts from a patient with an Arg228→Gln mutation in the complex I subunit encoded by the nuclear NDUFS2 gene, the addition of riboflavin was able to significantly increase ATP production (215). Because the NDUFS2-encoded protein does not contain an FMN binding site, it was suggested that the mutation either interfered with the interaction between a flavo-protein and FMN or that riboflavin has a general stabilizing effect on complex I. In a survey of 9 patients with complex I deficiency, the myopathy of 1 patient dramatically improved dur-ing treatment with riboflavin (9 mg/d) and L-carnitine (216). Complex I activity rose 17-fold to normal levels after 7 mo of therapy. Several other cases of riboflavin-responsive complex I myopathies have likewise been reported (217, 218).

5例线粒体肌病合并复杂I型缺乏症,核黄素(35~60 mg/d)有效3例,酶活性正常。在培养的成纤维细胞中,NDUFS 2基因编码的复杂I亚基存在Arg 228→Gln突变,核黄素的加入能显著提高ATP的产量。因为NDUFS 2编码的蛋白质不包含FMN结合位点,结果表明,该突变或干扰了黄酮蛋白与FMN的相互作用,或核黄素对配合物I具有一般的稳定作用。在对9例复杂I型缺乏症患者的调查中,1例肌病明显改善了核黄素(9mg/d)和L-肉碱的治疗效果。治疗7mo后,复合物I活性提高17倍,降至正常水平。另外几例核黄素应答复合物Ⅰ型肌病也有报道。

Mitochondrial defects were analyzed in 3 patients from a large consanguineous family and in 1 unrelated patient who all had exercise intolerance since early childhood and complex I deficiencies (218). Supplementation with 100 mg riboflavin/d resolved many clinical complications. A biopsy taken in one of the patients after 2 y of riboflavin therapy showed an increase in complex I activity from 16% to 47% of control.

3例大血亲家系线粒体缺陷分析在1例无血缘关系的患者中,他们从小就有运动不耐受和复杂的I型缺陷。添加100 mg核黄素/d可缓解临床并发症。其中一位患者在接受核黄素治疗2y后的活检显示复合I活性从对照组的16%提高到47%。

Mitochondrial transfer RNA leucine (UUR): complex I deficiency, MELAS syndrome, migraine, and myopathy A 32-mo-old patient with a complex I deficiency, an associated myopathy, and a 3250T→C mutation in the gene for mitochondr-ial transfer RNA (tRNA) leucine (UUR) (see OMIM 590050; also discussed in the section on niacin) had a sustained clinical response to riboflavin (50 mg/d) (219). The authors refer to reports of riboflavin being effective in 11 patients with complex I deficiency, although the underlying cause was not known in these cases. Another patient with a mutation (3243A→G) in the same mitochondrial gene for tRNA leucine (UUR), who initially pre-sented with MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) syndrome at age 19, had pre-viously responded to a mixture of riboflavin and nicotinamide, although the vitamins were not tested individually (220).

线粒体转移RNA亮氨酸(UUR):复杂I型缺乏症,梅拉斯综合症,偏头痛和肌病一位32岁的复杂I型缺乏症患者,一种相关的肌病,线粒体转移RNA基因的3250 T→C突变(TRNA)亮氨酸(UUR)(见OMIM 590050;也在关于烟酸的一节中讨论)对核黄素(50毫克/天)有持续的临床反应。作者提到了11例复杂I型缺乏症患者核黄素有效的报道,尽管在这些病例中根本原因尚不清楚。另一例trna亮氨酸线粒体基因突变(3243 3A→G)的患者,他们最初接受了mLAS治疗。(线粒体脑肌病、乳酸酸中毒和中风样发作)在19岁的时候,曾经对核黄素和烟酰胺的混合物有反应,尽管没有单独测试维生素。

Thirteen electron transport chain proteins are coded for and synthesized in the mitochondria, of which 7 contribute to complex I. If the tRNA mutations incur a poor fidelity of leucine incorporation during mitochondrial translation, it is plausible that complex I would be more prone to defects than would other complexes. Another possible explanation for the specific complex I defect is that there is a critical leucine in a cofactor binding site of complex I that is incorporated into the complex I peptide with only moderate fidelity. FMN is an important cofactor for complex I, which could explain why riboflavin responsiveness has been reported in patients with these tRNA mutations.


Of the 3 mitochondrial encephalomyopathies [MELAS, myoclonus epilepsy associated with ragged-red fibers (MERRF), and chronic progressive external ophthalmoplegia (CPEO)] the mitochondrial mutation 3243A→G appears to be specific to MELAS patients; it was found in 26 of 31 MELAS patients and in 1 of 29 CPEO patients and was absent in 5 MERRF patients and 50 control subjects (221). Migraine can be a prominent fea-ture in patients affected by mitochondriopathies such as MELAS syndrome and has been treated with high doses of riboflavin (169; see also the discussion of MTHFR above).

线粒体脑肌病的3种[MELAS,肌肉阵发性癫痫与粗糙的红色纤维(MERRF),及慢性进行性外眼肌麻痹(CPEO)]线粒体突变3243 3A→G可能是特异性的MELAS患者;在31例MELAS患者中有26例和29例CPEO患者中有1例未发现,在5例MERRF患者和50例正常人中未发现。偏头痛是线粒体病(如MELAS综合征)患者的突出表现,并已接受大剂量核黄素治疗。

Methionine synthase reductase: homocystinuria and mental retardation
See the discussion in the section on cobalamin.
Dihydrolipoamide dehydrogenase: lactic acidosis See the discussion in the section on lipoic acid.


Tissue concentrations and toxicity 组织浓度和毒性
No UL has been defined for riboflavin intake because there have been few reports of adverse effects with doses in the hun-dreds of milligrams (7). A migraine study mentioned above recorded 2 adverse effects of 400 mg riboflavin/d—diarrhea and polyuria—in 2 of 28 patients (169).


The rate of absorption of riboflavin is proportional to intake and increases when riboflavin is ingested along with other foods (7). In a small group of cirrhosis patients, a single 40-mg oral dose of riboflavin was shown to raise plasma riboflavin 13.7-fold and flavocoenzymes 1.4-fold over baseline (222). A randomized clinical trial determined that the maximum amount of riboflavin that can be absorbed from a single oral dose is 27 mg for adults (223). Thus, the percentage of high doses of vitamins that is actually taken up in plasma or cells depends strongly on mode and fre-quency of dosage delivery.


NIACIN (VITAMIN B-3) 烟酸 (维生素B-3)

The DRI for niacin is 16 mg niacin equivalents/d for men and 14 mg equivalents/d for women (7), where 1 niacin equivalent is 1 mg niacin obtained through the diet or the metabolism of tryptophan. The term niacin is often used synonymously with nicotinic acid. Nicotinamide, the amide form of nicotinic acid, is a building block for both nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP) (7). Rossmann folds are  strands connected by  helix crossover elements and compose nucleotide binding sites. They appear to be the most important structure for NAD(P) binding in at least one group of NAD(P)-dependent proteins. Common motifs include the GxxxGxG phosphate binding pattern of glycines (where x is any amino acid), a ribose binding aspartate, and a nicotinamide-ribose binding YxxxK motif. The adenine binding motif found in many FAD binding proteins was found in only a few NAD(P) binding proteins (150). The following NAD-dependent enzymes are summarized in Table 6.


Mitochondrial aldehyde dehydrogenase (NAD+): alcohol intolerance and flushed face in Asians, alcohol-induced vasospastic angina, Alzheimer disease, and oral, esophageal, and stomach cancer

线粒体醛脱氢酶 (NAD+):亚洲人对酒精的不容忍和脸红,酒精引起的血管紧张性心绞痛,阿尔茨海默病、口腔癌、食道癌和胃癌

Mitochondrial aldehyde dehydrogenase (NAD+) (ALDH2) catalyzes the NAD-dependent oxidation of acetaldehyde, which is formed by the oxidation of ethanol by alcohol dehydrogenase (see OMIM 100650). The single genetic factor most strongly correlated with reduced alcohol consumption and incidence of alcoholism is the naturally occurring variant of ALDH2, which contains a Glu487→Lys substitution. The Lys487 allele of ALDH2 (also called ALDH2*2) is found in 50% of the Asian population and is associated with a phenotypic loss of ALDH2 activity in both heterozygotes and homozygotes. ALDH2-deficient individuals exhibit an adverse response to ethanol consumption, which is probably caused by elevated concentrations of blood acetalde-hyde (224). The Glu487→Lys variant has been shown to exhibit a 150-fold increase in Km for its NAD cofactor (225).

线粒体醛脱氢酶(NAD)(ALDH 2)催化乙醛的NAD依赖氧化,乙醇由乙醇脱氢酶氧化而成 (see OMIM 100650). 与减少饮酒和酗酒发生率密切相关的单一遗传因素是自然发生的ALDH 2变异体,其含有Glu487或Lys取代。在50%的亚洲人群中发现了ALDH 2的Lys 487等位基因(又称ALDH 2*2)与杂合子和纯合子ALDH 2活性的表型丧失有关。ALDH 2缺乏的个体对乙醇消费表现出不良反应,这可能是由于血中乙酰丙氨酸-海德浓度升高所致。Glu487或Lys变体已显示出其NAD辅因子的Km增加了150倍。

High blood acetaldehyde is potentially carcinogenic and neu-rotoxic, and the correlation between Glu487→Lys and several cancers has been well established: deficient ALDH2 activity due to the polymorphism has been associated with oral cancer, esophageal cancer, stomach cancer, Alzheimer disease, and alco-hol-induced vasospastic angina.

高血乙醛具有潜在的致癌性和新毒性,Glu 487→Lys与几种癌症之间的相关性已经得到了很好的证实:ALDH 2基因多态性导致的ALDH 2活性缺失与口腔癌有关,食管癌,胃癌,阿尔茨海默病,以及铝引起的血管紧张性心绞痛。

ALDH2 and glutathione transferase M 1 polymorphisms were studied in 191 patients with oral cancer and in 121 control subjects without oral cancer who had a history of alcohol use (226). The incidences of inactive ALDH2 and glutathione transferase M 1 in the cancer group with an alcohol-drinking habit were 34.2% and 67.5%, higher than in the noncancer group with an alcohol-drinking habit (15.1% and 45.5%, respectively). Another study found the ALDH2*2 allele to be overrepresented in Japan-ese alcoholics with esophageal, stomach, and oropharyngolaryn-geal cancers (227), further illustrating the risk of developing cancer in individuals harboring the variant ALDH2 enzyme.

191例口腔癌患者ALDH 2和谷胱甘肽转移酶M1多态性的研究在121名无口腔癌病史的对照组中,他们有饮酒史。有饮酒习惯的癌症组ALDH 2和谷胱甘肽转移酶M1的发生率分别为34.2%和67.5%,有饮酒习惯的非癌症组高于非癌症组(分别为15.1%和45.5%)。另一项研究发现,ALDH 2*2等位基因在伴有食道癌、胃癌和口咽管癌的日本酗酒者中过度表达。进一步说明携带变异ALDH 2酶的人患癌症的风险。

The polymorphism is also a risk factor for late-onset Alzheimer disease. The frequency of the ALDH2*2 allele is 48.1% in late-onset Alzheimer disease patients (n = 447) com-pared with 37.4% in control subjects matched by sex, age, and region (P = 0.001) (228). The added risk was present in both men (P = 0.01) and women (P = 0.02). In addition, the APOE*E4 allele of the apolipoprotein E gene was confirmed as an inde-pendent risk factor for late-onset Alzheimer disease (P = 0.002). The odds ratio for late-onset Alzheimer disease in carriers of the ALDH2*2 allele was almost twice that in noncarriers. Among patients homozygous for the APOE*E4 allele, the age at onset of late-onset Alzheimer disease was significantly lower in those with than in those without the ALDH2*2 allele. In addition, dosage of the ALDH2*2 allele significantly affected age at onset of patients homozygous for the APOE*E4 allele. It would be of interest to determine whether long-term niacin use could prevent or delay the onset of Alzheimer disease or relieve present Alzheimer disease in patients with the polymorphism.

多态也是迟发性阿尔茨海默病的危险因素.迟发性阿尔茨海默病患者中ALDH 2*2等位基因频率为48.1%(n=447),与按性别、年龄和区域匹配的对照组的37.4%相比,差异有显着性(P=0.001)。男性(P=0.01)和女性(P=0.02)都有增加的风险。此外,载脂蛋白E基因的APOE*E4等位基因被证实为迟发性阿尔茨海默病的独立危险因素(P=0.002)。ALDH 2*2等位基因携带者迟发性阿尔茨海默病的优势比几乎是非携带者的两倍。在APOE*E4等位基因纯合子患者中,有ALDH 2*2等位基因者晚发性阿尔茨海默病发病年龄明显低于无ALDH 2*2等位基因者。此外,ALDH 2*2等位基因的剂量显著影响APOE*E4等位基因纯合患者的发病年龄。长期使用的烟酸是否可以预防或延缓阿尔茨海默病发作或缓解多态性患者中的阿尔茨海默病的研究将会非常有意义。

TABLE 6 Enzymes that use an NAD or NADP (niacin) cofactor 1

Defective enzyme and EC no.
Reaction catalyzed
Disease or condition
OMIM no.
Aldehyde dehydrogenase
(NAD+) (
Mitochondrial matrix
Aldehyde + NAD + H2O → acid + NADH
Cancer risk from high blood acetaldehyde
Autosomal dominant
Glucose-6-phosphate 1-dehydrogenase (
Glucose-6-phosphate + NADP →6-phosphogluconolactone + NADPH
Oxidation-induced hemolytic anemia, favism
6-phosphogluconolactone + NADPH
Complex I
(mitochondrial transfer RNA mutations)
Electron transport enzyme
Complex I deficiency, elevated blood lactate,and pyruvate
Dihydropteridine reductase (
NAD(P)H + BH2 → NAD(P) + BH4
Phenylketonuria II, hyperphenylalaninemia,and cognitive dysfunction
Autosomal recessive
Long-chain-3-hydroxyacyl-CoA dehydrogenase
Mitochondrial matrix
3-Hydroxyacyl-CoA + NAD → 3-oxoacyl-CoA + NADH
-Oxidation defect, hypoglycemia,cardiomyopathy, and sudden death
1 BH
2, dihydrobiopterin; BH4, tetrahydrobiopterin; OMIM, Online Mendelian Inheritance in Man (4).

Alcohol ingestion induced anginal attacks in 16 of 66 patients without the Glu487→Lys mutation, in 8 of 22 heterozygotes, and in 1 of 3 patients homozygous for the mutation (229). The intervals between alcohol ingestion and the onset of attacks were shorter in ALDH2*2 homozygotes (0.17 h) and heterozygotes (1.5 ± 0.6 h) than ALDH2*1 (ie, Glu487 allele) homozygotes (5.4 ± 0.6 h). The amount of ethanol that induced the attacks was significantly greater in control subjects (96.1 mL) than in ALDH2*2 homozygotes (11 mL) and heterozygotes (42.5 mL). Although the frequency of anginal attacks induced by alcohol ingestion did not differ between the ALDH-deficient and normal homozygotes, anginal attacks were induced in the ALDH-deficient patients by a smaller amount of alcohol. Thus, niacin intake may help to ameliorate some of the deleterious effects of alcohol con-sumption such as anginal attacks.

66例无Glu487→Lys突变的患者中,16例因酒精摄入引起的心绞痛发作,在22个杂合子中有8个,其中1例为纯合子突变(229).ALDH 2*2纯合子(0.17h)和杂合子(1.5±0.6h)与ALDH 2*1(Glu487等位基因)纯合子(5.4±0.6h)相比,摄入酒精的间隔时间缩短。对照组(96.1 mL)的乙醇量显著高于ALDH 2*2纯合子(11 ML)和杂合子(42.5 mL)。虽然ALDH缺乏的纯合子和正常的纯合子因酒精摄入引起的心绞痛发作的频率没有差别,在ALDH缺乏的患者中,少量酒精会引起心绞痛发作.因此,烟酸的摄入可能有助于改善酒精摄入的一些有害影响,如心绞痛袭击。

With use of concentrations of the glycated hemoglobin as an assay, the Glu487→Lys polymorphism was also suggested to be a risk factor for hyperglycemia in persons with diabetes (230, 231). However, the acetaldehyde adduct of hemoglobin may cochro-matograph with glycated hemoglobin and has not been ruled out as the cause of the findings. The amount of hemoglobin adducts formed is a function of the concentration and number of expo-sures to acetaldehyde (232).


A significant genetic difference was found in the ALDH2 gene between a group of Japanese patients with alcoholic pancreatitis and control subjects (233). The frequency of the ALDH2*1 allele was found to be 0.681 and that of the ALDH2*2 allele to be 0.319 in the control subjects; these values were 0.935 and 0.065 in the patients, respectively. Most of the patients (27 of 31) were ALDH2*1/2*1, only 4 were ALDH2*1/2*2, and none of the patients were ALDH2*2/2*2. These results indicate that genetic polymorphism of the ALDH2 gene decreases the risk of becom-ing an alcoholic and hence getting pancreatitis.

一组日本酒精性胰腺炎患者的ALDH 2基因与对照组相比有显著的遗传差异。对照组ALDH 2*1等位基因频率为0.681,ALDH 2*2等位基因频率为0.319;这些值分别为0.935和0.065。大多数患者(31人中27人)为ALDH 2*1/2*1,只有4人为ALDH 2*1/2*2,所有患者均为ALDH2*2/2*2。这些结果表明,ALDH 2基因的遗传多态性降低了酒精性胰腺炎的风险。

The Glu487→Lys polymorphism results in an ALDH2 enzyme with 8% enzymatic activity (234) and a 150-fold increased Km for NAD (225). Administration of nicotinic acid (235) or nicotinamide (236), which have been shown to increase intracellular NAD concentrations, might reverse or prevent the carcinogenic and other effects of the polymorphism. A 6-y case-control study in Italy with > 1000 participants found niacin intake to be inversely correlated with esophageal cancer risk (237). Similar investigations might be done on a population of Asian descent.

Glu487→Lys多态性导致ALDH 2酶活性仅仅为8%,而NAD使得其KM增加了150倍。烟酸或烟酰胺,已经被证明能增加细胞内NAD的浓度,可能逆转或防止多态的致癌和其他影响。意大利一项为期6个月的病例对照研究发现,烟酸摄入量与食管癌风险成反比关系。可以对亚裔人口进行类似的调查。
Glucose-6-phosphate 1-dehydrogenase: hemolytic anemia and favism

Glucose-6-phosphate 1-dehydrogenase (G6PD; see OMIM 305900) is an X-linked cytosolic enzyme that generates NADPH in the oxidative branch of the pentose phosphate pathway. Reduced NADPH is a key electron donor in reductive biosyn-thetic reactions and in the defense against oxidizing agents, possibly through the maintenance of reduced glutathione con-centrations. Additionally, G6PD expression is enhanced by gen-eral oxidative stress (238).

葡萄糖-6-磷酸1-脱氢酶(G6PD;见OMIM 305900)是一种X-连接的胞浆酶,在磷酸戊糖途径的氧化分支中产生NADPH。还原NADPH是还原生物合成反应中的一个关键电子供体,也是防御氧化剂的关键电子供体,可能是通过维持还原型谷胱甘肽的浓度。此外,g6pd的表达也被氧化应激所增强。

G6PD is one of the most polymorphic enzymes and G6PD deficiency is the single most common metabolic disorder, with an estimated 400 million persons thought to be affected world-wide (239). This is because many defects in conserved regions of G6PD, which result in a reduced enzyme activity, confer an increased resistance to malarial infection. Although some forms of G6PD deficiency are asymptomatic, others result in neonatal jaundice, chronic nonspherocytic anemia, acute episodic hemolytic anemia (caused by oxidative stress such as ingestion of fava beans), drug-induced hemolysis, and hemolysis induced by infections. A mild phenotype, characterized by neonatal jaun-dice, favism, and hemolytic anemia, has become common in the world (240), arising in regions of past malaria risk such as Africa, India, the Mediterranean, and Southeast Asia (241).


G6PD mutations compromise the body’s ability to protect against oxidative stress, as shown by the hemolytic response by many deficient individuals to fava beans, which are known to contain the oxidants vicine and divicine. Red blood cells in particular are susceptible to lysis mediated by oxidative stress because of their lack of mitochondria and subsequent reliance on G6PD and one other pentose phosphate pathway enzyme for the production of NADPH. Tobacco smoke is known to contain sev-eral oxidants (242) and may be a source of deleterious oxidative stress on persons around the world who are G6PD deficient. Because at least one common variant of G6PD has been shown to have a decreased binding affinity for NADP, it might follow that nicotinic acid or nicotinamide administration to raise intra-cellular NAD and NADP concentrations would strengthen the body’s reductive capacity and reverse the deleterious effects of the deficiency. Although NAD concentrations have been shown to be increased by high concentrations of nicotinic acid (235) and nicotinamide (236), NADP concentrations do not appear to have been examined.


Defects in G6PD usually result in reduced enzymatic activity and a lower ratio of NADPH to NADP. Although some defects, including the Mediterranean polymorphism Ser188→Phe, do not affect cofactor binding (243), many G6PD defects, including at least one polymorphism, result in an increased Km for NADP and directly alter the NADP binding site. That polymorphism (G6PD Orissa, or Ala44→Gly) was found in a rural region in southern India and resulted in an enzyme with 15% activity and a 5-fold increased Km for NADP (59 compared with 12 mol/L) (244). Of 677 males screened in the Orissa region, 81 (12%) were G6PD deficient. Twenty-eight of the 81 G6PD-deficient men were fur-ther characterized, and 25 of them (89%) had an Ala44→Gly sub-stitution. This gives a polymorphic frequency of 11%.

G6PD中的缺陷通常导致酶活性降低和NADPH与Nadp的比例降低。虽然有一些缺陷,包括地中海多态Ser188→phe,但不影响辅因子结合。许多G6PD缺陷,包括至少一个多态性,导致一个NADP的KM增加和直接更改NADP绑定站点。这种多态性(G6PD Orissa,或Ala44→Gly)是在印度南部的一个农村地区发现的产生了一种活性为15%的酶和NADP的Km增加了5倍(59与12 mol/L相比),在Orissa地区筛查的677名男性中,81名(12%)G6PD缺陷。81例G6PD缺乏的男性中有28例具有皮毛特征,其中25例(89%)有Ala44→Gly取代。多态频率为11%。

A 514C→T missense mutation resulting in a Pro172→Ser amino acid substitution was found in a woman with chronic non-spherocytic hemolytic anemia (245). G6PD activity in this woman was 15% of normal in cultured skin fibroblasts, and the Km for NADP was raised nearly 4-fold (51 compared with 14 mol/L). When the mutant G6PD protein was expressed and purified from E. coli, activity was still decreased and Km increased. Another (rare) mutation, G6PD Santiago de Cuba Gly447→Arg, results in an enzyme with increased Km (43 compared with 3–5 mol/L) (243).

在一例慢性非球形溶血性贫血患者中发现了一个514 C→T错义突变,导致了Pro172Ser氨基酸的替换。在培养的皮肤成纤维细胞中,G6PD活性为正常人的15%。NADP的Km提高近4倍(51比14 mol/L)。当突变体G6PD蛋白从大肠杆菌中得到表达和纯化后,活性下降,Km增加。另一种罕见的突变,G6PJ447(古巴圣地亚哥)G4447a导致Km增加的酶(43,3~5 mol/L)(243)。

Many other residues have been implicated as residing in the NADP binding site because mutants either had an increased Km for NADP (G6PD Riverside Gly410→Cys) or could be (re)activated by high concentrations of NADP (G6PD Iowa Lys386→Glu), or both (G6PD Tomah Cys385→Arg, G6PD Bev-erly Hills Arg387→His, and G6PD Nashville Arg393→His) (246, 247). These results implicated residues 385–393 in the binding site. The structure of human G6PD, which was recently solved, confirms that these residues are likely responsible for cofactor binding (248). In particular, mutations at 389, 393, 394, and 398 reside near the structural NADP molecule. It seems clear that mutations at other sites could also alter protein conforma-tion so as to disrupt a cofactor binding site, which may explain their altered cofactor binding.

许多其他的残基被认为居住在NADP结合位点中,因为突变体对NADP的Km值要么增加了 (G6PD Riverside Gly410→Cys)或者被高浓度的NADP(G6PD,爱荷华Lys 386→Glu)激活,或(G6PD Tomah Cys 385→Arg,G6PD Bev-aryHills Arg 387→His,和G6PD Nashville Arg 393→His)。这些结果牵涉到残基385-393在装订地点。人类G6PD的结构,这件事最近被解决了,确认这些残基可能与辅因子结合有关。特别是389、393、394和398的突变位于NADP结构分子附近。显然,其他位点的突变也可能改变蛋白质的构象,从而破坏辅因子结合位点,这可能解释了它们改变的辅助因子结合。

Searches in the BLAST database (249) suggested that amino acids 29–210 are likely responsible for an NADP binding or recognition site and that this region is well conserved over a diverse set of organisms (data not shown). Two well-conserved residues (Ser188 and Ala44) that are affected by polymor-phisms—G6PD Mediterranean Ser188→Phe (one of the most common polymorphisms) and G6PD Orissa Ala44→Gly (which increases the Km for NADPH 5-fold)—fall into this putative NADP binding site.

在BLAST数据库中搜索,表明29-210氨基酸可能与NADP结合或识别位点有关而且这一区域在一组不同的有机体上是非常保守的(数据没有显示)。两个保守性很好的残基(Ser188和Ala 44),它们受到多相结构的影响-g6pd地中海Ser188→phe(最常见的多态性之一)而G6PD Orissa Ala44→Gly(使NADPH的Km增加5倍)-属于这个假定的NADP结合位点。

Mitochondrial transfer RNA leucine (UUR): MELAS syndrome 线粒体转移RNA亮氨酸(UUR):粒线体脑肌症候群

A tRNA mutation could result in a defective complex I via the incorporation of a critical leucine residue in complex I with low fidelity. Alternatively, because complex I depends on more mito-chondrial-encoded components than any other complex, it is possible that the nonspecific low-fidelity of leucine incorpora-tion would affect complex I more than the other complexes.


A MELAS patient with a mutation at nucleotide 3243 of the mitochondrial gene for tRNA leucine (UUR) (see OMIM 590050; also discussed in the section on riboflavin) was given nicotinamide therapy (1 g 4 times/d), which resulted in large reductions in blood lactate (40%) and pyruvate (50%) by day 3 of treatment (although the clinical effect of the treatment was temporary and the patient eventually died) (236). Blood NAD concentrations (a measure of intracellular erythrocyte concentration) were raised 24-fold by the sixth week of treatment, and it is speculated that the NAD increase with nicotinamide administration was probably universal because it occurred in a time- and dose-dependent man-ner in cultured fibroblasts from both the patient and the control subjects. The authors hypothesized that there was a complex I defect leading to an altered interaction between complex I and NADH that was responsible for the decreased complex I activity in the patient. The Km of complex I for NADH in skeletal muscle from the patient was similar to that in the control subjects; thus, nicotinamide supplementation was effective in this condition because of an enhancement of complex I activity with normal Km. In another case, a patient with the tRNA leucine (UUR) mutation at mitochondrial DNA base pair 3243 who initially presented with MELAS syndrome at the age of 19 y was clinically respon-sive to a mixture of riboflavin and nicotinamide, although the vitamins were not tested individually (220).

1例MELAS患者tRNA亮氨酸(UUR)线粒体基因3243核苷酸突变(UUR)(见OMIM 590050;也会在核黄素一节中讨论)烟酰胺治疗(1克4次/d),导致血乳酸大量减少(40%)和丙酮酸(50%)治疗的第3天(虽然治疗的临床效果是暂时的,病人最终死亡)。血NAD浓度(测定细胞内红细胞浓度)在治疗的第六周就提高了24倍,据推测,随着烟酰胺的使用,NAD的增加可能是普遍的,因为它发生在一段时间内-以及患者和对照组成纤维细胞的剂量依赖性。作者假设存在一个复杂的I缺陷,导致复合物I和NADH之间的相互作用改变,这是导致患者复杂I活性下降的原因。患者骨骼肌NADH复合物I的Km与对照组相似;因此,在这种情况下,添加烟酰胺是有效的,因为它增强了正常KM的复合物I的活性。在另一种情况下,一位患有tRNA亮氨酸的病人 (UUR) 线粒体dna碱基对3243突变最初在19岁时出现MELAS综合征,临床上对核黄素和烟酰胺混合物有反应,虽然没有单独测试维生素。

Dihydropteridine reductase: phenylketonuria II, hyperphenylalaninemia, and cognitive dysfunction

Dihydropteridine reductase (DHPR) utilizes the NAD-NADH redox system to catalyze the recycling of dihydrobiopterin to tetrahydrobiopterin. The tetrahydrobiopterin cofactor is used by the phenylalanine, tyrosine and tryptophan hydroxylases, which are necessary for dopamine and serotonin synthesis as well as nitric oxide synthase. Phenylalanine hydroxylase, when defec-tive, causes classic phenylketonuria (type I).

二氢喋啶还原酶 (DHPR)利用NAD-NADH氧化还原系统催化二氢生物蝶呤的再循环合成四氢生物蝶呤。四氢生物蝶呤辅因子被苯丙氨酸所使用,酪氨酸和色氨酸羟化酶,这对于多巴胺是必需的和5-羟色胺合成以及一氧化氮合酶。苯丙氨酸羟化酶,当失败时,会引起典型的苯丙酮尿症(I型).

The biochemical features of DHPR deficiency (see OMIM 261630), a disorder of biopterin metabolism resulting from defects in DHPR, involves hyperphenylalaninemia due to a block in the conversion of phenylalanine to tyrosine that is less severe than that of classic phenylketonuria. DHPR deficiency also involves deficient concentrations of various neurotransmitters in the central nervous system, causing severe neurologic symptoms. This is because of the reduced availability of tetrahydrobiopterin for tyrosine and tryptophan hydroxylases, as well as the compet-itive inhibition of these 2 hydroxylases by 7,8-dihydrobiopterin (N Blau, unpublished observations, 2001), which is the rearrange-ment product of normal dihydrobiopterin (6,7-dihydrobiopterin). Tetrahydrobiopterin deficiency may be an underappreciated cause of hyperphenylalaninemia and phenylketonuria; thus, it would be of interest to know how many children treated for phenylketonuria actually have the atypical form of the disease that is due to DHPR deficiency.

DHPR缺乏的生化特征(见OMIM 261630),由DHPR缺陷引起的生物蝶呤代谢紊乱,高苯丙氨酸血症是由于苯丙氨酸转化为酪氨酸的阻滞,比经典的苯丙酮尿症严重。DHPR缺乏还涉及中枢神经系统中各种神经递质的浓度不足,引起严重的神经症状。这是因为四氢生物蝶呤对酪氨酸和色氨酸羟化酶的可用性降低,以及7,8-二氢生物蝶呤对这2种羟化酶的竞争性抑制作用。这是正常二氢生物蝶呤(6,7-二氢生物蝶呤)的重排产物.四氢生物蝶呤缺乏可能是高苯丙氨酸血症和苯丙酮尿症的一个未被重视的原因;因此,有兴趣知道有多少治疗苯丙酮尿症的儿童实际上患有由DHPR缺乏症引起的非典型疾病。

More than 20 mutations in DHPR have been assigned to each of the 7 exons, with polymorphisms assigned to exons 3 and 4 (250). Two mutations in exon 1 could affect the ability of DHPR to bind the NAD cofactor: the first, Leu14→Pro, results in a noncon-servative substitution within the  βαβ structure (Rossmann fold) required for NADH binding and is suggested to result in an unstable protein subject to rapid degradation. Another mutation, Gly17→Val, resides in the highly conserved motif involved in NADH binding (251). At least one of these mutations results in no detectable immunoprecipitation and a severe phenotype. It is plausible that niacin administration could raise NADH concen-trations to stabilize these cofactor binding mutants or overcome Km defects caused by similar mutations.
在这7个外显子中,有20多个DHPR突变被分配给每个外显子,第3和第4外显子的多态性。外显子1的两个突变可能影响DHPR结合NAD辅助因子的能力:第一个,亮氨酸14-Pro、结果在βαβ结构中出现了一个非保守的替换(Rossmann fold) NADH结合所必需的,并被建议导致一种不稳定的蛋白质的快速降解。又一次突变,Gly 17→Val,位于NADH结合所涉及的高度保守的基序中。这些突变中至少有一个导致无法检测到的免疫沉淀和严重的表型。烟酸可以提高NADH浓度,稳定这些辅助因子结合突变体,或克服由类似突变引起的KM缺陷,这是合理的。

NADH directly increases the catalytic activity of DHPR in rat PC 12 cells (252), and it appears that activation of the defective enzyme via increased concentrations of NADH may serve as an additional benefit in humans. It is plausible that niacin-remediable defects in DHPR occur in humans and that they are the result of a decreased affinity for NADH.

NADH直接提高DHPR在大鼠PC 12细胞中的催化活性,而且看来,通过增加NADH浓度来激活有缺陷的酶,可能对人类有额外的好处。这是合理的,烟酸补救的缺陷在人类发生DHPR和他们的结果是降低了对NADH的亲和力。

Treatment of phenylalanine hydroxylase deficiency with tetra-hydrobiopterin, which bypasses the DHPR reaction, has been successful (253), which affirms that proper tetrahydrobiopterin availability is essential for this pathway. However, tetrahydro-biopterin therapy is not useful in DHPR deficiency because DHPR is involved in the recycling, and not biosynthesis, of tetrahydro-biopterin. Thus, bypassing the DHPR reaction with tetrahydrobio-pterin therapy would require equimolar amounts of phenylalanine. On the other hand, increasing intracellular NADH concentrations would hypothetically increase the tetrahydrobiopterin recycling activity of DHPR and this could alleviate the reduced availability of tetrahydrobiopterin.


In a study of 88 infants treated for phenylketonuria, between 48% and 80% of subjects had intakes of preformed niacin, but not a variety of other vitamins, below two-thirds of the 1968 rec-ommended dietary allowance (254).


Long-chain-3-hydroxyacyl-CoA dehydrogenase  subunit: hypoglycemia, cardiomyopathy, and sudden death
The mitochondrial trifunctional protein, composed of 4 αand 4 β subunits, is responsible for the last 3 steps of the β-oxidation of long-chain fatty acids, which is the main source of energy in the heart. The subunit contains the long-chain-3-hydroxyacyl-CoA dehydrogenase (LCHAD), which catalyzes the following NAD-dependent reaction: R-CHOH-CH2-CO-S-CoA + NAD → R-CO-CH2-CO-S-CoA + NADH + H+.

线粒体三功能蛋白,由4个α和4个β亚基组成,负责β氧化长链脂肪酸的最后三个步骤,这是心脏的主要能量来源。该亚基含有长链-3-羟基酰基-辅酶A脱氢酶(LCHAD),催化以下NAD依赖反应:R-CHOH-CH2-CO-S-CoA + NAD → R-CO-CH2-CO-S-CoA + NADH + H+.

Mitochondrial trifunctional protein deficiency resulting from impaired LCHAD activity (see OMIM 600890) is the second most common inborn error of fatty acid metabolism, second onlyto MCAD deficiency (discussed in the section on riboflavin). Clinical complications include hypoglycemia, cardiomyopathy, and sudden death. In addition, severe maternal illness (eg, acute fatty liver) during pregnancy often accompanies mitochondrial trifunctional protein deficiency in the fetus (255).

LCHAD活性受损所致线粒体三功能蛋白缺乏症(见OMIM 600890)是脂肪酸代谢的第二大先天错误,二是MCAD缺陷(在核黄素一节中讨论)。临床并发症包括低血糖、心肌病和猝死。此外,严重的产妇疾病(如急性脂肪肝),妊娠期常伴有胎儿线粒体三功能蛋白缺乏。

The DNA mutation 1528G→C in the subunit, resulting in an Glu510→Gln substitution (Glu474→Gln in some papers), was found to be directly responsible for the loss of LCHAD activity and subsequent illness, although it does not seem to affect over-all conformation or subunit conformation because no difference in molecular weight was found between wild-type and mutant proteins. The allele frequency of G1528 was found to be 87% in 34 LCHAD-deficient patients, and there is speculation that the 1528G→C mutation affects the active site of the dehydrogenase domain of mitochondrial trifunctional protein (256).

基因突变1528 G→C在亚基中,导致Glu510→Gln替换(Glu474→Gln在一些论文中),被认定对LCHAD活动的损失负有直接责任和随后的疾病,虽然它似乎没有影响所有的构象或亚单位构象,因为在分子量没有发现野生型和突变型蛋白质。G 1528等位基因频率在34例LCHAD缺陷患者中为87%,推测1528 G→C突变影响线粒体三功能蛋白脱氢酶结构域的活性位点。

We have assigned the Glu510→Gln mutation to the likely NAD binding domain (amino acids 358–542) by querying the Con-served Domain Database of the National Center for Biotechnology Information (257) with the LCHAD subunit protein sequence. These results were verified by aligning the protein sequence of LCHAD with that of the short-chain enzyme, SCHAD [the first 200 amino acids of which are responsible for NAD binding (258)], by using the Pairwise BLAST tool (249). Amino acids 27–314 of SCHAD lined up with amino acids 361–640 of LCHAD with 33% identity, 52% similarity, and 3% gaps. Residue Glu510 is con-served in the 2 enzymes. Although it appears that kinetic studies have not been performed on LCHAD, it would be of interest to study the NAD binding affinity of the mutant enzyme and to test the responsiveness of LCHAD-deficient patients to therapy with nicotinic acid or nicotinamide, pre- or postnatal.


Hyperlipidemia and heart disease 高脂血症与心脏病

Patients with hyperlipidemia, an inheritable set of disorders 高脂血症患者,一组可遗传的疾病
involving altered lipid metabolism, were studied for response to colestipol, lovastatin, simvastatin, niacin, and placebo (259). (Statins are inhibitors of the cholesterol biosynthetic enzyme, 3-hydroxy-3-methylglutaryl CoA reductase.) Although niacin was not tested alone (but rather in conjunction with colestipol or simvastatin), it appears to have improved HDL, triacylglycerol, and cholesterol concentrations in patients.


Combined niacin and statin use has been recommended because of success in clinical trials for the reduction in cardio-vascular events and improvement in progression or regression of coronary lesions (260). The niacin-statin treatment regimen appears to provide a unique combination of marked LDL-cholesterol reduction along with favorable changes in HDL cho-lesterol, lipoprotein(a), and triacylglycerol. A review of the use of niacin to prevent cardiovascular disease and related complica-tions gives evidence of multiple trials of successful treatment with niacin, including the Coronary Drug Project, the largest of the trials studied, which concluded that niacin monotherapy leads to significant decreases in recurrent myocardial infarctions and cerebrovascular events (261).


The benefits of niacin treatment in the lowering of LDL cho-lesterol was tested in a randomized, controlled, double-blind study involving 201 men and women with elevated LDL-cholesterol values (in the 75th to 95th percentiles) (262). Four treatment groups (receiving daily niacin doses of 2000, 1500, 1250, and 1000 mg) were compared with placebo and diet-treated control groups. The groups given 2000 and 1500 mg had significant reductions in LDL cholesterol (26% and 19.3%, respectively),total cholesterol (18.4% and 13.3%), and the ratio of total to HDL cholesterol (20.4% and.4%) when compared with the placebo and diet-treated control groups. Smaller improvements were seen in HDL-cholesterol and triacylglycerol concentrations. Blood chem-istry monitoring indicated that a reduction in LDL-cholesterol concentration strongly correlated with an increase in baseline concentrations of some enzymes for niacin-treated subjects.


Schizophrenia 精神分裂症

“It is supposed that the favorable therapeutic effects of nico-tinamide, nicotinic acid and their active biological form—NAD—are realized due to the mechanisms of their functioning in the ner-vous system, for treating schizophrenia, epilepsy and other diseases of the nervous system” (263). Hoffer (264) and Pauling (265) review literature pertaining to the use of various forms of niacin to treat schizophrenia. They found several studies in which success was reported with niacin therapy. However, these conclusions have been criticized (266) for failure of the investi-gators to support their claims with evidence from double-blind and placebo-controlled studies, which are necessary to ascertain the efficacy of vitamin treatment of schizophrenia. See also the discussion of MTHFR in the section on folic acid.


Chronic fatigue syndrome 慢性疲乏综合征
Eight of 26 patients (31%) with chronic fatigue syndrome responded favorably to NADH treatment as opposed to only 2 of 26 control subjects (8%) (267). Although NADH therapy appears to be helpful in some patients, the cause of this syndrome is unknown and clinical assessment is sometimes difficult.


Necrobiosis lipoidica 类脂质渐进性坏死
Nicotinamide treatment improved 8 of 13 patients with this granulomatous condition, which involves abnormalities in der-mal collagen, vascular supply of the skin, and immunologic responses (268).


Dihydrolipoamide dehydrogenase: lactic acidosis See the discussion in the section on lipoic acid.
二氢硫辛酰胺脱氢酶; 乳酸酸中毒见关于硫辛酸一节的讨论。

Methionine synthase reductase: homocystinuria and mental retardation 蛋氨酸合成酶还原酶:高胱氨酸尿和智力迟钝

See the discussion in the section on cobalamin. 见关于钴胺一节的讨论

Tissue concentrations and toxicity 组织浓度和毒性

The DRI manual enumerates various adverse effects of sup-plemental niacin use, but these effects are usually associated with doses of nicotinic acid of ≥ 1500 mg/d (7). It appears that nicotinamide produces fewer side effects than nicotinic acid. This difference could be due to study bias, however, if signifi-cantly fewer studies with nicotinamide have been performed.

DRI手册列举了服用硝酸氢钠的各种不良反应,但这些作用通常与≥1500 mg/d的烟酸剂量有关。看来烟酰胺产生的副作用比烟酸少,这种差异可能是由于研究偏见,然而,如果显着地减少了对烟酰胺的研究。

Niacin administration raises NAD concentrations in rodents. In mice, the relation of niacin concentration in the diet to NAD in skin fits a logarithmic function, suggesting that NAD content approaches saturation at 0.5–1.0% niacin (g niacin/kg diet) supplementation (269). In rats, 2 wk of dietary nicotinic acid supplementation (500 and 1000 mg/kg diet) caused elevated con-centrations of NAD in the blood, liver, heart, and kidney, whereas nicotinamide caused elevated concentrations only in the blood and liver, compared with controls fed a diet containing 30 mg nicotinic acid/kg. Both nicotinic acid and nicotinamide, at 1000 mg/kg diet, cause elevations in liver NAD, by 44% and 43%,respectively (270). As mentioned above, nicotinamide has been shown to increase human intracellular NAD concentrations (236). Doses of nicotinic acid of 100 mg/d raise human lymphocyte NAD concentrations 5 times above baseline (235). At higher concentrations, passive diffusion predominates, with doses of 3–4 g niacin almost completely absorbed (271).

烟酸可提高啮齿动物体内NAD浓度。在小鼠中,饮食中烟酸浓度与皮肤NAD的关系符合对数函数,表明NAD含量在0.5%~1.0%烟酸增补剂时接近饱和 (g niacin/kg diet)。大鼠日粮中添加烟酸(500 mg/kg和1000 mg/kg)2wk可引起大鼠血液中NAD浓度升高,肝脏、心脏和肾脏,而烟酰胺只引起血液和肝脏中的浓度升高,与对照组相比,添加30毫克烟酸/千克。烟酸和烟酰胺,1000毫克/千克的饮食,引起肝脏NAD升高,分别为44%和43%。如上文所述,烟酰胺可增加人细胞内NAD的浓度。剂量为100 mg/d的烟酸使人淋巴细胞NAD浓度比基线高出5倍。高浓度时,以被动扩散为主,3-4 g烟酸几乎完全吸收。

BIOTIN (VITAMIN B-7) 生物素(维生素B-7)

The DRI for biotin is 30 μg/d (7).生物素的相对分子质量比为30μg/d
Holocarboxylase synthetase: multiple carboxylase deficiency, organic aciduria, seizures, and ataxia Holocarboxylase synthetase (HCS), or biotin–[propionyl-CoA-carboxylase (ATP-hydrolysing)] ligase (Table 7), catalyzes 1) the formation of biotinyl-AMP from biotin and ATP, and 2) the transfer of biotin from biotinyl-AMP to enzymatically inactive apocarboxylases to form active holocarboxylases (272). Specifically, HCS catalyzes the biotinylation of the 4 biotin-dependent carboxylases found in humans: the mitochondrial propionyl-CoA carboxylase, pyruvate carboxylase, -methylcrotonyl-CoA car-boxylase, and the cytosolic acetyl-CoA carboxylase.


Multiple carboxylase deficiency due to HCS deficiency (see OMIM 253270) presents in children anywhere from the time of birth to 15 mo of age. Symptoms include organic aciduria, feed-ing difficulties, neurologic abnormalities (subependymal cysts, hypotonia, impaired consciousness, seizures, and ataxia), and cutaneous changes (rash and alopecia). Supplemental biotin (10 mg/d, compared with an DRI of 30 μg/d) can commonly pro-vide sufficient substrate to increase HCS enzymatic function (when the Km is increased and the Vmax is decreased) and thereby permit biotinylation of the 4 carboxylases (273).

HCS缺乏症致多发性羧化酶缺乏症(见OMIM 253270)从出生到15岁的任何地方的儿童礼物。症状包括有机酸尿,喂养困难,神经异常(室管膜下囊肿、低张力、意识受损、癫痫和共济失调),和皮肤改变(皮疹和脱发)。补充生物素(10 mg/d,而dRI为30μg/d)通常能提供足够的底物来增加hcs的酶功能(当Km增加,Vmax降低时),从而允许4种羧化酶的生物素化。

Cowan et al (274) reported the first biotin-responsive patient, who displayed acidurias reflecting deficiencies in multiple car-boxylase enzymes. Oral biotin treatment (10 mg/d) significantly decreased urine acid concentrations. The same group was the first to diagnose and treat an HCS deficiency case prenatally (275). An elevated Km (> 100 times) of HCS for biotin as well as a depressed Vmax were found in fibroblasts from the child.
Cowan等人,报告了第一位对生物素有反应的病人,他表现出酸尿症,反映了多种羧化酶的缺陷。口服生物素(10 mg/d)可显著降低尿酸浓度。同一组是第一个诊断和治疗hcs缺乏症的人。在儿童成纤维细胞中发现,生物素的Km(>100倍)升高,Vmax降低。

Two other patients with HCS deficiency had Km values 14 and 28 times greater than normal at 7.2 and 3.7 μmol/L (compared with the control value of 0.260 μmol/L) (n = 5). The Vmax of the enzyme from the patients was also significantly lower than that of the control subjects (276).


Analysis was performed on a mutant, Val550→Met, which resides in the putative biotin binding site (277). In fibroblasts transfected with the Val550→Met cDNA, the Km for biotin (0.943 mol/L) was larger than the value found for the wild-type cDNA (0.145 mol/L). Additionally, the Vmax decreased to 10 pmol · min-1 · mg-1 in the mutant compared with a wild-type Vmax of 60 pmol · min-1 · mg-1.

对一个突变体Val550→Met进行了分析,该突变体位于假定的生物素结合位点上。转染Val550→MetcDNA的成纤维细胞中,生物素的Km(0.943 mol/L)大于野生型的Km(0.145 mol/L)。突变体Vmax降至10 pmol·min-1·mg-1,野生型Vmax为60 pmol·min-1·mg-1。

Of 6 different point mutations analyzed in the HCS gene, 2 are frequent among patients with multiple carboxylase deficiency: Val550→Met and Arg508→Trp (which appears to be spread worldwide across ethnic groups). Dupuis et al (278) reported that “four of the mutations cluster in the putative biotin-binding domain as deduced from the corresponding E. coli enzyme and consistent with an explanation for biotin-responsiveness based on altered affinity for biotin. The two others may define an additional domain involved in biotin-binding or biotin-mediated sta-bilization of the protein.”

在HCS基因分析的6个不同的点突变中,多发性羧化酶缺乏症患者中2例多见:Val550→Met和Arg 508→Trp(这似乎遍及世界各地的种族群体)。Dupuis等人(278)报告说,“从相应的大肠杆菌酶中推断出的生物素结合区的四个突变簇,与生物素反应的解释是一致的-基于生物素亲和力的改变。另外两个可能定义了另一个与生物素结合或生物素介导的蛋白质合成有关的结构域。“

Dupuis et al (278) characterized the Arg508→Trp mutation, found in 4 (3 heterozygous, 1 homozygous) of 9 multiple car-boxylase deficiency patients screened, as residing in the biotin binding site. “We anticipate that the four mutations in the biotin-binding region of HCS will account for the high Km for biotin measured in patients with neonatal MCD. For example, two of the patient fibroblast lines we studied, JRi and MC, had a reported Km of 0.346 and 0.048 mol/L, respectively, compared with 0.015 mol/L for the normal enzyme. JRi was found to have an [Arg508→Trp] mutation and MC was found to have a [Val550→Met] mutation (in each case, the second mutation has yet to be identified). While it is premature to conclude that these mutations are causative of the elevated Km, their location in the biotin-binding region and the conservation of three of the four mutations among human, Paracoccus denitrificans, E. coli, Bacil-lus subtilis, Salmonella typhimurium, mouse and yeast biotin lig-ases is consistent with this notion” (278).

Duet等人,对9例多重羧化酶缺乏症患者中4例(3例杂合子,1例纯合子)的arg 508→Trp突变进行了鉴定,发现该突变位于生物素结合位点。“我们预计,HCS生物素结合区的四个突变将解释在新生儿MCD患者中生物素含量高的KM值,例如,我们研究的两种患者成纤维细胞系JRI和MC的Km分别为0.346和0.048 mol/L,正常酶分别为0.015 mol/L和0.015 mol/L。JRI被发现有一个[arg 508→trp]突变,mc被发现有一个[val550→meet]突变(在每种情况下,第二个突变都有y)。et to be identified).虽然认为这些突变是KM升高的原因还为时过早,它们在生物素结合区的位置以及人类四种突变中三种的保守性,假单胞菌、大肠杆菌、枯草芽孢杆菌、伤寒沙门氏菌、小鼠和酵母生物素酶均符合这一概念。

Of 7 HCS mutations analyzed, 2 (Gly581→Ser and delThr610) were found to reside in the putative biotin binding region of HCS and resulted in increased Km values by 45-fold and 3-fold, respectively. The other 5 mutations were outside the biotin binding region. Administering biotin to Gly581→Ser mutant cells in culture increased propionyl-CoA carboxylase activity to control levels, whereas such treatment did not affect other mutant lines that had mutations outside the putative biotin binding domain (279).
分析7个hcs突变中,2例(Gly 581→Ser和delThr 610)被发现存在于hcs的生物素结合区使Km值分别提高45倍和3倍.其余5个突变位于生物素结合区以外。将生物素应用于Gly 581→Ser突变细胞培养,可提高丙酰基辅酶A羧化酶活性,达到对照水平,然而,这种处理并不影响其他突变系,这些突变系在假定的生物素结合域之外有突变。

By prenatal diagnosis, a 33-fold elevated Km for biotin was found in a fetus (Km patient, 0.221 μmol/L; control subject, 0.007 μmol/L). The mother was given 10 mg biotin/d and the newborn, who was clinically well, was maintained on biotin treatment after birth at 20 mg/d (280).


The Km measured from amniocytes of a woman pregnant with another HCS-deficient child diagnosed prenatally was 12 times greater than control, and Vmax was 2% of control (281). Biotin responsiveness was shown in vitro, with the restoration of car-boxylase activities to 51–58% of normal. The infant’s Km was increased as well to 0.060 μmol/L (control: 0.007 μmol/L). The mother was treated prenatally and the infant was clinically well at birth.


Five biotin-responsive patients with a defect in holocarboxylase synthesis were reported by Suormala et al (282). Enzyme activities and Km were measured and clear evidence was presented that many HCS cases respond to biotin because of a Km defect in the enzyme. In 3 patients, normalization of biochemical indexes required doses of 20–40 mg/d. The fourth patient required a dose of 100 mg biotin/d before her skin rash disappeared, but she remained mentally retarded and showed slightly elevated urinary organic acid excretion. The results in the 5 patients suggest a pri-mary defect in HCS resulting from a decreased affinity for biotin, in one patient combined with a decreased Vmax.

Suormala等人报告了5例生物素应答患者的全羧化酶合成缺陷。对酶活性和Km进行了测定,并有明确的证据表明,许多HCS病例是由于生物素存在Km缺陷而对生物素产生反应的。3例患者生化指标正常化需剂量20~40 mg/d。第四位病人在皮疹消失之前需要服用100毫克生物素/天,但她仍然智力迟钝,尿有机酸排泄略有增加。5例患者的结果提示HCS存在PRI-Mary缺陷,这是由于与生物素的亲和力降低所致,1例合并Vmax降低。

A new polymorphism, 1121C→T, was identified in the mutational analysis of 7 patients with HCS deficiency (283). Note also that there are many known mutations in HCS that do not affect the biotin binding site; thus, an altered Km would not explain those cases.


Tissue concentrations and toxicity 组织浓度和毒性

There seems to be good evidence that pharmacologic doses of biotin increase biotin concentrations in tissues and plasma (284). Normal plasma and whole-blood biotin concentrations are 2 nmol/L (277). The serum biotin concentration of one patient taking 20 mg biotin/d was raised to 4.8 μmol/L, which was 4.5 times greater than the Km for biotin of his HCS enzyme (285). More generally, 10 mg oral biotin daily is believed to produce concentrations of biotin in plasma of 1.3 mol/L, well above the Km for biotin of HCS of most patients with HCS deficiency (285). Lower dosages (≥ 600 μg/d) used in another study raised plasma biotin concentrations 7-fold (from 0.3 to 2.8 nmol/L), whereas concentrations of the “quantitatively most important biotin metabolite, bisnorbiotin,” were raised 15.5 times in plasma post-supplementation (286).

似乎有很好的证据表明生物素的药理学剂量增加了组织和血浆中生物素的浓度。正常血浆和全血生物素浓度为2 nmol/L。1例服用20 mg生物素/d者,血清生物素浓度提高至4.8mol/L,比HCS酶中生物素的Km值高4.5倍。更普遍的是,每天10毫克的口服生物素被认为能在血浆中产生浓度为1.3 mol/L的生物素,大多数HCS缺乏症患者HCS生物素水平高于Km值。在另一项研究中,低剂量(≥600μg/d)可使血浆生物素浓度提高7倍(从0.3nmol/L提高到2.8nmol/L),然而,“定量最重要的生物素代谢物,双去甲生物素”在血浆补充后的浓度提高了15.5倍。

No UL for biotin has been set. Toxicity has not been reported in patients receiving daily doses of ≤ 200 mg orally and ≤ 20 mg intravenously for the treatment of biotin-responsive inborn errors of metabolism and acquired biotin deficiency (7).


COBALAMIN (VITAMIN B-12) 钴胺(维生素B-12)

The DRI for vitamin B-12 is 2.4 μg/d for adults (7). Cobalamin is the precursor to methylcobalamin and adenosylcobalamin, the bioactive cofactor forms of cobalamin. Cobalamin-dependent enzymes are listed in Table 8.


Methylmalonyl-CoA mutase: methylmalonic aciduria and cognitive dysfunction


Methylmalonyl-CoA mutase is a mitochondrial enzyme that requires adenosylcobalamin to catalyze the isomerization of methylmalonyl-CoA to succinyl-CoA. Deficiency of methyl-malonyl-CoA mutase leads to methylmalonic aciduria (see OMIM 251000). Symptoms include multiple episodes of life-threatening organic acidosis and hyperammonemia associated with low-normal intelligence in the first years of life. Patients often respond to pharmacologic supplements of cobalamin (cyanoco-balamin or hydroxycobalamin) leading to a reduction in methyl-malonate accumulation. It is possible that from one-third to one-half of mutations in methylmalonyl-CoA mutase confer a reduced ability to bind cobalamin cofactor. A newborn screening program identified 17 children with methylmalonic aciduria, of whom 7 (41%) were cobalamin responsive (287).

甲基丙二酰辅酶是一种线粒体酶这就需要腺苷钴胺催化甲基丙二酰-辅酶A异构化为琥珀酰辅酶A。甲基丙二酰辅酶缺乏导致甲基丙二酸尿(见OMIM 251000)。症状包括多起危及生命的有机酸中毒和高氨血症相关的低正常智力在生命的头几年。病人经常对钴胺(氰基巴拉明或羟基钴胺)的药理学补充剂产生反应,从而减少了丙二酸甲酯的积累。甲基丙二酰辅酶变异的三分之一到一半可能降低了钴胺辅助因子的结合能力。一项新生儿筛查发现17名患有甲基丙二酸尿的儿童,其中7名(41%)对钴胺有反应。

Enzymes from fibroblasts of 4 remediable patients had ele-vated Km values for adenosylcobalamin, suggesting a perturbation in cofactor binding (3). The nonremediable genetic defects con-stitute about two-thirds of those found and the remediable defects about one-third (3). The latter defective proteins retain some enzyme activity (2–75% of control) and have an increased Km for adenosylcobalamin of 200–5000 times normal (288–290).


Kinetic analysis of one cobalamin-responsive patient showed abnormal binding of the coenzyme, adenosylcobalamin, for its methylmalonyl-CoA mutase apoenzyme, ie, a Km of 38 mmol/L compared with the control Km of 0.015 mmol/L. A decreased Vmax (14% of control) was found as well. It was concluded that the defect was “at the [adenosylcobalamin]-binding site since the Km for the substrate, [methylmalonyl-CoA], is similar to con-trols whereas the Km for [adenosylcobalamin] binding differs by 2,600-fold” (290).

一例钴胺反应患者的动力学分析显示辅酶腺苷钴胺异常结合,甲基丙二酰辅酶A酶的Km为38 mmol/L,与对照KM的0.015 mmol/L相比,A的Vmax降低了14%。我们的结论是,缺陷是“在[腺苷钴胺]结合位点,因为KM为底物,[甲基丙二酰辅酶A]与对照组相似,而[腺苷钴胺]结合的Km值相差2,600倍“。

In an examination of the fibroblasts from 2 other patients with a cobalamin-remediable phenotype, a decreased affinity of the mutant enzyme for adenosylcobalamin was found. The Km values of the mutant enzymes for adenosylcobalamin were 280 and 17 mmol/L, compared with control Km values of 0.06–0.07 mol/L (an 2000-fold increase in Km). The Vmax of both enzymes was decreased to 20% and 5% of control (288).
在对其他2例钴胺可修复表型的成纤维细胞的检查中,突变酶对腺苷钴胺的亲和力降低。腺苷钴胺突变酶的Km值分别为280和17 mmol/L。与对照相比,Km值为0.06-0.07mol/L(公里数增加2000倍)。两种酶的Vmax分别为对照的20%和5%。

Two types of mutations have been described, those leading to no detectable activity (mut0), which are not corrected by excess cobalamin, and those exhibiting residual activity (mut), which are corrected by excess cobalamin. X-ray structure analy-ses showed many of the latter mutations to be in the cobalamin binding site of the enzyme (291). This observation is consis-tent with a Km mutation as an explanation for the cobalamin-dependent phenotype.


Altered enzymes without detectable residual mutase activity (< 0.1%) were found in those patients not responsive to cobalamin (289). None of 7 mut0 mutant lines examined had any detectable mutase activity, even when assayed in 1 mmol adenosylcobalamin/L (a value >10000 times the control Km for adenosylcobalamin). The 7 mutant lines with mut activity (0.5–50% of control) showed an increased activity in cell extracts with hydroxycobalamin supplementation. These latter altered enzymes had a 50- to 5000-fold elevated Km for adenosyl-cobalamin and one mutase examined turned over at a rate 3–4 times higher than that of the control enzyme when the cells were grown in hydroxycobalamin-supplemented medium. Six, and possibly all 7, of these had an elevated Km for adenosylcobalamin ranging from 2 to 290 mol/L (control Km: 0.04–0.08 mol/L). The Vmax was also decreased: 7–725 pmol·min1 ·mg1 com-pared with control values of 1053–1827 pmol·min1 ·mg1. Five of 8 mutase heterozygotes examined expressed some mutase activity with reduced affinity for cofactor (289).

未检测到残余变位酶活性的改变酶 (< 0.1%) 在那些对钴胺没有反应的病人身上发现。检测到的7个变异系中没有一个具有任何可检测到的变位酶活性,即使在1 mmol腺苷钴胺/L中测定 (a值>10000倍于对照公里的腺苷钴胺)。7个具有mut活性的突变系(占控制的0.5%-50%)添加羟钴胺可提高细胞提取物的活性。后一种改变的酶对亚丁酰钴胺有50到5000倍高的km和其中一个变位酶的翻转率要高出3-4倍当细胞在添加羟钴胺的培养基中生长时,比对照酶的作用更明显。其中6种,可能全部7种,腺苷钴胺的Km升高范围从2到290 mol不等。/L(对照Km:0.04-0.08mol/L)。Vmax也降低:7~725 pmol·min1·mg1com,与对照值1053~1827 pmol·min1·mg1相比,差异有显着性(P<0.01)。8种变位酶杂合子中有5种表达了一定的变位酶活性。余因子的有限性

In another study of cell lines from patients with methyl-malonic aciduria, 3 of 4 exhibited cobalamin-responsiveness. The Gly717→Val mutant enzyme was expressed in cell culture and was found to have a 1000-fold higher Km for adenosylcobal-amin and an increase in activity in response to high concentra-tions of cobalamin. Four novel mutations described are near the carboxyl end of the protein and are hypothesized to reside in the adenosylcobalamin binding site (292, 293).

在另一项对甲基丙二酸尿患者细胞株的研究中,4例中有3例表现出钴胺反应.Gly 717→val突变酶在细胞培养中表达,并被发现其对腺苷酰辅酶的Km值是对照酶的1000倍以及高钴胺浓度引起的活性增加。所描述的四个新的突变位于蛋白的羧基端附近,并且假设它们位于腺苷钴胺结合位点。

Methionine synthase: homocystinuria and neurologic dysfunction 蛋氨酸合成酶:同晶体尿症与神经功能障碍

Methionine synthase (5-methyltetrahydrofolate–homocysteine S-methyltransferase) catalyzes the cobalamin-dependent methy-lation of homocysteine, using 5-methyltetrahydrofolate as the methyl donor (see OMIM 156570). Defects in methionine synthase result in hyperhomocysteinemia and are implicated as the lesion in the cblG complementation group of disorders in cobalamin metabolism (294).

蛋氨酸合酶(5-甲基四氢叶酸-同型半胱氨酸S-甲基转移酶)催化同型半胱氨酸依赖钴胺的方法,以5-甲基四氢叶酸为甲基供体(see OMIM 156570).蛋氨酸合成酶缺陷导致高同型半胱氨酸血症并被认为是钴胺代谢紊乱cblG互补群中的病变。

The cblG group generally has reduced methionine synthase activity even under optimal conditions; thus, primary defects in the catalytic subunit of the enzyme may be responsible for this subgroup. The cblG group shows biochemical heterogeneity with respect to the binding of cellular cobalamin to methionine syn-thase. In extracts of cell lines from most patients, the methyltrans-ferase binds 75% of cellular cobalamin, even though little of it is methylcobalamin. In a few lines, however, the methyltransferase is devoid of bound cobalamin of any form. This suggests the presence of mutations in the cobalamin binding domain of the methyltransferase, strengthening the possibility that the cblG group results from primary deficiencies in the methionine synthase apoenzyme (295). Hydroxycobalamin should be instituted (1 mg/d intramuscularly initially, then tapered to 1–3 mg/wk) as soon as the disorder is diagnosed (295).


Early treatment of methylcobalamin deficiency may prevent major neurologic complications of these diseases. One child who received hydroxycobalamin therapy before and after birth devel-oped cognitively normally (296).


TABLE 7 Enzymes that use a biotin cofactor1 使用生物素辅助因子的酶

Defective enzyme and EC no.
Reaction catalyzed
Disease or condition
OMIM no.
Holocarboxylase synthetase 羧化全酶合成酶(
Cytoplasmic and mitochondrial
Apocarboxylases + biotin →holocarboxylases
Multiple carboxylase deficiency, 多羧化酶缺乏症
metabolic acidosis,
代谢性酸中毒 hypotonia,seizures, 张力减退,癫痫,and lethargy (sometimes developmental delay or coma) 昏睡(有时发育迟缓或昏迷)
Autosomal recessive
1 OMIM, Online Mendelian Inheritance in Man (4).

Enzymes that use an adenosylcobalamin or methylcobalamin cofactor1

Defective enzyme and EC no.
Reaction catalyzed
Disease or condition
OMIM no.
Methylmalonyl-CoA mutase (
甲基丙二酰-CoA 变位酶
Isomerization of methylmalonyl-CoA → succinyl-CoA
Methylmalonic acidemia, 甲基丙二酸血症,metabolic ketoacidosis, 代谢性酮症酸中毒 and cognitive dysfunction
Autosomal recessive
Methionine synthase (蛋氨酸合成酶
Homocysteine + 5-methyl-THF → methionine + THF
Homocystinuria, 高胱氨酸尿,failure to thrive,发育迟缓 and neurologic complications神经学并发症;
Autosomal recessive常染色体隐性
Methionine synthase reductase (
MS-cob(II)alamin + NADPH + SAM → MS-methylcob(I)alamin + S-adenosylhomocysteine + NADP
Homocystinuria and mental retardation
1 MS, methionine synthase; OMIM, Online Mendelian Inheritance in Man (4); SAM, S-adenosylmethionine; THF, tetrahydrofolate.

Of 2 patients described in another study, the first had greatly diminished steady state levels of methionine synthase mRNA (297). The biochemical data on the second patient’s cell line (cblG WG1892) implicated mutations in the carboxyl-terminal S-adeno-sylmethionine binding domain and the intermediate cobalamin binding domain. Two mutations were detected in cblG WG1892: the conversion of a conserved proline (1173) to a leucine residue and a deletion of an isoleucine residue (881). The investigators concluded, “The crystal structure of the C-terminal domain of the E. coli methionine synthase predicts that the proline to leucine mutation could disrupt activation since it is embedded in a sequence that makes direct contacts with the bound S-adenosyl-methionine. Deletion of isoleucine in the B12-binding domain would result in shortening of a -sheet. Our data provide the first evidence for mutations in the methionine synthase gene being culpable for the cblG phenotype. In addition, they suggest directly that mutations in methionine synthase can lead to elevated homocysteine, implicated both in neural tube defects and in cardiovas-cular diseases” (297).

在另一项研究中描述的2名患者中,第一次大幅度降低了蛋氨酸合成酶mRNA的稳态水平。第二病人细胞系的生化指标(CblG WG1892)羧基端S-腺苷-三甲基氨酸结合域的连锁突变和中间钴胺结合域。在cblG WG1892中检测到两个突变:保守的脯氨酸(1173)转化为亮氨酸残基和异亮氨酸残基的缺失。调查人员得出结论,“大肠杆菌蛋氨酸合成酶C末端结构域的晶体结构预测,脯氨酸向亮氨酸突变可能破坏激活,因为它嵌入在一个序列中直接与S-腺苷甲硫氨酸结合。B_(12)结合区异亮氨酸的缺失将导致a-片的缩短.我们的数据提供了第一个证据表明蛋氨酸合成酶基因的突变是cblG表型的罪魁祸首。他们直接暗示蛋氨酸合成酶的突变会导致同型半胱氨酸升高,既与神经管缺陷有关,也与心脏疾病有关“

Two methionine synthase mutations that are candidates for causing the cblG disease are located in the vicinity of the cobalamin binding domain: one is the same deletion of isoleucine 881 mentioned above; the other is amino acid substitution His920→Asp. A polymorphism, Asp919→Gly (resulting from 2756A→G, mutant allele frequency 15%), was identified at an adjacent residue, and thus may also be near or in the cobalamin binding site (298). The polymorphism has been associated with lower plasma homocysteine concentrations (299, 300), which is puzzling and suggests that this polymorphism, which has been postulated to modify an amino acid on a helix involved with cofactor binding, is an activating mutation.

引起cblG病的两个蛋氨酸合成酶突变位于钴胺结合区附近:一是上述异亮氨酸881的缺失;另一种是氨基酸取代His 920→Asp.一个多态性,Asp919→Gly(由2756A→G引起,突变等位基因频率为15%),在邻近的残基上被识别,因此也可能在钴胺结合位点附近或附近。该多态性与血浆同型半胱氨酸浓度降低有关。这是一个令人费解的问题,表明这种多态是一种激活的突变,这种多态被认为是为了修饰一个与辅因子结合有关的螺旋上的一个氨基酸。

Of 2 unrelated boys with a cblG defect due to methionine synthase deficiency, one improved immediately on switching to hydroxycobalamin from cyanocobalamin (which caused respira-tory depression and lethargy in the patient). It appears that treat-ment with intramuscular injections of hydroxycobalamin alleviates megaloblastic anemia and stabilizes neurologic deterioration in children with the cblG defect but may not completely correct hypotonia and developmental delay or improve the anorexia or poor weight gain associated with cblG disease (301).


Ample evidence seems to suggest that defects in methionine synthase can account for some cblG patients. Some mutations appear to affect cobalamin binding and thus serve as an explanation for the response to cobalamin in some patients. There is also evidence that the cblG complementation group is heterogeneous (302).


Methionine synthase reductase: homocystinuria and mental retardation 蛋氨酸合成酶还原酶:高胱氨酸尿和智力迟钝

Methionine synthase reductase [MSR; (methionine syn-thase)–cobalamin methyltransferase (cob(II)alamin reducing)] is responsible for the reductive methylation and reactivation of methionine synthase with S-adenosylmethionine as a methyl donor (see OMIM 602568). MSR is a member of the ferredoxin-NADP reductase family of electron transferases, containing the FMN, FAD, and NADPH binding sites necessary to maintain methionine synthase in its functional state.

蛋氨酸合成酶还原酶[MSR;(蛋氨酸合成酶)-钴胺甲基转移酶(COB(II)AlaminReduction)]以S-腺苷甲硫氨酸为甲基供体,负责蛋氨酸合成酶的还原甲基化和重新激活(见OMIM 602568)。MSR是铁氧还蛋白-NADP还原酶家族中的一员,含有FMN、FAD和NADPH结合位点,是维持蛋氨酸合成酶功能状态所必需的。

MSR deficiency is associated with the cblE complementation group of cobalamin deficiencies. Over time, the highly reactive cobalamin(I) cofactor of methionine synthase is oxidized to the inert cobalamin(II) form, rendering the enzyme inactive (294). Symptoms of MSR defects include microcephaly, psychomotor retardation, episodic reduced consciousness, megaloblastic anemia, increased plasma free homocysteine (> 20 mol/L), low plasma methionine (< 10 mol/L), and increased excretion of formiminoglutamate.

MSR缺乏症与钴胺缺乏症的cblE互补组有关。随着时间的推移,高活性钴胺(I)蛋氨酸合成酶的辅助因子被氧化成惰性钴胺(II)形式,使酶失活.MSR缺陷的症状包括小头畸形、精神运动性迟滞、间歇性意识减退、肥大型Mia、血浆游离同型半胱氨酸升高(>20 mol/L),低血浆蛋氨酸(<10 mol/L),增加甲酰谷氨酸的排泄。

In one case report, a female patient with MSR deficiency was treated with several vitamins and cofactors and her clinical progress was followed for 17 y (303). With high-dose folic acid treatment, biochemical abnormalities such as formiminogluta-mate excretion and homocystinuria nearly normalized, but clinical and hematologic abnormalities remained. When folate was replaced by methylcobalamin, alertness, motor function, speech, and electroencephalogram results improved and biochemical features were similar but mean corpuscular volume increased. The best control of symptoms was observed with a combination of folate and methylcobalamin. At the age of 17 y, the patient remained severely mentally retarded. In cultured fibroblasts, methionine synthesis was reduced to 0.03 nmol · mg1 · 16 h1 compared with control values of 2.4–6.9 nmol · mg1 · 16 h1. Complementation studies indicated the cblE defect. These studies suggest a role for folate in addition to cobalamin in treatment (303).


The standard therapy consists of parenterally administered hydroxycobalamin (1–3 mg/wk) but not cyanocobalamin, and sometimes the additional administration of folic acid and betaine. The oldest known patient was first diagnosed with cblE disease at the age of 25 y (304). He had megaloblastic anemia at the age of 7 wk, which was treated with hydroxycobalamin (500 g/d) and folic acid (5 mg/d) for 5 d, resulting in a prompt rise in hemoglobin concentrations even though megaloblastosis persisted. The therapy was continued with 1 mg cyanocobalamin intramuscularly every 8 wk and 5 mg folic acid /d orally. During the following months, he showed progressive neurologic deficits including developmental delay, pigmentary retinopathy, nystagmus, and seizures. Despite intensified therapy, the neurologic symptoms progressed. The therapy was changed to parenteral administration of hydroxycobalamin (1 mg twice a week), which, over a period of 5 mo, resulted in a normalization of methionine concentrations and a reduction in homocysteine concentrations but did not influence the neurologic symptoms.

标准疗法包括肠外注射羟钴胺(1-3毫克/周),但不含氰钴胺,有时补充叶酸和甜菜碱。已知年龄最大的病人在25岁时首次被诊断患有cblE病。他7周时患有巨幼细胞性贫血,用羟钴胺(500 g/d)和叶酸(5mg/d)治疗5d,导致血红蛋白浓度迅速上升,即使巨细胞增生持续存在。每8wk肌注氰钴胺1mg,口服叶酸5mg。在接下来的几个月里,他表现出进行性神经功能缺陷,包括发育迟缓,色素性视网膜病变,眼球震颤和癫痫。尽管加强了治疗,但神经症状仍有进展。治疗改为肠外注射羟钴胺(每周1毫克,每周两次),在5年的时间里,导致蛋氨酸浓度正常化,同型半胱氨酸浓度降低,但不影响神经系统症状。

Characterization of defects in cblE patients showed several mutations in the gene encoding MSR. Of the 11 mutations identified in one study, 3 were nonsense mutations (294). The remaining 8 mutations were found throughout the coding region and involved substitutions or in-frame disruptions of the coding sequence. Of 7 mutations not identified in the control population, 3 were located in the vicinity of the proposed FMN binding site and 2 more were found to be associated with the FAD and NADPH binding regions.


Cobalamin treatment seems to bypass the genetic defect because MSR does not use a cobalamin cofactor. We suggest that physicians consider the benefits of riboflavin, the precursor to FMN and FAD, and niacin, the precursor of NADP, in addition to cobalamin and folate when treating patients with cobalamin disorders.


Tissue concentrations and toxicity 组织浓度和毒性
There is no defined UL for cobalamin and cyanocobalamin 钴胺和氰钴胺没有明确的UL
(the form used in the United States and Canada). Therapy has resulted in few adverse effects with doses ≤ 5000 μg/d (7).(在美国和加拿大使用的形式)。使用剂量为≤5000μg/d的药物治疗几乎没有副作用。

The DRI for folic acid is 400 g/d (7). 叶酸的DRI为400 g/d

The crystal structure of a folate binding enzyme (dihydrofolate reductase) complexed with folate has been solved to 2.3 Å and residues that directly interact with folate have been identified (305). The folate-dependent enzymes are summarized in Table 9.


Methylenetetrahydrofolate reductase (NADPH): homocysteinemia, schizophrenia, rages, depression, central nervous system dysfunction, and neural tube defects


MTHFR (also discussed in the section on riboflavin) cat-alyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate (see OMIM 236250). The latter is the predominant circulatory form of folate and the main carbon donor for the remethylation of homocysteine to methion-ine. Patients with severe MTHFR deficiency (0–20% residual activity) present in infancy or adolescence with developmental delay, motor and gait dysfunction, seizures, schizophrenic disturbances, and other neurologic abnormalities; they are also at risk of vascular complications. MTHFR mutations, including the 677C→T polymorphism, lead to elevated plasma homo-cysteine concentrations, a risk factor for vascular disease and possibly schizophrenia.

MTHFR(也在核黄素一节中讨论)CAT-分析了5,10-亚甲基四氢叶酸转化为5-甲基四氢叶酸(见OMIM 236250)。后者是叶酸的主要循环形式是同型半胱氨酸再甲基化的主要碳供体。严重MTHFR缺乏症(0-20%残留活动)的患者在婴儿期或青春期出现发育迟缓,运动和步态障碍,癫痫发作,精神分裂,以及其他神经功能异常;他们也有血管并发症的危险。MTHFR突变,包括677c→T多态性,导致血浆同型半胱氨酸浓度升高,这是血管疾病和精神分裂症的危险因素。

Recurrent episodes of folate-responsive schizophrenic-like behavior were documented in a mildly retarded adolescent girl with homocystinuria and homocysteinemia without hyperme-thioninemia who lacked the habitus associated with CBS deficiency (306). Enzymes involved in homocysteine-methionine metabolism were shown to be normal. A defect in the ability to reduce 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofo-late was shown and MTHFR activity was 18% of control values. The girl was treated with oral folic acid and all her psychotic behavior ceased. Supplementation with folic acid (20 mg/d) for 14 d led to a decrease in homocysteine excretion and progressive improvement in intellectual function over the next 3 mo without further medication. The girl left the hospital without medication and was readmitted later, at which point folic acid and vitamin B-6 induced major improvements again. This is one of 4 patients described since 1975 (307).


Two children who were found to have homocystinuria after they were examined for rages and seizures were initially thought to have a biochemical defect in the conversion of homocysteine to methionine. They both responded favorably to low-dose folic acid (0.8–3 mg/d) with a decrease in urinary homocystine and other improvements, but the benefits only lasted several months, at which time homocystine concentrations increased and rages resumed. In one case, double the amount of folate and a low-protein diet caused improvement; in the other, betaine and a low-protein diet were effective. The authors suggested that the biochemical defect was a deficient MTHFR activity that is par-tially responsive to folate therapy (308).

两名儿童在被检查为狂怒和癫痫发作后发现有同频尿症,最初被认为在同型半胱氨酸转化为甲硫氨酸方面存在生化缺陷。它们对低剂量的叶酸都有很好的反应 (0.8–3 mg/d)随着尿同型晶体的减少和其他方面的改善,但福利只持续了几个月,此时,同型晶体浓度增加,狂暴再次出现。在一种情况下,两倍量的叶酸和低蛋白饮食导致改善;另一方面,甜菜碱和低蛋白饮食是有效的.作者认为,生物化学缺陷是MTHFR活性不足,对叶酸治疗的反应是正常的。

The Km of the E. coli mutant protein homologous to the human 677C→T variant was measured and found to not differ significantly from controls (165). FAD binding was affected—likely as a result of an increased Km for the coenzyme—but the decreased affinity of MTHFR for FAD was abolished under conditions of high folate. It was thus hypothesized that folic acid therapy low-ers homocysteine in TT individuals by increasing enzyme affinity for FAD. FAD binding is similarly impaired in the recombinant human enzyme, which was recently purified (164). The more severe cases discussed above may have responded to folate through increases in enzyme affinity for FAD or by overcoming a decreased affinity for the folate substrate itself.


Another reason for lowering homocysteine concentrations by riboflavin, vitamin B-12, folate, and vitamin B-6 supplementation is the reduction of anger and hostility. Positive and significant associations were reported between hostility and homocysteine concentrations in both men and women and between anger and homocysteine concentrations in men (309).


The 677C→T polymorphism in MTHFR was examined in persons with schizophrenia, major depression, and bipolar disor-der (310). The TT variant was found in 12% of 419 control subjects, 21% of 297 patients with schizophrenia (P < 0.0006; P < 0.002 after Bonferroni correction), 28% of 32 patients with major depression (P < 0.06; P < 0.02 after Bonferroni correc-tion), and 13% of 40 patients with bipolar disorder (NS). The authors pointed out that the oxidation product of homocysteine, homocysteic acid, exerts potent excitatory effects (310). Joober et al (311) also found an overrepresentation of the TT variant in persons with schizophrenia who responded to neuroleptics compared with that in control subjects (311).

检测了精神分裂症、重度抑郁症和双相情感障碍患者MTHFR 677c→T多态性。419例正常人中TT变异率为12%,在297例精神分裂症患者中为21%(P<0.0006;P<0.002)。32例重度抑郁症患者中28%(P<0.06;P<0.02),40例双相情感障碍(NS)患者中占13%。作者指出,同型半胱氨酸的氧化产物-同型半胱氨酸-具有很强的兴奋性作用。Joober等人,在精神分裂症患者中,与对照组相比,对抗精神病药物有反应的精神分裂症患者中TT变异的比例也过高。

In another study, high homocysteine concentrations were found in 9 of 20 patients with schizophrenia (312). The thermolabile 677C→T polymorphism was screened for in a follow-up study of 11 patients with high homocysteine concentrations. Seven of the 11 patients, 6 males and 1 female, had the homozygous TT geno-type. One male patient was heterozygous and all 3 normal homozygotes were females. In the patients who were homozygous for the polymorphism, homocysteine concentrations did not respond to vitamin B-12 but were normalized by folate supple-mentation. In the healthy homozygotes, however, homocysteine concentrations were reduced by vitamin B-12 alone. It was concluded that homozygosity for thermolabile MTHFR may be a risk factor for schizophrenia-like psychosis, and that this risk might be reduced by folate supplementation (313). In a small study (314), homocysteine was significantly higher in patients with schizo-phrenia who had low serum folate concentrations (n = 6) than in control subjects with low serum folate concentrations (n = 8).

在另一项研究中,20例精神分裂症患者中有9例发现高同型半胱氨酸。在11例高同型半胱氨酸患者的随访研究中,筛选了热摩尔677c→T多态性。11名病人中有7名,其中男性6例,女性1例,均为纯合子TT Geno型。1例男性为杂合子,3例正常纯合子均为女性。在多态纯合子的患者中,同型半胱氨酸浓度对维生素B-12没有反应,而是通过叶酸的增强而正常化。然而,在健康的纯合子中,纯半胱氨酸浓度仅靠维生素B1 2就降低了.结论:热摩尔mtfr纯合子可能是精神分裂样精神分裂症的危险因素,补充叶酸可降低此风险。在一个小的研究中,血清叶酸浓度较低的分裂性膈病患者(n=6)的同型半胱氨酸明显高于低血清叶酸浓度的正常人(n=8)。

Two reports did not find a link between schizophrenia, the 677C→T polymorphism, and hyperhomocysteinemia. In one report, no significant difference in the frequency of TT individu-als was found between the 343 patients with schizophrenia and 258 control subjects studied. It was concluded that the 677C→T polymorphism is unlikely to have played a major role in the pathogenesis of schizophrenia or affective disorders in the sample population (315). Another group found no significant differences in plasma homocysteine concentrations between the 210 patients with schizophrenia and 218 control subjects stud-ied. The distributions of the T allele and TT genotype frequencies were similar in both groups (40% and 15%). Thus, it was con-cluded that impaired homocysteine metabolism is unlikely to play a role in schizophrenia (316).


We suggest that clinical trials of B vitamin therapy (including folate and riboflavin) in relation to schizophrenia and rages are warranted on the basis of the association of higher homocysteine concentrations with anger (309) and schizophrenia (312) and the association of the TT genotype with schizophrenia (310). Homocysteine accumulation can be an indicator of a defective enzyme in the methylation pathway and treatment with vitamin precursors of substrates and cofactors in that pathway such as riboflavin, vitamin B-12, folate, and vitamin B-6 may be benefi-cial in managing rages and schizophrenia.

Folate is a well-established measure for preventing NTDs. Various studies have implicated the 677C→T mutation and high homocysteine in NTDs and others have shown a decrease in NTD prevalence in mothers who take folic acid perinatally (317). Although the etiology of NTDs is likely multifactorial and 677C→T alone is certainly not responsible for NTDs, a possible explanation for folate-responsiveness in individuals with the polymorphism could relate to the fact that incubation of the variant enzyme with high concentrations of folate abolishes the reduced FAD binding capacity of 677C→T MTHFR (165). It is unclear whether perinatal use of riboflavin, the precursor of FAD, would be of additional benefit for some mothers at risk of delivering a child with an NTD.

叶酸是预防NTDs的一种行之有效的措施.各种研究都暗示了677c→T突变和高同型半胱氨酸在NTDs中的存在还有一些研究表明,在围产期服用叶酸的母亲中,NTD的患病率有所下降。虽然NTDs的病因可能是多因素和677c的,但单是→T并不是NTDs的病因。这种多态个体对叶酸反应性的一个可能解释可能与叶酸浓度高的变异酶孵育可消除r有关。677c→T MTHFR的FAD结合能力,目前尚不清楚围产期使用核黄素(FAD的前身)是否会对一些有可能接生NTD儿童的母亲带来额外的好处。

Methionine synthase: homocystinuria and neurologic dysfunction 蛋氨酸合成酶:高胱氨酸尿和神经功能障碍

One patient with 36% of normal residual methionine synthase activity improved significantly with folic acid treatment (318). (See OMIM 156570 and the section on cobalamin for further information on methionine synthase.)

1例残馀36%蛋氨酸合成酶活性正常的患者经叶酸治疗后明显改善(关于蛋氨酸合成酶的进一步信息,请参阅OMIM 156570和钴胺一节。)。

Dihydrofolate reductase: megaloblastic anemia and neurologic symptoms

Dihydrofolate reductase uses NADPH to catalyze the successive reductions of folate to 7,8-dihydrofolate to 5,6,7,8-tetrahydro-folate (see OMIM 126060). In one patient with megaloblas-tic anemia and decreased enzymatic activity, oral folic acid (5 mg/d) resulted in a sustained 3-y remission (500 g/d had no effect) (319). When folate therapy was discontinued, the patient relapsed.

二氢叶酸还原酶利用NADPH催化将叶酸连续还原成7,8-二氢叶酸为5,6,7,8-四氢叶酸(见OMIM 126060)。1例巨幼细胞性贫血患者酶活性降低,口服叶酸(5mg/d)可持续缓解3~y(500 g/d)。当叶酸治疗停止时,病人又复发了。

Dihydrofolate reductase deficiency was reported in 3 children presenting with a megaloblastic anemia shortly after birth (320). A deoxyuridine suppression test was abnormal in 2 of the children and was only corrected with folinic acid, 5-formyltetrahy-drofolate. A hematologic response was also evident after folinic acid therapy, although this therapy may bypass the defect.


Glutamate formiminotransferase: mental retardation Glutamate formiminotransferase uses PLP to transfer the formimino group from formimino glutamate to tetrahydrofolate to form 5-formyltetrahydrofolate (folinic acid). A defect in this enzyme results in excretion of formimino glutamate (see OMIM 229100). Four of 5 original patients reported by Arakawa (321) had mental and physical retardation; enzymatic activity ranged from 14% to 54% of normal.

谷氨酸亚胺甲基转移酶:智力缺陷谷氨酸亚胺甲基转移酶使用PLP将甲酰亚胺基从谷氨酸甲酰转移到四氢叶酸,形成5-甲酰四氢叶酸(叶酸)。这种酶的缺陷导致谷氨酸甲醛的排泄(见OMIM 229100)。Arakawa报告的5名原始患者中有4人(321人)有智力和身体发育迟缓;酶活性为正常人的14%~54%。
Five additional patients were reported with the deficiency; one was a 42-y-old woman whose elevated urinary concentrations of formiminoglutarate fell to normal with 30 mg folic acid/d and who improved with continued folate therapy (322). As measured by decreased excretion of formimino glutamate, 2 of 8 patients responded to treatment with high folic acid (323, 324).

Physicians might consider treatment with pyridoxine (cofactor precursor) in addition to folate (substrate precursor) in patients who present with a defect in glutamate formiminotrans-ferase. Folinic acid therapy, which would bypass the metabolic defect, should be effective as well.


Folate membrane transport: dyserythropoiesis, central nervous system dysfunction, and megaloblastic anemia Congenital malabsorption of folate (see OMIM 229050) results clinically in hypotonia, lethargy, seizures, megaloblastic anemia, mental retardation, and ataxia and biochemically in low folate concentrations in serum, red blood cells, and cere-brospinal fluid (320). A patient with hereditary dyserythropoiesis (without anemia) had reduced membrane transport of 5-methyltetrahydrofolate by red blood cells (325). Total uptake, uptake velocity, and maximal velocity of uptake were all significantly less than in control subjects. The patient’s measured Km was 0.27 mol/L (Vmax 0.095 pmol · 109 cells · min1) whereas that in control subjects was 0.50 mol/L (Vmax 0.301 pmol · 109 cells · min1). Although the Vmax was lower in the patient, the Km did not appear to be the primary defect. However, the patient’s daughter had an elevated Km of 0.93 mol/L, suggesting a reduced affinity of the transport sys-tem for 5-methyltetrahydrofolate.

叶酸膜转运:异常红系造血,中枢神经系统功能障碍,和巨幼细胞贫血先天性叶酸吸收不良(see OMIM 229050) 结果临床表现为低张力,嗜睡、癫痫、巨幼细胞性贫血,智力迟钝,共济失调和低浓度叶酸在血清、红细胞和脑脊液中的生物化学含量。1例遗传性甲状腺发育不良(无贫血)患者红细胞减少了5-甲基四氢叶酸的膜转运。总摄取、摄取速度和最大摄取速度均明显低于对照组。患者的Km值为0.27mol/L(Vmax为0.095 pmol·109个细胞·min1),对照组为0.50mol/L(Vmax为0.301 pmol·109个细胞·min1)。虽然Vmax在患者中较低,但Km并不是主要的缺陷。然而,病人的女儿的KM升高了0.93 mol/L,表明Tran的亲和力降低了5-甲基四氢叶酸的运动系统。

Four cases of congenital malabsorption of folate with megaloblastic anemia, central nervous system abnormalities, and defec-tive gastrointestinal absorption of folates responded at least partially to folic acid (40 mg oral) (322). A review of folate meta-bolic errors states that 12 cases of defective transport of folate across the intestine and the blood-brain barrier have been reported. High doses of oral folic acid (5–40 mg) or lower parenteral doses can reverse the hematologic abnormalities and digestive symp-toms involved with the condition (320). A Km explanation is not definitive because transport of folate through an alternative system at high concentrations has not been ruled out.


Seizures 癫痫发作

Folinic acid has been used in treating early-onset intractable seizures (unresponsive to anticonvulsants and pyridoxine) and can elicit an immediate response (326).

Folylpoly--glutamate carboxypeptidase: homocysteinemia Folylpoly--glutamate carboxypeptidase (-glutamyl hydro-lase), an enzyme that is anchored to the intestinal brush border membrane, is responsible for cleaving terminal glutamate residues from folylpoly--glutamates (see OMIM 600934), the predominant naturally occurring form of dietary folates. Inabil-ity to cleave glutamyl residues reduces the intestinal absorption of folates and decreases folate availability for the remethyla-tion of homocysteine to methionine (see the discussion of methionine synthase in the section on cobalamin), resulting in hyperhomocysteinemia.
叶酸聚谷氨酸羧肽酶:同型半胱氨酸血症叶酸聚,谷氨酸羧肽酶,一种锚定在肠刷边界膜上的酶,是一种有效的酶。可用于从叶酸中切割末端谷氨酸残基(见OMIM 600934),这是膳食叶酸的主要自然存在形式。酶解谷氨酰基残留量减少叶酸的肠道吸收,降低叶酸对同型半胱氨酸再甲基化为甲硫氨酸的有效性(见关于钴胺的一节中关于蛋氨酸合成酶的讨论),RES。高同型半胱氨酸血症。

A C-to-T transition at base pair 1561 was found in 6 (8%) of 75 healthy individuals (327). The polymorphism causes a mis-sense mutation, His475→Tyr that decreases protein activity by 53% as measured in transfected COS-7 cells. As expected, indi-viduals with the polymorphism (heterozygotes) have lower serum folate and higher homocysteine (significant) concentrations and lower red blood cell folate concentrations (NS). Such individuals may benefit from folate supplementation through raised body folate concentrations and lowered homocysteine. This therapy would likely bypass the defect because supplements contain the monoglutamate form of folate and thus do not require the action of folylpoly--glutamate carboxypeptidase. Nevertheless, it would be of interest to measure the kinetic properties of the enzyme as well as the ability of exogenous polyglutamate-folates to over-come the defect.


Tissue concentrations and toxicity 组织浓度和毒性

A UL for folate intake from supplements and fortified foods has been set at 1000 g/d for adults and 300 g/d for 2-y-olds increasing to 800 g/d for 16-y-olds (7), although higher amounts seem warranted in many cases. One patient mentioned above had serum folate concentrations of 185 mg/L (normal con-centrations are 6 g/L) and red blood cell folate concentrations of 591 mg/L (normal concentration: 160 g/L) after 4 mo of supplementation with 12 mg folic acid/d (325). A recent report showed that 5 mg folate/d raises serum folate concentrations 6–7 times and red blood cell folate concentrations 2 times com-pared with placebo (328). Diets high in folate have also been shown to raise serum folate concentrations up to 85% (329). One study suggests that increasing plasma folates in individuals above the third quartile of folate intake is not feasible. In a double-blind, placebo-controlled study of 82 alcoholic subjects receiving 1 mg/d for 18.5 d, it was found that whole-blood folate in these individu-als in the highest quartile of whole-blood folate (initially 3.73–7.70 nmol/g hemoglobin) could not be raised. However, sub-jects in the lowest 3 quartiles did show an increase with folate supplementation. The concentration in the lowest quartile (initially 0.71–2.06 nmol/g hemoglobin) was raised significantly by 0.8 nmol/g hemoglobin and the second lowest (initially 2.08–2.83 nmol/gm hemoglobin) by 0.75 nmol/g hemoglo-bin (330). It would be useful to test nonalcoholics as well (see the discussion of folate membrane transport above) and to measure tetrahydrofolate concentrations because alcohol interferes with folate absorption.

从补充剂和强化食品中摄取叶酸的UL,成人为1000克/天,2岁的为300克/天,16岁的儿童为800克/天。虽然在许多情况下似乎需要更高的数额。1例患者血清叶酸浓度为185 mg/L(正常浓度为6g/L)和红细胞叶酸浓度为591 mg/L(正常浓度:160克/升)4mo后添加12 mg叶酸/d。最近的一份报告显示,5毫克叶酸/日可使血清叶酸浓度提高6-7倍,红细胞叶酸浓度提高2倍,与安慰剂相比,可使血清叶酸浓度提高6-7倍。高叶酸水平的饮食也使血清叶酸浓度提高到85%。一项研究表明,在叶酸摄入量第三四分位以上的个体增加血浆叶酸是不可行的。在一项双盲安慰剂对照研究中,82名酒类受试者每天服用1mg/d,持续18.5天,结果发现,全血叶酸在全血叶酸的四分位数最高(最初为3.73-7.70nmol/g血红蛋白)不能提出。然而,在最低的3四分位数中,叶酸的添加量确实有所增加。最低四分位数的浓度(最初为0.71-2.06nmol/g血红蛋白)0.8nmol/g血红蛋白显著升高,0.75nmol/g血红蛋白升高幅度次之(最初为2.08~2.83 nmol/g血红蛋白)。因为酒精会干扰叶酸的吸收,所以也可以测试非酒精性的人(见上面关于叶酸膜转运的讨论)和测量四氢叶酸的浓度。古斯堪的那维亚语(Old Norse)

The adequate intake of vitamin K is 90 g for women and120 g for men (8). The vitamin K–dependent proteins dis-cussed below are summarized in Table 10.


γ-Glutamyl carboxylase: hemophilia γ-谷氨酰羧化酶:血友病
γ-Glutamyl carboxylase, with bound vitamin K in the presence of oxygen and carbon dioxide, converts glutamic acid residues to γ-carboxyglutamic acid residues on the amino-terminal regions of precursor forms of prothrombin (factor II) and factors VII, IX, and X (see OMIM 137167). These γ-carboxyglutamic acid residues are necessary for calcium-dependent phospholipid bind-ing by the vitamin K–dependent clotting factors and are prereq-uisites for normal blood coagulation (331).

谷氨酸羧化酶(γ-Glutamyl羧化酶)在氧气和二氧化碳存在下,结合维生素K,将谷氨酸残基转化为谷氨酸残基。γ-羧基谷氨酸残基位于凝血酶原(因子II)和因子VII、IX和X的氨基酸末端区域(见OMIM 137167)。这些,γ-羧基谷氨酸残基是钙依赖性磷脂与维生素K依赖的凝血因子结合所必需的,也是正常凝血的先决条件。

The binding sites for the γ-carboxylation recognition site con-taining propeptide and carboxylatable glutamate residues of a vitamin K–dependent substrate protein have been localized to the amino-terminal 250 residues of the enzyme. The carboxyl-terminal regions of the enzyme are important for conversion of vitamin K hydroquinone to vitamin K epoxide, a reaction that occurs concomitantly with carboxylation and is catalyzed by the vitamin K–dependent carboxylase. In addition, catalysis of vita-min K oxygenation by the enzyme is regulated by the availabil-ity of carboxylatable substrate (332).

含γ羧基化前肽的结合位点一种依赖于维生素K的底物蛋白的羧基谷氨酸残基已被定位于氨基末端250个酶的残基。该酶的羧基端区对维生素K对苯二酚转化为环氧维生素K具有重要意义,一种与羧化同时发生的反应,由维生素K依赖的羧化酶催化。此外,该酶对Vita-min K氧化的催化作用还受羧化底物的有效性调节。

The kinetic properties of a naturally occurring mutation in human -glutamyl carboxylase, Leu394→Arg, have been stud-ied (333). The mutant has a 5-fold higher Km (32.8 ± 5.4 mol/L) for vitamin K hydroquinone, the reduced form of vitamin K, than does the control (7.0 ± 1.2 mol/L). The coagulation activities of patients with combined deficiencies of vitamin K–dependent coagulation factors were partially corrected by the administration of vitamin K and vitamin K restored carboxylase activity from a low level to 33% of wild type (333). Thus, this seems to be a vitamin K–responsive Km mutant.

本文研究了人谷氨酰羧化酶(Leu 394→arg)自然突变的动力学性质。突变体对维生素K氢醌的Km(32.8±5.4mol/L)比对照高5倍(32.8±5.4mol/L)。联合缺乏维生素K依赖性凝血因子患者的凝血活性通过服用维生素K进行部分校正和维生素K使羧化酶活性从野生型的低水平恢复到33%。因此,这似乎是一个对维生素K敏感的KM突变体。

An infant girl with abnormal bleeding and some skeletal abnormalities who showed deficiency of vitamin K–dependent clotting factors II (8% of normal), VII (22%), IX (28%), and X (15%) was put on treatment consisting of intramuscular injec-tions of vitamin K and physiotherapy (331). After 7 d of treat-ment, the concentrations of factors II, VII, IX, and X rose to 60%, 65%, 112%, and 56% of controls, respectively. The patient was discharged with vitamin K injections (0.5 mg/kg body wt) every other day (later changed to 10 mg/d). Another patient with a Trp501→Ser mutation and deficiency of the same vitamin K– dependent factors was also responsive to vitamin K therapy (5 mg/d) and a binding defect was suspected: “the mutation may affect either the vitamin K-binding site or the propeptide-binding site” (334).

一名异常出血及部分骨骼异常的婴儿,显示缺乏维生素K-依赖凝血因子II(正常8%)、VII(22%)、IX(28%)和X(15%)被用于肌肉内损伤维生素K和理疗。治疗7d后,II、VII、IX、X因子浓度分别为对照组的60%、65%、112%和56%。患者每隔一天接受维生素K注射(0.5mg/kg体重)(后改为10 mg/d)。另一位患有Trp 501→Ser突变和缺乏相同的维生素K依赖因子的患者也对维生素K治疗(5mg/d)有反应,并怀疑存在结合缺陷:可能影响维生素K结合位点或前肽结合位点“

A patient congenitally deficient in factors II, VII, IX, and X was studied after a follow-up of 15 y (335). At birth, these fac-tors, when determined by clotting assays, were undetectable. After therapy with vitamin K1, the clotting activity of these fac-tors rose but never exceeded 18% of normal. Some molecules of the patient’s prothrombin lacked the normal complement of -carboxyglutamic acid residues. It was suspected that this rep-resents either a defective -carboxylation mechanism within the hepatocyte or faulty vitamin K transport; a Km mutation in -glutamyl carboxylase affecting vitamin K binding would be a plausible explanation. Vitamin K therapy could be tried in cases of inborn errors of blood clotting.


Propeptide of factor IX: hemophilia 因子Ⅸ前肽 :血友病

Blood clotting requires the posttranslational modification 凝血需要翻译后的修饰

(γ-carboxylation) and proteolysis of several blood clotting factors. The γ-carboxylation reaction is performed by γ-glutamyl carboxylase in the presence of vitamin K, carbon dioxide, and oxygen and precedes cleavage. A proteolysis cascade is required for clotting factor activation, in which the cleavage of each factor activates a proteolytic activity in the subse-quent protein so that the cascade can continue. The propeptide sequence of vitamin K–dependent proteins, such as factor IX propeptide, is a critical factor in the regulation of γ-carboxylation. One highly conserved residue of factor IX propeptide in par-ticular, the alanine at position 10 (A-10), seems to influence the carboxylation reaction. A patient was investigated that had a 6346G→A transition in genomic DNA, resulting in a muta-tion, A-10T, in the factor IX propeptide (336). The mutation resulted in the carboxylating enzyme, -glutamyl carboxy-lase, having a 33-fold increased Km for propeptide, as well as a less marked rise in Km of the enzyme-propeptide complex for vitamin K. The Km of the complex containing the wild-type propeptide was 4.2 mol/L, whereas the Km of the com-plex with the mutant A-10T propeptide for vitamin K was 9.3 mol/L and the Km of the complex with another mutant propeptide, A-10G, for vitamin K was 8.6 mol/L. These authors concluded, “Thus, both enzyme-peptide complexes containing variant peptides have lower affinities for vitamin K than the complex containing the wild-type peptide, but the dif-ference is not marked” (336). (See OMIM 306900.) It would be of interest to know whether patients would benefit from vitamin K therapy.

(γ-羧化)和几种凝血因子的蛋白水解:γ羧化反应是在维生素K、二氧化碳和氧气存在下,γ-谷氨酰基羧化酶发生裂解反应.凝血因子激活需要一个蛋白水解级联,在这个过程中,每一个因子的断裂都会激活亚硒蛋白中的一个蛋白水解活性,从而使级联能够继续下去。维生素K依赖蛋白的前肽序列,如第九因子,是调节γ羧化的关键因素。第九因子的一个高度保守的残基,即位于第10位(A-10)的丙氨酸,似乎影响了羧化反应。一名病人在基因组dna中进行了6346 G→A转换,导致第九因子前肽A-10T的突变。突变导致羧化酶,-谷氨酰羧酰化酶,前肽的Km增加33倍,此外,维生素K的酶原肽复合物的Km也没有明显增加。含有野生型前肽的复合物的Km为4.2mol/L,与突变型A-10T前肽的Km为9.3mol/L,Km为9.3mol/L。突变型前肽A-10G对维生素K的含量为8.6mol/L。这些作者得出结论:“因此,两种含有变异肽的酶肽复合物对维生素K的亲和力都比含有野生型肽的复合物低,但差异很大。无标记“(见OMIM 306900。)了解患者是否能从维生素K治疗中获益是很有兴趣的。

Tissue concentrations and toxicity 组织浓度和毒性

In vivo concentrations of vitamin K can be clinically manipu-lated (333). Plasma menaquinone-4 concentrations reached a maximum (a 10-fold increase) at 3 h after administration of 4 mg menaquinone-4 to 6 infants aged 5 d (337).


TABLE 9:Enzymes that use a folate cofactor or substrate1 使用叶酸辅助因子或底物的酶

Defective enzyme and EC no.
Reaction catalyzed
Disease or condition
OMIM no.
Methylenetetrahydrofolate reductase (NADPH) (
5,10-Methylene-THF + NADPH → 5-methyl-THF + NADP
Homocystinuria, 高胱氨酸尿,vascular complications, 血管并发症,retardation发育迟缓,seizures癫痫,
psychiatric problems, 精神问题and neurologic abnormalities 神经异常(including schizophrenia, rages, and depression)包括精神分裂症,愤怒和抑郁
Autosomal recessive
Methionine synthase (
Cytoplasmic 细胞质
Homocysteine + 5-methyl-THF →methionine + THF
Homocystinuria 高胱氨酸尿
Autosomal recessive
Dihydrofolate reductase (
Cytoplasmic? 细胞质
Dihydrofolate + NADPH →tetrahydrofolate + NADP
Megaloblastic anemia 巨幼红胞性贫血and neurologic abnormalities神经异常
Autosomal recessive
Glutamate formiminotransferase 谷氨酸亚胺甲基转移酶(
THF + N-formimino-glutamate →5-formimino-THF + glutamate
Mental retardation智力迟钝
Autosomal recessive
Folylpoly-γ-glutamate carboxypeptidase
Extracellular and lysosomal
Cleaves terminal glutamate off folylpoly--glutamates 末端谷氨酸从叶酸-谷氨酸中分离出来
1 OMIM, Online Mendelian Inheritance in Man (4); THF, tetrahydrofolate.

TABLE 10 Enzymes that use a vitamin K cofactor1 使用维生素K辅助因子的酶

Defective enzyme
Reaction catalyzed
Disease or condition
OMIM no.
γ-Glutamyl carboxylase[size=9.0000pt]
Integral membrane protein
Glutamic acid of propeptide → -carboxyglutamic acid
血友病 and
decreased γ-carboxyglutamate and clotting factorsγ-羧基谷氨酸与凝血因子
Autosomal recessive
Propeptide of factor IX
Extracellular )细胞外
Glutamic acid of propeptide → γ-carboxyglutamic acid


The adequate intake of vitamin D (calciferol, or vitamin D3) is 5 g for middle-aged persons and 10 g for older persons (338). Two successive hydroxylations of vitamin D in the liver and kidney produce the hormonally active form, calcitriol (1,25-dihydroxyvitamin D3).

维生素D(钙素或维生素D 3)的适当摄入量中老年人为5克,老年人为10克。肝脏和肾脏中的维生素D连续两次羟化产生激素活性形式-钙基三醇(1,25-二羟基维生素D 3)。

Vitamin D receptor: vitamin D–dependent rickets II Calcitriol binds to the vitamin D receptor (see OMIM 601769),a nuclear transcription factor that regulates gene expression and is essential for the normal development of bone and the promo-tion of calcium transport across the small intestine. Defects in the vitamin D receptor lead to hypocalcemic vitamin D–dependent rickets, congenital total lipodystrophy, and persistent mullerian duct syndrome. The first known patient with a missense mutation in the vitamin D receptor hormone binding domain harbored a Arg271→Leu substitution and was not responsive to calcitriol (≤50 g/d), most likely because of a 1000-fold decreased affinity of vitamin D receptor for calcitriol in vitro (339).

维生素D受体:维生素D依赖性佝偻病Ⅱ钙三醇与维生素D受体结合(见OMIM 601769),调节基因表达的核转录因子和对于骨骼的正常发育是必不可少的和促进钙在小肠的转运。维生素D受体的缺陷导致维生素D依赖的佝偻病,先天性全脂营养不良,以及持续的毛拉管综合征。第一位在维生素D受体激素结合域发生错义突变的患者携带Arg 271→Leu替代物,对钙基三醇(≤50g/d)没有反应,很可能是因为维生素D受体在体外的亲和力降低了1000倍。

Other patients with missense mutations affecting calcitriol binding have, however, responded to high-dose vitamin D ther-apy (340–342). Sequence analysis of a hyporesponsive vitamin D receptor gene from one patient revealed a C-to-G transversion (His305→Gln) that caused an 8-fold decreased protein affinity for calcitriol (340). The patient was effectively treated with high doses (12.5 g/d) of calcitriol. Two other point mutations, Ile314→Ser and Arg391→Cys, have been found that confer reduced calcitriol-dependent activation of vitamin D receptor (341). Vitamin D receptor with the Arg391→Cys mutation was par-tially activated by high concentrations of hormone in vitro, which was reflected in the only partial responsiveness of the patient to calcitriol. On the other hand, vitamin D receptor activity of the Ile314→Ser mutant was more easily rescued by calcitriol, and the patient with this mutation was almost completely cured by calcitriol therapy. A similar patient (aged 18 mo) with a decreased affinity of vitamin D receptor for calcitriol responded well to administered hormone (20 g/d) with a resolution of serum calcium and phosphorous concentrations; marked clinical improvement, including the ability to stand and walk; and pro-gressive healing of the rickets (342).

其他有影响降钙素结合的错义突变的病人有,然而,对高剂量的维生素D治疗有反应。对一例患者维生素D受体基因的序列分析显示,C到G转换(His 305→Gln)使蛋白质对降钙素的亲和力降低了8倍。这位病人有效地接受了大剂量的治疗(12.5 g/d)的降钙素。另外两个点突变(ile 314→ser和arg 391→cys)被发现可以降低维生素D受体的钙基三醇依赖性激活。Arg 391→Cys突变的维生素D受体在体外被高浓度的激素激活,这反映在病人对降钙素唯一的部分反应。另一方面,Ile 314→Ser突变体的维生素D受体活性更容易被骨化三醇所挽救,并且该突变的患者经钙柠檬酸治疗几乎完全治愈。一名类似的患者(18岁),维生素D受体对钙基三醇的亲和力降低激素(20g/d)对血清钙磷浓度有较好的反应;显著的临床改善,包括站立和行走的能力,以及有利于佝偻病的治疗。

Three vitamin D receptor polymorphic alleles [polyA (long), BsmI (bb), and TaqI (TT)] were found in higher frequencies in colon cancer patients than in control subjects and were thus associated with an increased rate of cancer (343). Such reports rein-force the need to decipher genotype-phenotype relations, with the ultimate goal of catering medical interventions to the needs of individuals. If increased concentrations of calcitriol could overcome a protein defect associated with cancer, vitamin D therapy could be important for reducing cancer risk associated with such defects in the vitamin D receptor.

三种维生素D受体多态性等位基因 [polyA (long), BsmI (bb), and TaqI (TT)] 在结肠癌患者中发现的频率高于对照组,因此与癌症的发生率有关。这样的报道迫使我们必须破译基因型-表型关系,以满足个人需要的医疗干预为最终目标。如果增加钙基三醇的浓度可以克服与癌症相关的蛋白质缺陷,维生素D治疗对于减少与维生素D受体缺陷相关的癌症风险可能很重要。

In a study of the involvement of vitamin D deficiency (serum 25-hydroxyvitamin D3 < 50 nmol/L) in prostate cancer development, young men (40–51 y old) with low serum vitamin D con-centrations were at the greatest risk of developing prostate cancer (344). Cellular studies in prostate cancer cells suggested that vitamin D up-regulates androgen receptor expression, whereas androgens seem to up-regulate vitamin D receptor (344). If defects in vitamin D receptor (or androgen receptor) also predispose individuals to prostate cancer, such an activation of receptors by vitamin D administration seems like a possible protective measure for preventing against the onset of cancer in individuals (especially young men) with vitamin D receptor defects.

维生素D缺乏的相关性研究(血清25-羟维生素D 3<50 nmol/L)在前列腺癌的发展过程中,血清维生素D含量较低的年轻男性(40-51岁)患前列腺癌的风险最大。对前列腺癌细胞的细胞研究表明维生素D能上调雄激素受体的表达,而雄激素似乎能上调维生素D受体,如果维生素D受体(或雄激素受体) 的缺陷也会使人患前列腺癌,维生素D受体的激活似乎是预防维生素D患者(尤其是年轻男性)癌症的一种可能的保护措施。你知道吗?

By 1994, 50 cases of vitamin D receptor defects had been reported. Treatment is usually 20 g/d of the bioactive form, calcitriol, or 5 mg/d of the dietary form, vitamin D2, plus oral calcium and phosphate (345).Calciferol 1-hydroxylase: vitamin D–dependent rickets I The mitochondrial cytochrome P450c1gene codes for a cal-ciferol 1-hydroxylase (calcidiol 1-monoxygenase) that converts 25-hydroxyvitamin D3 to the hormone calcitriol. A genetic deficiency in the renal proximal tubules causes a pseudo–vitamin D–deficiency called rickets (see OMIM 264700). The P450c1 gene was analyzed in 19 individuals from 17 families representing various ethnic groups (346). All patients had P450c1 mutations on both alleles. In the French Canadian population, among whom vitamin D–dependent rickets I is common, 9 of 10 alleles bore the haplotype 4-7-1 and carried the mutation 958G. Patients are treated with a physiologic dose of calcitriol; thus, the hormone is replaced, but the remediation does not appear related to a change in Km.

到1994年,报告了50例维生素D受体缺陷。治疗通常是20克/天的生物活性形式,钙三醇,或饮食形式的5毫克/天,维生素D 2,加上口服钙和磷酸盐。沉钙固醇1-羟化酶:维生素D:依赖性佝偻病Ⅰ线粒体细胞色素P450c1沉钙固醇1-羟化酶:维生素D基因编码它将25-羟基维生素D 3转化为降钙素。肾近端小管遗传缺陷导致假性-维生素D缺乏称为佝偻病(见OMIM 264700)。对来自不同民族的17个家系的19名个体进行了p450c1基因分析。两种等位基因均有P450c1突变。在加拿大的法裔人口中,其中维生素D依赖型佝偻病我很常见,10个等位基因中有9个携带单倍型4-7-1,并携带958G突变。患者接受生理剂量的降钙素治疗,因此,激素被替代,但补救措施似乎与Km的变化无关。


Morphea is a skin-associated scleroderma, a disease of the connective tissue involving increased collagen synthesis and deposition in various organs and skin. A significant clinical improvement was observed in 3 patients with generalized morphea who were given 0.50–0.75 g calcitriol/d (347). If the mechanism of action—possibly immunoregulatory or growth inhibitory—involved altered binding for the vitamin hormone, then it seems plausible that remediation of scleroderma or morphea with vitamin D results from raising the rate of some reaction in that pathway.


Tissue concentrations and toxicity 组织浓度和毒性

Data accumulated in the DRI manual suggest a direct relation between vitamin D intake and 25-hydroxyvitamin D concentrations. The UL of dietary vitamin D is 50 g/d and adverse effects have been seen at concentrations ranging from 250 to 1250 g/d (338).
DRI手册中积累的数据表明维生素D摄入量与25-羟基维生素D浓度之间存在直接关系。膳食维生素D的UL为50 g/d,在250~1250 g/d的浓度范围内出现了不良反应。

α-Tocopherol is the main form of the lipid-soluble vitamin E α-生育酚是脂溶性维生素E的主要形式。

in animal tissues and plasma. The DRI for vitamin E is 15 mg/d (  1.5 IU/mg = 22.5 IU/d) as -tocopherol (348).
在动物组织和血浆中。维生素E的DRI为15 mg/d(1.5 IU/mg=22.5 IU/d)As-生育酚

α-Tocopherol transfer protein: ataxia with isolated vitamin E deficiency α-生育酚转运蛋白:单纯性维生素E缺乏症共济失调

With structural similarity to other lipophilic vitamin bind-ing proteins, α-tocopherol transfer protein (TTP), present in the liver and cerebellum, is responsible for the incorporation of α-tocopherol into lipoproteins and for the transport of α-tocopherol between membranes. An autosomal recessive dis-ease characterized by ataxia with isolated vitamin E deficiency (AVED, see OMIM 277460) is caused by mutations in TTP. Patients with AVED retain normal intestinal absorption of vitamin E, but have defective incorporation of vitamin E into VLDLs by hepatic cells. The disease involves abnormally low serum concentrations of α-tocopherol, absent tendon reflexes, cardiomyopathy, and intel-lectual decline. The prevention of neuronal damage associated with AVED is typically mediated by lifelong supplementation with high doses of vitamin E (800 mg/d), and other symptoms can be averted if therapy is started early enough.

与其他亲脂维生素结合蛋白结构相似,α-生育酚转运蛋白(TTP),存在于肝脏和小脑,负责α-生育酚与脂蛋白的结合以及α-生育酚在膜间的转运。一种具有分离维生素E缺陷性共济失调的常染色体隐性不容易性(艾维德,见OMIM 277460)是由TTP突变引起的。患者肠内维生素E吸收正常,但有缺陷的维生素E掺入到VLDLs肝细胞。这种疾病包括血清α-生育酚浓度异常低,肌腱反射缺失,心肌病和智力下降。预防AVED相关的神经元损伤通常是通过终生补充高剂量维生素E(800 mg/d)来实现的,如果开始治疗,其他症状可以避免。够早的了。

In 3 individuals, vitamin E responsiveness was attributed to mutations in the gene encoding TTP (349). Two siblings were com-pound heterozygotes for a 421G→A transition (Glu141→Lys) and a 513-514 TT insertion. A third case from another family was homozygous for a 552G→A splice site mutation. Serum α-tocopherol concentrations dropped below normal with treatment withdrawal, confirming the impaired ability of AVED patients to conserve α-tocopherol in the body. Serum α-tocopherol concentrations were raised when treatment was reinstated.

在3个个体中,维生素E反应性是由编码TTP的基因突变引起的。两个兄弟姐妹分别为421 G→A转换(Glu141TT Lys)和513-514TT插入的COM-磅杂合子。另一个家系的第三个病例是552 G→A剪接位点突变的纯合子。停药后血清α-生育酚浓度降至正常水平,证实α患者体内保存α-生育酚的能力受损。恢复治疗后血清α-生育酚浓度升高。

The effectiveness of high-dose vitamin E treatment (800 mg/d) for 1 y was quantitatively measured in 24 AVED patients with use of the ataxia rating scale (350). All participants had the 744delA mutation in TTP, which is common to AVED patients in Tunisia. Mean scores on the ataxia rating scale decreased from 45 to 35 over the year, with statistically significant incremental drops at 3, 6, 9, and 12 mo. Serum vitamin E concentrations normalized as well.

应用共济失调评定量表,定量测定了24例老年痴呆患者服用高剂量维生素E(800 mg/d)治疗1y的疗效。所有参与者都在TTP中发生了744DELA突变,这对于突尼斯的Ave患者是常见的。共济失调评分量表的平均评分从45岁下降到35岁,在3,6,9和12 mo时,有统计学意义的递增下降。血清维生素E浓度也已正常化。

The success of vitamin E may be attributed to either the nonenzymatic saturation of serum or the saturation of the hepatic TTP enzymes so as to accelerate vitamin E incorporation into VLDL. The latter scenario would likely entail the overcoming of an altered binding of TTP with vitamin E.


Tissue concentrations and toxicity 组织浓度和毒性

The UL of vitamin E on the basis of supplementation with α-tocopherol is 1000 mg/d (1500 IU) as a result of adverse effects including increased risk of hemorrhage (348). In 2 patients mentioned above, the reinstatement of α-tocopherol treatment showed a linear relation to serum α-tocopherol concentrations. The maximal dosage (40 mg · kg body wt1 · d1) resulted in a plasma concentration > 50 mol/L (349).

在补充α-生育酚的基础上,维生素E的UL为1000 mg/d(1500 IU),这是由于不良反应(包括增加出血风险)造成的。在上述2例患者中,α-生育酚治疗的恢复与血清α-生育酚浓度呈线性关系.最大剂量(40 mg·kg体重WT1·D1)导致血浆浓度>50 mol/L。


No DRI has been set for tetrahydrobiopterin. 未对四氢生物蝶呤进行DRI。

Phenylalanine hydroxylase: phenylketonuria II (mild hyperphenylalaninemia)


Phenylalanine hydroxylase (PAH; phenylalanine 4-monoxyge-nase), the enzyme responsible for classic phenylketonuria (OMIM 261600), utilizes tetrahydrobiopterin to convert pheny-lalanine into tyrosine, a critical step in dopamine biosynthesis. Defects in PAH often lead to mental retardation as a result of the accumulation of phenylalanine and its neurotoxic metabolites.

苯丙氨酸羟化酶 (PAH; phenylalanine 4-monoxyge-nase),引起经典苯丙酮尿症的酶(OMIM 261600),利用四氢生物蝶呤将苯丙氨酸转化为酪氨酸,这是多巴胺生物合成的关键步骤。PAH的缺陷往往导致精神发育迟缓,这是由于苯丙氨酸及其神经毒性代谢产物的积累所致。

Four patients with mild hyperphenylalaninemia (sometimes termed nonphenylketonuria hyperphenylalaninemia) responded to tetrahydrobiopterin therapy (5 or 10 mg/kg body wt) with a decrease in elevated serum phenylalanine concentrations (253). Because there were no abnormalities in urinary pteridine or DHPR activity, and mutations were detected in the PAH gene, it was presumed that these cases reflected a novel subtype of PAH deficiency responsive to cofactor supplementation. The authors suggested that the mutants “probably form mutant PAH with a high Michaelis-Menten constant Km for tetrahydrobiopterin. It is likely that [tetrahydrobiopterin] supplementation increased the intracellular [tetrahydrobiopterin] concentration to restore residual PAH activity and/or to stabilize the mutant PAH molecules” (253). The patients’ protein defects were characterized in a screen of mutations typical of classic phenylketonuria. The patients, who were all compound heterozygotes, harbored mutations in PAH that are present in classic phenylketonuria. Other similar reports of successful tetrahydrobiopterin treatment support the view that tetrahydrobiopterin therapy is effective in some PAH-deficient patients because of Km variants of the enzyme (351, 352). A 60-mg dose of tetrahydrobiopterin (20 mg/kg) was used to significantly decrease blood phenylala-nine in one of the patients, who was continued on 45 mg/d (352).

轻度高苯丙氨酸血症4例(有时称为非苯丙酮尿症、高苯丙氨酸血症)四氢生物蝶呤治疗(5或10 mg/kg体重)可降低血清苯丙氨酸浓度。因为没有异常的尿蝶啶或DHPR活性,在PAH基因中检测到突变,推测这些病例反映了一种新的PAH缺乏症亚型。作者提出该突变体“很可能形成突变的PAH,具有高度的米氏-梅内顿常数Km,用于四氢生物蛋白。[四氢生物蝶呤]的补充很可能增加细胞内[四氢生物蝶呤]浓度,以恢复残留的PAH活性和/或稳定突变的PAH分子。患者的蛋白质缺陷的特征是一个典型的典型苯丙酮尿症突变筛查。这些病人都是复合杂合子,在经典苯丙酮尿症中存在的PAH中的钻孔突变。其他成功的四氢生物蝶呤治疗成功的报告也支持这样的观点,即四氢生物蝶呤治疗部分PAH缺乏的患者是有效的,因为该酶的km变体。其中一名患者服用60毫克四氢生物蝶呤(20毫克/公斤),可显著降低血苯拉拉-9,持续45毫克/天。

In Portugal, the third most common mutation in the PAH gene (8.9% of mutant alleles), Val388→Met, has a reduced enzymatic activity and a 3.7-fold increased Km for tetrahydrobiopterin (82 mol/L) as compared with the wild type (22 mol/L) (353). Although the mutation does not seem to reside in the putative pterin binding motif, it does affect cofactor binding and thus may prove to be another tetrahydrobiopterin-remediable form.

在葡萄牙,PAH基因第三常见突变(8.9%的突变等位基因),Val388→Met,与野生型(22 mol/L)相比,四氢生物蝶呤(82 mol/L)的酶活性降低,Km增加3.7倍。虽然这种突变似乎并不存在于推测的翼龙结合基序中,它确实影响辅助因子结合,因此可能被证明是另一种四氢生物蝶呤-可补救的形式。

A recent review (354) evaluated the 3 reports of tetrahydro-biopterin-responsiveness to date (253, 352, 355) and stated that tetrahydrobiopterin therapy is effective in some PAH-deficient patients because the primary defects affect cofactor binding. In fact, several of the PAH mutations in tetrahydrobiopterin-responsive individuals have been assigned to regions of cofactor interaction (354). It remains to be seen, however, what percent-age of hyperphenylalaninemias are due to tetrahydrobiopterin-responsive variants of PAH. We suggest that tetrahydrobiopterin therapy be considered with any case of phenylketonuria that might not be a classic case. The PAH Mutation Analysis Con-sortium Database contains information on the hundreds of mutations found in PAH (356).

最近的一次审查评估了迄今为止有关四氢生物蝶呤的3份报告(253, 352, 355)并指出四氢生物蝶呤治疗部分PAH缺乏的患者是有效的,因为原发性缺陷影响辅助因子结合。事实上,对四氢生物蝶呤有反应的个体中的几个PAH突变已经被分配到辅助因子相互作用的区域。然而,由于四氢生物蝶呤反应变异的PAH,高苯丙氨酸血症的年龄是多少还有待观察.我们建议用四氢生物蝶呤治疗任何可能不是典型病例的苯丙酮尿症。PAH突变分析Con-sortium数据库包含了在PAH中发现的数百个突变的信息。


No DRI has been set for S-adenosylmethionine.未对S-腺苷甲硫氨酸进行DRI测定.

Guanidinoacetate N-methyltransferase 胍基乙酸-N-甲基转移酶

[size=9.0000pt]S-Adenosylmethionine, a common methyl donor, is used by guanidinoacetate N-methyltransferase (see OMIM 601240), which catalyzes the last step in creatine synthesis, the methylation of guanidoacetate to creatine. Guanidinoacetate N-methyltransferase deficiency is a rare inborn error of metabolism that leads to creatine deficiency. Creatine administration, which bypasses the metabolic defect, alleviates symptoms of guanidinoacetate N-methyltransferase deficiency (357). Because the concentration of guanidoacetate, which has neurotoxic effects, remains high after creatine supplementation, S-adenosylmethionine administration could be of additional benefit. It would also be useful to elucidate the primary defect of the guanidinoacetate N-methyltransferase protein.


The DRI for pantothenic acid, the nutritional precursor of coenzyme A, is 5 mg/d for adults (7). 辅酶A的营养前体泛酸的DRI为成人每日5 mg/d

3-Methylglutaconic aciduria and cardiomyopathy 3-甲基谷氨酸尿与心肌病

4-Methylglutaconate is an intermediate in the catabolism of leucine, but whereas the primary metabolic defect in type I 3-methylglutaconic aciduria has been described (namely, methylglutaconyl-CoA hydratase deficiency), no specific defect in the type II presentation has as yet been identified (see OMIM 302060).
3-甲基谷氨酸是亮氨酸分解代谢的中间产物,然而,对于Ⅰ型3-甲基谷氨酸尿的原发性代谢缺陷却有描述(即甲基谷氨酸-辅酶A水合酶缺乏症),到目前为止,还没有发现II型表现的具体缺陷(见OMIM 302060)。

In one case report, a young boy presented with dilated cardiomyopathy, growth failure, neutropenia, low serum cholesterol, and increased urinary excretion of 3-methylglutaconic and 3-methylglutaric acids (358). At a point when the patient was moribund, large doses of pantothenic acid, a precursor of coenzyme A, produced a dramatic and sustained improvement in myocardial function, growth, neutrophil cell count, hypocholes-terolemia, and hyperuricemia, which suggested that a limitation in the availability of coenzyme A was the fundamental patho-logic process in this condition. The dose of pantothenate was increased from 15 mg/d at the beginning to 3   50 mg/d. It is unclear why the patient responded to pantothenate, but it is possible that he had a defect in a CoA-metabolizing enzyme such as pantothenic acid kinase.

在一个案例中,一个小男孩患有扩张型心肌病,生长衰竭,中性粒细胞减少,3-甲基谷胱甘肽和3-甲基戊二酸的低血清胆固醇和尿排泄增加。在患者濒死的时刻,大剂量的泛酸,辅酶A的前体,使心肌功能有了显著的持续改善,生长、中性粒细胞计数、低胆固醇血症和高尿酸血症,说明在这种条件下,辅酶A的有效性受到限制是最基本的病理过程。泛酸剂量从开始时的15 mg/d增加到3 50 mg/d。目前还不清楚为什么病人对泛雌生殖有反应,但这可能是他有缺陷,在辅酶代谢酶,如泛酸激酶。

In a study of 25 mothers of children with birth defects (psychomotor retardation of unknown cause and microcephaly), 6 were found to excrete large amounts of 3-methylglutaconic acid (16 times that of control subjects) and 3-methylglutaric acid (6 times that of control subjects) (359). It is thus possible that feeding pantothenic acid to women with high concentrations of 3-methylglutaconic and 3-methylglutaric acid might lower the excretion rate of the 2 acids, normalize metabolism, and prevent future birth defects.


Pantothenate kinase: Hallervorden-Spatz syndrome and pantothenate kinase–associated neurodegeneration


Pantothenate kinase is a cytosolic enzyme responsible for the first step in the biosynthesis of CoA from pantothenic acid (vitamin B5). Four genes encoding pantothenate kinase have been identified: PANK1 (expressed in heart, liver, kidney), PANK2 (ubiquitous), PANK3 (predominantly liver), and PANK4 (ubiqui-tous, predominantly muscle). Mutations in PANK2, which is the most abundantly expressed form in the brain, were recently impli-cated in pantothenate kinase–associated neurodegeneration (see OMIM 234200), an autosomal recessive neurodegenerative disorder characterized clinically by dystonia and often optic atrophy or pigmentary retinopathy and biochemically by iron deposits in the basal ganglia and globus pallidus (360). The mutations identified in PANK2 fall into exons 1C, 2, 3, 4, 5, and 6. Missense mutations resulting in nonconservative amino acid changes were found in 32 of 38 classical pantothenate kinase–associated neurodegener-ation cases. All 17 mutations found in atypical cases were mis-sense mutations. It seems plausible that some of these mutations will lower pantothenate kinase activity by affecting the affinity of the enzyme for pantothenate substrate. Such cases may prove to be responsive to high-pantothenate therapy.

泛酸激酶是由泛酸(VitB 5)合成辅酶A的第一步,是一种胞浆酶。已鉴定出四个编码泛酸激酶的基因:PANK 1(表达于心脏、肝脏、肾脏)、PANK 2(普遍存在)、PANK 3(以肝脏为主)和PANK 4(以肌肉为主)。PANK 2基因突变,它是大脑中最丰富的表达形式,最近在泛酸激酶相关神经变性中被植入(见OMIM 234200),以肌张力障碍为特征的常染色体隐性神经退行性疾病化热视神经萎缩或色素性视网膜病变化热以及基底节区和苍白球区的铁沉积。PANK 2的突变属于外显子1C、2、3、4、5和6。38例经典泛酸激酶相关神经退行性变病例中,32例出现错义突变,导致非保守性氨基酸改变。在非典型病例中发现的所有17种突变均为错义突变。似乎有可能的是,这些突变中的一些将降低泛酸激酶的活性,通过影响酶与泛酸底物的亲和力。这种情况可能被证明是对高泛酸盐疗法的反应。

Tissue concentrations and toxicity 组织浓度和毒性

No UL for pantothenic acid has been established because there have been no reports of adverse affects (7).没有建立泛酸的UL,因为没有任何不良影响的报告。

No DRI has been set for lipoic acid. 没有DRI已设置硫辛酸。
二氢硫辛酰胺脱氢酶: lactic acidosis, cerebral cortical atrophy, and hearing loss 乳酸酸中毒、大脑皮层萎缩和听力损失

Deficiency of dihydrolipoamide dehydrogenase, the E3 component of all 3 mitochondrial α-ketodehydrogenase complexes (pyruvate, α-ketoglutarate, and branched-chain α-ketoacid), results in decreased activity of the dehydrogenases and lactic acidosis (OMIM 246900). Lipoic acid is covalently linked to a lysine residue in PDHC, KGDH, and BCKAD (see the section on thiamine).

二氢硫辛酰胺脱氢酶缺乏症,3种线粒体α-酮脱氢酶复合物的E3组分(丙酮酸,α-酮戊二酸,和支链α-酮酸),脱氢酶活性降低与乳酸酸中毒 (OMIM 246900).硫辛酸与PDHC、KGDH和BCKAD中的赖氨酸残基共价连接(见关于硫胺素的一节)。

An 8-mo-old boy with severe lactic acidosis was found to have dihydrolipoamide dehydrogenase deficiency (361). Dihy-drolipoamide dehydrogenase activity in the patient’s fibroblasts was reduced to 20% of the control and kinetic studies found an increased Km for NAD and NADH (382 and 83 mol/L, respec-tively) in the patient compared with control subjects (201 and 56 mol/L, respectively). No significant differences in the Km for lipoamide were found between control subjects and the patient, although this measurement was not definitive. Acidosis could not be relieved by thiamine, biotin, bicarbonate, protein restriction, or a ketogenic diet. Oral administration of lipoic acid (25–50 mg/kg) produced marked improvements in lactic and pyruvic acidemia, and the child continued to do well 2 y later, with clinical improvements.

一名患有严重乳酸酸中毒的8岁男童被发现患有二氢硫磷酰胺脱氢酶缺乏症。二氧磷酰胺脱氢酶活性在患者成纤维细胞中降低到对照组的20%,动力学研究发现NAD的Km增加和NADH分别为382和83 mol/L,对照组分别为201和56 mol/L。 在正常人和病人之间,对硫辛胺的知识管理没有明显的差异,尽管这个测量不是确定的。硫胺素、生物素、碳酸氢钠、蛋白质限制或生酮饮食不能缓解酸中毒。口服硫辛酸(25-50毫克/千克)可显著改善乳酸和丙酮酸血症,两年后,随着临床的改善,孩子继续做得很好。

Two other patients with Friedreich ataxia and dihydrolipoamide dehydrogenase deficiency had an 4-fold increased Km for both lipoamide substrate and NAD cofactor (362). It is unclear how the patients were treated. Future patients with a high Km for NAD may benefit from high-dose niacin treatment; physicians should consider riboflavin treatment as well because the lesion in at least one case of dihydrolipoamide dehydrogenase deficiency was a 3–base pair deletion in the FAD cofactor binding region of E3 (363).

另外两例弗里德里希共济失调和二氢硫辛酰胺脱氢酶缺乏症患者的脂酰胺底物和NAD辅助因子的Km都增加了4倍。目前尚不清楚这些病人是如何治疗的。未来高Km NAD患者可能受益于大剂量烟酸治疗;医生也应该考虑核黄素的治疗,因为至少一例二氢硫辛酰胺脱氢酶缺乏症的病灶是E3中fad辅助因子结合区3碱基对的缺失。

In a case of lipoate-responsive pyruvate dehydrogenase deficiency, PDHC and E1 activities were severely depressed in the patient. Lactate homeostasis responded to pharmaco-logic supplements of lipoic acid, but the child died at the age of 20 mo (364).


No DRI has been set for carnitine. 卡尼汀没有被设定为DRI。

Carnitine O-acyltransferase: fatty acid toxicity 肉毒碱O-酰基转移酶:脂肪酸毒性

Carnitine O-acyltransferase is responsible for transporting fatty acids into the mitochondria. An infant girl with defective carnitine O-acyltransferase died at 31 h of age with profound macrovesicu-lar fatty infiltration of liver, kidney, and muscle found on postmortem examination, suggestive of a defect in fatty acid -oxidation (365). Carnitine was not fed because the defect was found only on autopsy; thus, it is unclear whether the enzyme had a Km defect remediable by carnitine feeding, but it seems likely that other altered enzymes will. With age, carnitine O-acyltransferase activity decreases and the Km of carnitine O-acyltransferase for both carnitine and CoA increase in rat brain. Additionally, carni-tine supplementation restores activity (17).


Carnitine transporter 肉碱转运体
Primary systemic carnitine deficiency is due to a defect in the specific high-affinity carnitine transporter, which is expressed in most tissues and is responsible for bringing carnitine into the cytosol. This carnitine uptake defect, which is characterized by progressive infantile-onset carnitine-responsive cardiomyopathy, weakness, recurrent hypoglycemic hypoketotic encephalopathy, and failure to thrive, was identified in 2 unrelated patients (366). Each patient was a compound heterozygote with both alleles mutated by deletions and insertions and responded dramatically to high-dose carnitine supplementation. A low-affinity, high-concentration, nonspecific-diffusion uptake of carnitine into the cells was sus-pected, which bypassed the specific carrier-mediated transporter. Although these particular carnitine-responsive mutations were not likely to have affected the Km, other mutations could.


There is evidence that some diseases and conditions may be associated with an altered metabolism or altered binding of amino acids, metals, and hormones. The following examples are not necessarily conclusive Km remediable defects, but rather evi-dence of the wide array of genetic profiles and conditions that may fit the nutrient-remediable mold.


Thyroid hormone: neurologic defects 甲状腺激素:神经系统缺陷

Similar to the case with the vitamin D receptor (see the sec-tion on calciferol), mutations have been found in the thyroid hor-mone receptor β (see OMIM 190160) that affect the affinity for hormone ligand. Such mutations lead to increased circulating concentrations of thyroid hormone with normal or elevated con-centrations of thyroid-stimulating hormone in serum and defects in growth and neurologic development. One child with a Pro453→Thr missense mutation had significantly reduced tri-iodothyronine binding affinity and was treated successfully with triiodothyroacetic acid (367). This therapy has been successful in ≥ 8 other patients (368) and a 1994 review found 26 mutations localized to the hormone binding domain of the thyroid hormone receptor β  (369). The ability of in vitro synthesized mutant pro-teins to bind triiodothyronine was moderately or markedly reduced and the ability to activate or repress target gene expres-sion was impaired. A missense mutation found in affected het-erozygotes of one family caused a 12-fold decreased affinity of receptor for ligand (370). The evidence suggests that a Km muta-tion in the thyroid hormone receptor β  gene may be overcome by administration of triiodothyroacetic acid. The thyroid hormone receptor β  system may serve as a model for receptor mutations for other hormones.


Alanine and isoleucine: Huntington disease 丙氨酸和异亮氨酸:亨廷顿病

Alanine and isoleucine were found to be significantly lower in the plasma and cerebrospinal fluid of 16 Huntington disease patients than in that of 21 age-matched control subjects (371). It was hypothesized that defects in cellular uptake or metabolism of neutral amino acids could be a consistent feature of Hunting-ton disease. This suggests treatment with alanine and isoleucine if the defect is in transport and pyridoxine if the defect is in transamination.

Serine and glycine: 3-phosphoglycerate dehydrogenase deficiency, seizures, and microcephaly
丝氨酸和甘氨酸:3-磷酸甘油酸脱氢酶缺乏症 ,癫痫和小头畸形

3-Phosphoglycerate dehydrogenase deficiency (OMIM 601815) is an inborn error of serine biosynthesis. Patients are affected with con-genital microcephaly, psychomotor retardation, and intractable seizures. In 2 siblings studied, L-serine of ≤500 mg·kg1 ·d1 was not sufficient for seizure control (49). Addition of 200 mg glycine·kg1 ·d1 resulted in the complete disappearance of seizures, however, and electroencephalographic abnormalities grad-ually resolved after 6 mo. Biochemical abnormalities in this disor-der are found in the fasted state and consist of low concentrations of the amino acids serine and glycine in plasma and cerebrospinal fluid (49). This appears to be a replacement therapy for a deficiency of serine biosynthesis; thus, a Km defect in 3-phosphoglycerate dehydrogenase seems unlikely, but further mechanistic work needs to be done. Clinicians should use caution, however, because higher doses of serine (1400 mg·kg1 ·d1 ) have caused adverse effects (50).

3-磷酸甘油酸脱氢酶 (OMIM 601815)是丝氨酸生物合成的先天错误。患者患有先天性小头畸形、精神运动性迟滞和顽固性癫痫.在研究的两个兄弟姐妹中,≤500 mg·kg1·d1的L-丝氨酸不足以控制癫痫发作。添加200 mg甘氨酸·Kg1·D1可使癫痫完全消失,脑电图异常在6mo后逐渐消失。这种病的生化异常存在于禁食状态,包括血浆和脑脊液中低浓度的氨基酸丝氨酸和甘氨酸。这似乎是一种替代治疗丝氨酸生物合成不足;因此,3-磷酸甘油酸脱氢酶的Km缺陷似乎不太可能,但还需要进一步的机械工作。然而,临床医生应该谨慎,因为更高剂量的丝氨酸(1400 mg·Kg1·D1)已引起不良反应

Zinc: familial amyotrophic lateral sclerosis and Alzheimer disease 锌: 家族性肌萎缩侧索硬化症与阿尔茨海默病

Mutations in Cu/Zn superoxide dismutase (see OMIM 147450) cause 25% of familial amyotrophic lateral sclerosis. Several of the Cu/Zn superoxide dismutase mutants involved with familial amyotrophic lateral sclerosis have been found to have a decreased affinity for zinc (372, 373), up to 30-fold in some mutants (374). The loss of zinc from wild-type super-oxide dismutase approximately doubles the efficiency of the enzyme for catalyzing peroxynitrite-mediated tyrosine nitra-tion, suggesting that this gained function by superoxide dis-mutase in amyotrophic lateral sclerosis may be an indirect consequence of zinc loss. Nitration of protein-bound tyrosines is a permanent modification that can adversely affect protein function. Thus, the toxicity of superoxide dismutase mutants associated with amyotrophic lateral sclerosis may be related to enhanced catalysis of protein nitration subsequent to zinc loss (374). In a recent study, both wild-type and amyotrophic lateral sclerosis mutant superoxide dismutase protected motor neurons when replete with both copper and zinc. When the same proteins were made zinc deficient, all initiated apoptosis in the neurons (375).


Lammich et al (376) report endogenous -secretase activity was inhibited by a dominant negative form of a disintegrin and metalloprotease, namely ADAM 10 (see OMIM 602192), with a point mutation in the zinc binding site. ADAM 10 is associated closely with an -secretase activity; the authors found it to cleave a site within the amyloid  peptide sequence. It appears that increasing ADAM 10 expression or activity could possibly promote proteolytic cleavage of amyloid precursor protein within the amyloid  sequence, thus preventing the protein from being converted into insoluble amyloid , the proteinaceous component of amyloid plaques in brains of patients with Alzheimer disease. Because a mutation in the zinc binding site was found, it might be possible to stimulate the enzyme and rate of reaction via zinc administration.

Lambert等人,据报道,分解素和金属蛋白酶的一种主要阴性形式抑制了内源性分泌酶的活性,即Adam 10(见OMIM 602192),在锌结合位点发生点突变。ADAM10与-分泌酶活性紧密相关;作者发现它能切割淀粉样肽序列中的一个位点。在淀粉样蛋白序列中,增加ADAM 10的表达或活性可能促进淀粉样前体蛋白的蛋白水解,从而防止蛋白质转化为不溶性淀粉样蛋白。阿尔茨海默病患者大脑中淀粉样斑,块的蛋白质组分。因为锌结合位点的突变被发现了,可能通过锌给药刺激酶和反应速率。

Although zinc is a component of hundreds of important enzymes, the range between adequacy and toxicity is narrow (10). It is unclear whether zinc interventions will be successful.


Potassium 钾

Inosine 5 -monophosphate dehydrogenase (OMIM 146690)

肌苷5磷酸脱氢酶  (OMIM 146690)

catalyzes the oxidation of inosine 5 -monophosphate to xantho-sine 5 -monophosphate with the concomitant reduction of NAD to NADH. E. coli inosine 5 -monophosphate dehydrogenase is activated by several cations including potassium. K+ increases the rate constant for the pre–steady state burst of NADH pro-duction, possibly by increasing the affinity of NAD. Three mutant enzymes have been identified that increase the value of Km for K+: Asp13→Ala, Asp50→Ala, and Glu469→Ala. Both Asp13 and Glu469 appear to interact with the K+ binding site identified in Chinese hamster inosine 5 -monophosphate dehy-drogenase (377). (See also the discussion of BCKAD in the sec-tion on thiamine.)



Health food and drug stores sell a variety of high-dose B vita-min pills called B50, B100, and similar formulations. The time-release B100 pill contains 100 mg each of thiamine, riboflavin, niacin, pyridoxine, and pantothenic acid; 100 g each of vitamin B-12 and biotin; and 400 g folate. Except for folate and biotin, which are at or near the DRIs, these amounts approximate the high intakes discussed in this review. Until now, there has been little general support for high-dose B vitamin intake, so the presence of these pills on the market is puzzling. This review sug-gests that for some persons there might be a benefit from high-dose B vitamin treatment, although when there is, it would be desirable to find out which vitamin is responsible and to opti-mize the dose.

健康食品和药店出售各种高剂量的B型维生素A-min丸,称为B50,B 100和类似的配方。该缓释B100丸剂含有100mg的硫胺素、核黄素、烟酸、维生素B6和泛酸;维生素B-12和生物素各100克;叶酸400克。除了处于或接近DRI的叶酸和生物素外,这些量接近本综述中讨论的高摄入量。到目前为止,几乎没有人普遍支持高剂量维生素B的摄入,因此,这些药片在市场上的重要性是令人费解的。本综述认为,对于某些人来说,高剂量的B维生素治疗可能会有好处,虽然当存在时,需要发现哪些维生素是负责的,并对该剂量进行调理。


High-dose vitamin therapies have been efficacious in amelio-rating 50 genetic diseases. The diseases are usually due to variant enzymes with decreased affinity (increased Km) for vita-min-derived cofactors. Feeding high doses of the vitamin raises the tissue cofactor concentrations and thereby increases the activ-ity of the defective enzyme. Several polymorphisms in which the variant amino acid is at a coenzyme binding site result in reduced enzymatic activity, which is likely to be remediable by raising cellular cofactor concentrations through the administration of high doses of vitamins. Remediation would be useful if the primary reason for the selection of the polymorphism is no longer important and the polymorphism has deleterious side effects.


The examples discussed here are likely to represent only a small fraction of the total number of defective enzymes that would be responsive to therapeutic vitamins. It seems likely that many additional enzymes requiring PLP, TPP, NAD(P), FAD, or other cofactors will be found to have genetic variants that affect cofactor binding. For example, the ENZYME database includes > 100 entries each for FAD- and PLP-requiring enzymes (6), but we have found documentation of binding defects in <12 enzymes for either cofactor. Thus, both with polymorphisms and with the range of mutations causing severe to mild effects on phenotype, high vitamin administration is a potential remedy, and individu-als with additional information pertaining to the topics discussed in this review are encouraged to contribute to the growing body of knowledge at www.KmMutants.org. With the advent of genomics and individual polymorphism assessment, it will become possible to customize vitamin therapies to suit the geno-typic, and thus more specific, needs of individuals, instead of treating the phenotype. For now, for many of the conditions dis-cussed, high-dose B vitamin pills or high doses of individual vitamins are available to physicians as reasonably safe and potentially helpful therapies; however, the possibility of some accompanying side effects should not be discounted.


We acknowledge the helpful comments of Giovanna Ferro-Luzzi Ames, Hani Atamna, Samuel Barondes, Victor Hugo Espin, Balz Frei, Alexander Glazer, Christine Hansen, Arnold Huang, Jack Kirsch, Bill Klitz, Mark Levine, Jiankang Liu, Rowena Matthews, Victor McKusick, John Nides, Terry Schultz, Mark Shigenaga, Christine Skibola, Martyn Smith, and Lynn Wallock.

1. Cox TC, Bottomley SS, Wiley JS, Bawden MJ, Matthews CS, May BK. X-linked pyridoxine-responsive sideroblastic anemia due
to a Thr388–to-Ser substitution in erythroid 5–aminolevulinate syn-thase. N Engl J Med 1994;330:675–9.
2. Mudd SH, Skovby F, Levy HL, et al. The natural history of homo-cystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 1985;37:1–31.
3. Fenton WA, Rosenberg LE. Chapter 41. Disorders of propionate and methylmalonate metabolism. In: Scriver C, ed. The metabolic and molecular bases of inherited disease. 7th ed. New York: McGraw-Hill, Inc, 1995:1423–9.
4. McKusick VA, ed. Mendelian inheritance in man. A catalog of human genes and genetic disorders. 12th ed. Baltimore: Johns Hop-kins University Press, 1998. [Daily updated online version, OMIM, available from the National Center for Biotechnology Information. Internet: http://www.ncbi.nlm.nih.gov/omim.]
5. Elson-Schwab I, Poedjosoedarmo K, Arnes BM. KmMutants.org front page. Internet: http://www.KmMutants.org (accessed 2 Febru-ary 2002).
6. Swiss Institute of Bioinformatics. ENZYME. Enzyme nomenclature database. Release 27.0, October 2001, updates up to 1 Feb 2002. Internet: http://www.expasy.ch/enzyme (accessed 2 February 2002).
7. Institute of Medicine. Dietary reference intakes for thiamine, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline. Washington, DC: National Academy Press, 1998.
8. Institute of Medicine, Food and Nutrition Board. Dietary reference intakes for vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc. Washington, DC: National Academy Press, 2001:126–85.
9. National Research Council. Recommended dietary allowances. 10th ed. Washington, DC: National Academy Press, 1989.
10. Fosmire GJ. Zinc toxicity. Am J Clin Nutr 1990;51:225–7.
11. Levine M, Conry-Cantilena C, Wang Y, et al. Vitamin C pharmaco-
kinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci U S A 1996;93:3704–9.
12. Levine M, Wang Y, Padayatty SJ, Morrow J. A new recommended dietary allowance of vitamin C for healthy young women. Proc Natl Acad Sci U S A 2001;98:9842–6.
13. Pauling L. Orthomolecular psychiatry. Varying the concentrations of substances normally present in the human body may control mental disease. Science 1968;160:265–71.
14. McCarty MF. High-dose pyridoxine as an ‘anti-stress’ strategy. Med Hypotheses 2000;54:803–7.
15. Williams RJ. Biochemical individuality: the basis for the gene-totrophic concept. New Canaan, CT: Keats, 1998.
16. Stephens JC, Schneider JA, Tanguay DA, et al. Haplotype variation and linkage disequilibrium in 313 human genes. Science 2001;293: 489–93.
17. Liu J, Killilea DW, Ames BN. Age-associated mitochondrial oxida-tive decay: restoration of carnitine acetyltransferase substrate binding affinity and activity in brain by feeding old rats acetyl-L-carnitine and/or R--lipoic acid. Proc Natl Acad Sci U S A 2002;99:1876–81.
18. Shigenaga MK, Hagen TM, Ames BN. Oxidative damage and mito-chondrial decay in aging. Proc Natl Acad Sci U S A 1994;91:10771–8.
19. Beckman KB, Ames BN. The free radical theory of aging matures.
Physiol Rev 1998;78:547–81.
20. Hagen TM, Yowe DL, Bartholomew JC, et al. Mitochondrial decay
in hepatocytes from old rats: membrane potential declines, hetero-geneity and oxidants increase. Proc Natl Acad Sci U S A 1997;94: 3064–9.
21. Hagen TM, Ingersoll RT, Wehr CM, et al. Acetyl-L-carnitine fed to old rats partially restores mitochondrial function and ambulatory activity. Proc Natl Acad Sci U S A 1998;95:9562–6.
22. Lykkesfeldt J, Hagen TM, Vinarsky V, Ames BN. Age-associated decline in ascorbic acid concentration, recycling, and biosynthesis in rat hepatocytes—reversal with (R)-alpha-lipoic acid supplemen-tation. FASEB J 1998;12:1183–9.
23. Hagen TM, Ingersoll RT, Lykkesfeldt J, et al. (R)-alpha-lipoic acid-supplemented old rats have improved mitochondrial function, decreased oxidative damage, and increased metabolic rate. FASEB J 1999;13:411–8.
24. Hagen TM, Wehr CM, Ames BN. Mitochondrial decay in aging. Reversal through supplementation of acetyl-L-carnitine and N-tert-butyl-alpha-phenyl-nitrone. Ann N Y Acad Sci 1998;854:214–23.
25. Hagen TM, Liu J, Lykkesfeldt J, et al. Feeding acetyl-L-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress. Proc Natl Acad Sci U S A 2002;99: 1870-5.
26. Liu J, Head E, Gharib AM, et al. Memory loss in old rats is associ-ated with brain mitochondrial decay and RNA/DNA oxidation: par-tial reversal by feeding acetyl-L-carnitine and/or R--lipoic acid. Proc Natl Acad Sci U S A 2002:99:2356-61.
27. Guirard BM, Ames BN, Snell EE. Salmonella typhimurium mutants with alternate requirements for vitamin B6 or isoleucine. J Bacteriol 1971;108:359–63.
28. Kabil O, Toaka S, LoBrutto R, Shoemaker R, Banerjee R. Pyridoxal phosphate binding sites are similar in human heme-dependent and yeast heme-independent cystathionine beta-synthases. Evidence from 31P NMR and pulsed EPR spectroscopy that heme and PLP cofactors are not proximal in the human enzyme. J Biol Chem 2001;276:19350–5.
29. Wang T, Steel G, Milam AH, Valle D. Correction of ornithine accu-mulation prevents retinal degeneration in a mouse model of gyrate atrophy of the choroid and retina. Proc Natl Acad Sci U S A 2000; 97:1224–9.
30. Michaud J, Thompson G, Brody L, et al. Pyridoxine-responsive gyrate atrophy of the choroid and retina: clinical and biochemical cor-relates of the mutation A226V. Am J Hum Genet 1995;56:616–22.
31. Ramesh V, McClatchey A, Ramesh N, et al. Molecular basis of ornithine aminotransferase deficiency in B-6–responsive and -non-responsive forms of gyrate atrophy. Proc Natl Acad Sci U S A 1988; 85:3777–80.
32. Shih V, Mandell R, Berson E. Pyridoxine effects on ornithine ketoacid transaminase activity in fibroblasts from carriers of two forms of gyrate atrophy of the choroid and retina. Am J Hum Genet 1988;43:929–33.
33. Weleber RG, Kennaway NG, Buist NR. Vitamin B6 in management of gyrate atrophy of choroid and retina. Lancet 1978;2:1213 (letter).
34. Kennaway N, Stankova L, Wirtz M, Weleber R. Gyrate atrophy of the choroid and retina: characterization of mutant ornithine amino-transferase and mechanism of response to vitamin B6. Am J Hum
Genet 1989;44:344–52.
35. Mashima Y, Shiono T, Tamai M, Inana G. Heterogeneity and
uniqueness of ornithine aminotransferase mutations found in Japan-ese gyrate atrophy patients. Curr Eye Res 1996;15:792–6.
36. Hayasaka S, Saito T, Nakajima H, et al. Gyrate atrophy with hyper-ornithinaemia: different types of responsiveness to vitamin B6. Br J Ophthalmol 1981;65:478–83.
37. Tada K, Saito T, Omura K, Hayasaka S, Mizuno K. Hyperornithi-naemia associated with gyrate atrophy of the choroid and retina: in vivo and in vitro response to vitamin B6. J Inherit Metab Dis 1981;4: 61–2.
38. Mashima YG, Weleber RG, Kennaway NG, Inana G. Genotype-phenotype correlation of a pyridoxine-responsive form of gyrate atrophy. Ophthalmic Genet 1999;20:219–24.
39. Valle D, Simell O. Chapter 31. The hyperornithinemias. In: Scriver C, ed. The metabolic and molecular bases of inherited disease. 7th ed. New York: McGraw-Hill Inc, 1995:1147–85.
40. Barber GW, Spaeth GL. The successful treatment of homocystinuria with pyridoxine. J Pediatr 1969;75:463–78.
41. Kim YJ, Rosenberg LE. On the mechanism of pyridoxine responsive homocystinuria. II. Properties of normal and mutant cystathionine beta-synthase from cultured fibroblasts. Proc Natl Acad Sci U S A 1974;71:4821–5.
42. Lipson MH, Kraus J, Rosenberg LE. Affinity of cystathionine beta-syn-thase for pyridoxal 5-phosphate in cultured cells. A mechanism for pyridoxine-responsive homocystinuria. J Clin Invest 1980;66: 188–93.
43. Kozich V, de Franchis R, Kraus JP. Molecular defect in a patient with pyridoxine-responsive homocystinuria. Hum Mol Genet 1993;2: 815–6.
44. Kim CE, Gallagher PM, Guttormsen AB, et al. Functional modeling of vitamin responsiveness in yeast: a common pyridoxine-responsive cystathionine beta-synthase mutation in homocystinuria. Hum Mol Genet 1997;6:2213–21.
45. Shih VE, Fringer JM, Mandell R, et al. A missense mutation (I278T) in the cystathionine beta-synthase gene prevalent in pyridoxine-responsive homocystinuria and associated with mild clinical pheno-type. Am J Hum Genet 1995;57:34–9.
46. Fowler B. Recent advances in the mechanism of pyridoxine-responsive disorders. J Inherit Metab Dis 1985;8:76–83.
47. Mudd SA, Levy HL, Skovby F. Chapter 35. Disorders of transsulfu-ration. In: Scriver C, ed. The metabolic and molecular bases of inher-ited disease. 7th ed. New York: McGraw-Hill, Inc, 1995:1279–27.
48. Kraus JP. Cystathionine -synthase main page. Version cur-rent 6 March 2001. Internet: http://www.uchsc.edu/sm/cbs/cbsdata/ cbsmain.htm (accessed 2 February 2002).
49. de Koning TJ, Duran M, Dorland L, et al. Beneficial effects of L-serine and glycine in the management of seizures in 3-phospho-glycerate dehydrogenase deficiency. Ann Neurol 1998;44:261–5.
50. Hausler MG, Jaeken J, Monch E, Ramaekers VT. Phenotypic hetero-geneity and adverse effects of serine treatment in 3-phosphoglycerate dehydrogenase deficiency: report on two siblings. Neuropediatrics 2001;32:191–5.
51. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991;324: 1149–55.
52. Verhoef P, Kok FJ, Kruyssen DA, et al. Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:989–95.
53. May A, Bishop DF. The molecular biology and pyridoxine respon-siveness of X-linked sideroblastic anaemia. Haematologica 1998;83: 56–70.
54. Cotter PD, Rucknagel DL, Bishop DF. X-linked sideroblastic ane-mia: identification of the mutation in the erythroid-specific delta-aminolevulinate synthase gene (ALAS2) in the original family described by Cooley. Blood 1994;84:3915–24.
55. Harigae H, Furuyama K, Kudo K, et al. A novel mutation of the ery-throid-specific delta-aminolevulinate synthase gene in a patient with non-inherited pyridoxine-responsive sideroblastic anemia. Am J Hematol 1999;62:112–4.
56. Cotter PD, Baumann M, Bishop DF. Enzymatic defect in “X-linked” sideroblastic anemia: molecular evidence for erythroid delta-amino-levulinate synthase deficiency. Proc Natl Acad Sci U S A 1992;89: 4028–32.
57. Prades E, Chambon C, Dailey TA, Dailey HA, Briere J, Grandchamp B. A new mutation of the ALAS2 gene in a large family with X-linked sideroblastic anemia. Hum Genet 1995;95:424–8.
58. Cotter PD, May A, Fitzsimons EJ, et al. Late-onset X-linked sider-oblastic anemia. Missense mutations in the erythroid delta-aminole-vulinate synthase (ALAS2) gene in two pyridoxine-responsive patients initially diagnosed with acquired refractory anemia and ringed sideroblasts. J Clin Invest 1995;96:2090–6.
59. Cotter PD, May A, Li L, et al. Four new mutations in the erythroid-specific 5-aminolevulinate synthase ALAS2 gene causing X-linked sideroblastic anemia: increased pyridoxine responsiveness after removal of iron overload by phlebotomy and coinheritance of hered-itary hemochromatosis. Blood 1999;93:1757–69.
60. Furuyama K, Uno R, Urabe A, et al. R411C mutation of the ALAS2 gene encodes a pyridoxine-responsive enzyme with low activity. Br J Haematol 1998;103:839–41.
61. Harigae H, Furuyama K, Kimura A, et al. A novel mutation of the ery-throid-specific delta-aminolaevulinate synthase gene in a patient with X-linked sideroblastic anaemia. Br J Haematol 1999;106:175–7.
62. Gong J, Kay CJ, Barber MJ, Ferreira GC. Mutations at a glycine loop in aminolevulinate synthase affect pyridoxal phosphate cofac-tor binding and catalysis. Biochemistry 1996;35:14109–17.
63. Tada K, Yokoyama Y, Nakagawa H, Yoshida T, Arakawa T. Vitamin B6 dependent xanthurenic aciduria. Tohoku J Exp Med 1967;93:115–24.
64. Tada K, Yokoyama Y, Nakagawa H, Arakawa T. Vitamin B6 depen-dent xanthurenic aciduria (the second report). Tohoku J Exp Med
65. Gospe SM Jr. Current perspectives on pyridoxine-dependent
seizures. J Pediatr 1998;132:919–23.
66. Gordon N. Pyridoxine dependency: an update. Dev Med Child
Neurol 1997;39:63–5.
67. Gospe SM Jr, Olin KL, Keen CL. Reduced GABA synthesis in pyri-
doxine-dependent seizures. Lancet 1994;343:1133–4.
68. Takuma Y. ACTH therapy for infantile spasms: a combination ther-
apy with high-dose pyridoxal phosphate and low-dose ACTH. Epilepsia 1998;39(suppl):42–5.
69. Singh UK, Sinha RK. Pyridoxine dependent seizures. Indian Pediatr 1996;33:121–3.
70. Lott IT, Coulombe T, Di Paolo RV, Richardson EP Jr, Levy HL. Vitamin B6-dependent seizures: pathology and chemical findings in brain. Neurology 1978;28:47–54.
71. Yoshida T, Tada K, Arakawa T. Vitamin B6-dependency of glutamic acid decarboxylase in the kidney from a patient with vitamin B6 dependent convulsion. Tohoku J Exp Med 1971;104:195–8.
72. Baxter P, Griffiths P, Kelly T, Gardner-Medwin D. Pyridoxine-dependent seizures: demographic, clinical, MRI and psychometric features, and effect of dose on intelligence quotient. Dev Med Child Neurol 1996;38:998–1006.
73. Glenn GM, Krober MS, Kelly P, McCarty J, Weir M. Pyridoxine as therapy in theophylline-induced seizures. Vet Hum Toxicol 1995; 37:342–5.
74. Kure S, Sakata Y, Miyabayashi S, et al. Mutation and polymorphic marker analyses of 65K-and 67K-glutamate decarboxylase genes in two families with pyridoxine-dependent epilepsy. J Hum Genet 1998; 43:128–31.
75. Goto T, Matsuo N, Takahashi T. CSF glutamate/GABA concentra-tions in pyridoxine-dependent seizures: etiology of pyridoxine-dependent seizures and the mechanisms of pyridoxine action in seizure control. Brain Dev 2001;23:24–9.
76. Frimpter GW. Cystathioninuria: nature of the defect. Science 1965; 149:1095–6.
77. Pascal TA, Gaull GE, Beratis NG, Gillam BM, Tallan HH, Hirschhorn K. Vitamin B6–responsive and -unresponsive cystathion-inuria: two variant molecular forms. Science 1975;190:1209–11.
78. Gibbs DA, Watts RW. The action of pyridoxine in primary hyperox-aluria. Clin Sci 1969;37:565 (letter).
79. Danpure C, Purdue P. Chapter 75. Primary hyperoxaluria. In: Scriver C, ed. The metabolic and molecular bases of inherited dis-ease. 7th ed. New York: McGraw-Hill, Inc, 1995:2385–424.
80. Milliner DS, Eickholt JT, Bergstralh EJ, Wilson DM, Smith LH. Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria. N Engl J Med 1994;331:1553–8.
81. Toussaint C. Pyridoxine-responsive PH1: treatment. J Nephrol 1998;11(suppl):49–50.
82. Christenson JG, Dairman W, Udenfriend S. On the identity of DOPA decarboxylase and 5-hydroxytryptophan decarboxylase (immunological titration-aromatic L-amino acid decarboxylase-serotonin-dopamine-norepinephrine). Proc Natl Acad Sci U S A 1972;69:343–7.
83. Hyland K, Surtees RA, Rodeck C, Clayton PT. Aromatic L-amino acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a new inborn error of neurotransmitter amine synthesis. Neurology 1992;42:1980–8.
84. Maller A, Hyland K, Milstien S, Biaggioni I, Butler IJ. Aromatic L-amino acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a second family. J Child Neurol 1997;12:349–54.
85. Shigetomi S, Kuchel O. Defective 3,4-dihydroxyphenylalanine decar-boxylation to dopamine in hydralazine-treated hypertensive patients may be pyridoxine remediable. Am J Hypertens 1993;6:33–40.
86. Bishop DF, Henderson AS, Astrin KH. Human delta-aminolevulinate synthase: assignment of the housekeeping gene to 3p21 and the ery-throid-specific gene to the X chromosome. Genomics 1990;7:207–14.
87. Konopka L, Hoffbrand AV. Haem synthesis in sideroblastic anaemia. Br J Haematol 1979;42:73–83.
88. Meier PJ, Fehr J, Meyer UA. Pyridoxine-responsive primary acquired sideroblastic anaemia. In vitro and in vivo effects of vitamin B6 on decreased 5-aminolaevulinate synthase activity. Scand J Haematol 1982;29:421–4.
89. Higgins JJ, Kaneski CR, Bernardini I, Brady RO, Barton NW. Pyri-doxine-responsive hyper-beta-alaninemia associated with Cohen’s syndrome. Neurology 1994;44:1728–32.
90. Megson MN. Is autism a G-alpha protein defect reversible with nat-ural vitamin A? Med Hypotheses 2000;54:979–83.
91. Buitelaar JK, Willemsen-Swinkels SH. Autism: current theories regarding its pathogenesis and implications for rational pharma-cotherapy. Paediatr Drugs 2000;2:67–81.
92. Pfeiffer SI, Norton J, Nelson L, Shott S. Efficacy of vitamin B6 and magnesium in the treatment of autism: a methodology review and summary of outcomes. J Autism Dev Disord 1995;25:481–93.
93. Rimland B. Controversies in the treatment of autistic children: vita-min and drug therapy. J Child Neurol 1988;3(suppl):S68–72.
94. Rimland B, Callaway E, Dreyfus P. The effect of high doses of vita-min B6 on autistic children: a double-blind crossover study. Am J Psychiatry 1978;135:472–5.
95. Bhagavan HN, Coleman M, Coursin DB. The effect of pyridoxine hydrochloride on blood serotonin and pyridoxal phosphate contents in hyperactive children. Pediatrics 1975;55:437–41.
96. Martineau J, Barthelemy C, Garreau B, Lelord G. Vitamin B6, mag-nesium, and combined B6-Mg: therapeutic effects in childhood autism. Biol Psychiatry 1985;20:467–78.
97. Heeley AF, Roberts GE. A study of tryptophan metabolism in psy-chotic children. Dev Med Child Neurol 1966;8:708–18.
98. Kleijnen J, Knipschild P. Niacin and vitamin B6 in mental function-ing: a review of controlled trials in humans. Biol Psychiatry 1991;29:931–41.
99. Bonisch E. [Experiences with pyrithioxin in brain-damaged chil-dren with autistic syndrome.] Prax Kinderpsychol Kinderpsychiatr 1968;17:308–10 (in German).
100. Lelord G, Muh JP, Barthelemy C, Martineau J, Garreau B, Callaway E. Effects of pyridoxine and magnesium on autistic symptoms—initial observations. J Autism Dev Disord 1981;11:219–30.
101. Jonas C, Etienne T, Barthelemy C, Jouve J, Mariotte N. [Clinical and biochemical value of Magnesium + vitamin B6 combination in the treatment of residual autism in adults.] Therapie 1984;39:661–9 (in French).
102. Martineau J, Garreau B, Barthelemy C, Callaway E, Lelord G. Effects of vitamin B6 on averaged evoked potentials in infantile autism. Biol Psychiatry 1981;16:627–41.
103. Rimland B. Critique of “Efficacy of vitamin B6 and magnesium in the treatment of autism.” J Autism Dev Disord 1998;28:580–1.
104. Fernell E, Watanabe Y, Adolfsson I, et al. Possible effects of tetrahy-drobiopterin treatment in six children with autism—clinical and positron emission tomography data: a pilot study. Dev Med Child Neurol 1997;39:313–8.
105. Lerner V, Miodownik C, Kaptsan A, et al. Vitamin B6 in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry 2001;158:1511–4.
106. Lerner V, Kaptsan A, Miodownik C, Kotler M. Vitamin B6 in treat-ment of tardive dyskinesia: a preliminary case series study. Clin Neuropharmacol 1999;22:241–3.
107. Lovlie R, Daly AK, Blennerhassett R, Ferrier N, Steen VM. Homozygosity for the Gly-9 variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients. Int J Neuropsychopharmacol 2000;3:61–5.
108. Liao DL, Yeh YC, Chen HM, Chen H, Hong CJ, Tsai SJ. Associa-tion between the Ser9Gly polymorphism of the dopamine D3 recep-
tor gene and tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology 2001;44:95–8.
109. Lumeng L, Ryan MP, Li TK. Validation of the diagnostic value of plasma pyridoxal 5-phosphate measurements in vitamin B6 nutri-tion of the rat. J Nutr 1978;108:545–53.
110. Henderson JM, Codner MA, Hollins B, Kutner MH, Merrill AH. The fasting B6 vitamer profile and response to a pyridoxine load in normal and cirrhotic subjects. Hepatology 1986;6:464–71.
111. Evarsson A, Chuang JL, Wynn RM, Turley S, Chuang DT, Hol WG. Crystal structure of human branched-chain alpha-ketoacid dehydro-genase and the molecular basis of multienzyme complex deficiency in maple syrup urine disease. Structure Fold Des 2000;8:277–91.
112. Duran M, Wadman SK. Thiamine-responsive inborn errors of metab-olism. J Inherit Metab Dis 1985;8:70–5.
113. Scriver CR, Mackenzie S, Clow CL, Delvin E. Thiamine-responsive maple-syrup-urine disease. Lancet 1971;1:310–2.
114. Chuang DT, Ku LS, Cox RP. Thiamin-responsive maple-syrup-urine disease: decreased affinity of the mutant branched-chain alpha-keto acid dehydrogenase for alpha-ketoisovalerate and thiamin pyrophos-phate. Proc Natl Acad Sci U S A 1982;79:3300–4.
115. Fisher CW, Chuang JL, Griffin TA, Lau KS, Cox RP, Chuang DT. Molecular phenotypes in cultured maple syrup urine disease cells. Complete E1 alpha cDNA sequence and mRNA and subunit con-tents of the human branched chain alpha-keto acid dehydrogenase complex. J Biol Chem 1989;264:3448–53.
116. Fisher CW, Lau KS, Fisher CR, Wynn RM, Cox RP, Chuang DT. A 17-bp insertion and a Phe215→Cys missense mutation in the dihy-drolipoyl transacylase (E2) mRNA from a thiamine-responsive maple syrup urine disease patient WG-34. Biochem Biophys Res Commun 1991;174:804–9.
117. Herring WJ, McKean M, Dracopoli N, Danner DJ. Branched chain acyltransferase absence due to an Alu-based genomic deletion allele and an exon skipping allele in a compound heterozygote proband expressing maple syrup urine disease. Biochim Biophys Acta 1992; 1138:236–42.
118. Zhang B, Wappner RS, Brandt IK, Harris RA, Crabb DW. Sequence of the E1 alpha subunit of branched-chain alpha-ketoacid dehydro-genase in two patients with thiamine-responsive maple syrup urine disease. Am J Hum Genet 1990;46:843–6.
119. Chuang D, Shih V. Chapter 34. Disorders of branched chain amino acids and keto acid metabolism. In: Scriver C, ed. The metabolic and molecular bases of inherited disease. 7th ed. New York: McGraw-Hill, Inc, 1995:1239–77.
120. Elsas LJ II, Danner DJ. The role of thiamin in maple syrup urine disease. Ann N Y Acad Sci 1982;378:404–21.
121. Chuang DT. Maple syrup urine disease: it has come a long way. J Pediatr 1998;132:S17–23.
122. Backhouse O, Leitch RJ, Thompson D, et al. A case of reversible blindness in maple syrup urine disease. Br J Ophthalmol 1999;83: 250–1.
123. Shimomura Y, Kuntz MJ, Suzuki M, Ozawa T, Harris RA. Monova-lent cations and inorganic phosphate alter branched-chain alpha-ketoacid dehydrogenase-kinase activity and inhibitor sensitivity. Arch Biochem Biophys 1988;266:210–8.
124. Chuang JL, Wynn RM, Song JL, Chuang DT. GroEL/GroES-dependent reconstitution of alpha2 beta2 tetramers of human mitochondrial branched chain alpha-ketoacid decarboxylase. Obligatory interac-tion of chaperonins with an alpha beta dimeric intermediate. J Biol Chem 1999;274:10395–404.
125. Robinson BH. Chapter 44. Lactic acidemia (disorders of pyruvate carboxylase, pyruvate dehydrogenase). In: Scriver C, ed. The meta-bolic and molecular bases of inherited disease. 7th ed. New York: McGraw-Hill, Inc, 1995:1479–99.
126. Maesaka H, Komiya K, Misugi K, Tada K. Hyperalaninemia, hyper-pyruvicemia and lactic acidosis due to pyruvate carboxylase defi-ciency of the liver; treatment with thiamine and lipoic acid. Eur J Pediatr 1976;122:159–68.
127. Naito E, Ito M, Takeda E, Yokota I, Yoshijima S, Kuroda Y. Molec-ular analysis of abnormal pyruvate dehydrogenase in a patient with thiamine-responsive congenital lactic acidemia. Pediatr Res 1994;36: 340–6.
128. Narisawa K, Endo H, Miyabayashi S, Tada K. Thiamine responsive pyruvate dehydrogenase deficiency. J Nutr Sci Vitaminol (Tokyo) 1992;Spec No:585–8.
129. Scholte HR, Busch HF, Luyt-Houwen IE. Vitamin-responsive pyru-vate dehydrogenase deficiency in a young girl with external oph-thalmoplegia, myopathy and lactic acidosis. J Inherit Metab Dis 1992;15:331–4.
130. Wick H, Schweizer K, Baumgartner R. Thiamine dependency in a patient with congenital lacticacidaemia due to pyruvate dehydroge-nase deficiency. Agents Actions 1977;7:405–10.
131. Naito E, Ito M, Yokota I, Saijo T, Matsuda J, Kuroda Y. Thiamine-responsive lactic acidaemia: role of pyruvate dehydrogenase complex. Eur J Pediatr 1998;157:648–52.
132. Murakami N, Iso A, Naito E, Kuroda Y, Nonaka I. Thiamine respon-sive congenital lactic acidemia and type 1 muscle fiber atrophy. Brain Dev 1995;17:78 (letter).
133. Naito E, Ito M, Yokota I, et al. Concomitant administration of sodium dichloroacetate and thiamine in West syndrome caused by thiamine-responsive pyruvate dehydrogenase complex deficiency. J Neurol Sci 1999;171:56–9.
134. Ohtsuka Y, Ogino T, Asano T, Hattori J, Ohta H, Oka E. Long-term follow-up of vitamin B(6)-responsive West syndrome. Pediatr Neurol 2000;23:202–6.
135. Tripatara A, Korotchkina LG, Patel MS. Characterization of point mutations in patients with pyruvate dehydrogenase deficiency: role of methionine-181, proline-188, and arginine-349 in the alpha sub-unit. Arch Biochem Biophys 1999;367:39–50.
136. Labay V, Raz T, Baron D, et al. Mutations in SLC19A2 cause thi-amine-responsive megaloblastic anaemia associated with diabetes mellitus and deafness. Nat Genet 1999;22:300–4.
137. Diaz GA, Banikazemi M, Oishi K, Desnick RJ, Gelb BD. Mutations in a new gene encoding a thiamine transporter cause thiamine-responsive megaloblastic anaemia syndrome. Nat Genet 1999;22:309–12.
138. Borgna-Pignatti C, Marradi P, Pinelli L, Monetti N, Patrini C. Thi-amine-responsive anemia in DIDMOAD syndrome. J Pediatr 1989; 114:405–10.
139. Grill J, Leblanc T, Baruchel A, Daniel MT, Dresch C, Schaison G. Thiamine responsive anemia: report of a new case associated with a thiamine pyrophosphokinase deficiency. Nouv Rev Fr Hematol 1991; 33:543–4.
140. Barrett TG, Poulton K, Baines M, McCowen C. Muscle biochemistry in thiamin-responsive anaemia. J Inherit Metab Dis 1997;20:404–6.
141. Abboud MR, Alexander D, Najjar SS. Diabetes mellitus, thiamine-dependent megaloblastic anemia, and sensorineural deafness associ-ated with deficient alpha-ketoglutarate dehydrogenase activity. J Pediatr 1985;107:537–41.
142. Rogers LE, Porter FS, Sidbury JB Jr. Thiamine-responsive mega-loblastic anemia. J Pediatr 1969;74:494–504.
143. Rindi G, Patrini C, Laforenza U, et al. Further studies on erythro-cyte thiamin transport and phosphorylation in seven patients with thiamin-responsive megaloblastic anaemia. J Inherit Metab Dis 1994; 17:667–77.
144. Rajgopal A, Edmondnson A, Goldman ID, Zhao R. SLC19A3 encodes a second thiamine transporter ThTr2. Biochim Biophys Acta 2001; 1537:175–8.
145. Bakker HD, Scholte HR, Luyt-Houwen IE, van Gennip AH, Abeling NG, Lam J. Neonatal cardiomyopathy and lactic acidosis responsive to thiamine. J Inherit Metab Dis 1991;14:75–9.
146. Di Rocco M, Patrini C, Rimini A, Rindi G. A 6-month-old girl with cardiomyopathy who nearly died. Lancet 1997;349:616.
147. Davis RE, Icke GC, Thom J, Riley WJ. Intestinal absorption of thi-amin in man compared with folate and pyridoxal and its subsequent urinary excretion. J Nutr Sci Vitaminol (Tokyo) 1984;30:475–82.
148. Royer-Morrot MJ, Zhiri A, Paille F, Royer RJ. Plasma thiamine con-centrations after intramuscular and oral multiple dosage regimens in healthy men. Eur J Clin Pharmacol 1992;42:219–22.
149. Wrenn KD, Murphy F, Slovis CM. A toxicity study of parenteral thiamine hydrochloride. Ann Emerg Med 1989;18:867–70.
150. Denessiouk KA, Rantanen VV, Johnson MS. Adenine recognition: a motif present in ATP-, CoA-, NAD-, NADP-, and FAD-dependent proteins. Proteins 2001;44:282–91.
151. Dym O, Eisenberg D. Sequence-structure analysis of FAD-containing proteins. Protein Sci 2001;10:1712–28.
152. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111–3 (letter).
153. Ames BN. Cancer prevention and diet: help from single nucleotide polymorphisms. Proc Natl Acad Sci U S A 1999;96:12216–8.
154. Wallock LM, Tamura T, Mayr CA, Johnston KE, Ames BN, Jacob RA. Low seminal plasma folate concentrations are associated with low sperm density and count in male smokers and nonsmokers. Fertil Steril 2001;75:252–9.
155. Brattstreom L, Wilcken DE, Ohrvik J, Brudin L. Common methyl-enetetrahydrofolate reductase gene mutation leads to hyperhomo-cysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 1998;98:2520–6.
156. Kluijtmans LA, van den Heuvel LP, Boers GH, et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk fac-tor for cardiovascular disease. Am J Hum Genet 1996;58:35–41.
157. Shields DC, Kirke PN, Mills JL, et al. The “thermolabile” variant of methylenetetrahydrofolate reductase and neural tube defects: an eval-uation of genetic risk and the relative importance of the genotypes of the embryo and the mother. Am J Hum Genet 1999;64:1045–55.
158. James SJ, Pogribna M, Pogribny IP, et al. Abnormal folate metabo-lism and mutation in the methylenetetrahydrofolate reductase gene may be maternal risk factors for Down syndrome. Am J Clin Nutr 1999;70:495–501.
159. Kowa H, Yasui K, Takeshima T, Urakami K, Sakai F, Nakashima K. The homozygous C677T mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for migraine. Am J Med Genet 2000;96:762–4.
160. Shpichinetsky V, Raz I, Friedlander Y, et al. The association between two common mutations C677T and A1298C in human methylenete-trahydrofolate reductase gene and the risk for diabetic nephropathy in type II diabetic patients. J Nutr 2000;130:2493–7.
161. Wenstrom KD, Johanning GL, Johnston KE, DuBard M. Associa-tion of the C677T methylenetetrahydrofolate reductase mutation and elevated homocysteine levels with congenital cardiac malfor-mations. Am J Obstet Gynecol 2001;184:806–17.
162. Yoo JH, Choi GD, Kang SS. Pathogenicity of thermolabile methyl-enetetrahydrofolate reductase for vascular dementia. Arterioscler Thromb Vasc Biol 2000;20:1921–5.
163. Bezold G, Lange M, Peter RU. Homozygous methylenetetrahydro-folate reductase C677T mutation and male infertility. N Engl J Med 2001;344:1172–3.
164. Yamada K, Chen Z, Rozen R, Matthews RG. Effects of common poly-morphisms on the properties of recombinant human methylenete-trahydrofolate reductase. Proc Natl Acad Sci U S A 2001;98:14853–8.
165. Guenther BD, Sheppard CA, Tran P, Rozen R, Matthews RG, Ludwig ML. The structure and properties of methylenetetrahydro-folate reductase from Escherichia coli suggest how folate amelio-rates human hyperhomocysteinemia. Nat Struct Biol 1999;6:359–65.
166. Bates CJ, Fuller NJ. The effect of riboflavin deficiency on methyl-enetetrahydrofolate reductase (NADPH) (EC and folate metabolism in the rat. Br J Nutr 1986;55:455–64.
167. Hustad S, Ueland PM, Vollset SE, Zhang Y, Bjorke-Monsen AL, Schneede J. Riboflavin as a determinant of plasma total homocys-teine: effect modification by the methylenetetrahydrofolate reduc-tase C677T polymorphism. Clin Chem 2000;46:1065–71.168. Shimakawa T, Nieto FJ, Malinow MR, Chambless LE, Schreiner PJ, Szklo M. Vitamin intake: a possible determinant of plasma homo-cyst(e)ine among middle-aged adults. Ann Epidemiol 1997;7:285–93.
169. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 1998;50:466–70.
170. Sandor PS, Afra J, Ambrosini A, Schoenen J. Prophylactic treatment of migraine with beta-blockers and riboflavin: differential effects on the intensity dependence of auditory evoked cortical potentials. Headache 2000;40:30–5.
171. Koch MC, Stegmann K, Ziegler A, Schroter B, Ermert A. Evaluation of the MTHFR C677T allele and the MTHFR gene locus in a Ger-man spina bifida population. Eur J Pediatr 1998;157:487–92.
172. Kirke PN, Molloy AM, Daly LE, Burke H, Weir DG, Scott JM. Maternal plasma folate and vitamin B12 are independent risk factors for neural tube defects. Q J Med 1993;86:703–8.
173. Czeizel AE. Primary prevention of neural-tube defects and some other major congenital abnormalities: recommendations for the appropriate use of folic acid during pregnancy. Paediatr Drugs 2000;2:437–49.
174. Ueland PM, Hustad S, Schneede J, Refsum H, Vollset SE. Biologi-cal and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 2001;22:195–201.
175. Wrone EM, Zehnder JL, Hornberger JM, McCann LM, Coplon NS, Fortmann SP. An MTHFR variant, homocysteine, and cardiovascu-lar comorbidity in renal disease. Kidney Int 2001;60:1106–13.
176. Kawashiri M, Kajinami K, Nohara A, et al. Effect of common meth-ylenetetrahydrofolate reductase gene mutation on coronary artery dis-ease in familial hypercholesterolemia. Am J Cardiol 2000;86:840–5.
177. Morita H, Taguchi J, Kurihara H, et al. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation 1997;95:2032–6.
178. Gallagher PM, Meleady R, Shields DC, et al. Homocysteine and risk of premature coronary heart disease. Evidence for a common gene mutation. Circulation 1996;94:2154–8.
179. Hobbs CA, Sherman SL, Yi P, et al. Polymorphisms in genes involved in folate metabolism as maternal risk factors for Down syndrome. Am J Hum Genet 2000;67:623–30.
180. Stern LL, Mason JB, Selhub J, Choi SW. Genomic DNA hypo-methylation, a characteristic of most cancers, is present in peripheral leukocytes of individuals who are homozygous for the C677T poly-morphism in the methylenetetrahydrofolate reductase gene. Cancer Epidemiol Biomarkers Prev 2000;9:849–53.
181. Junker R, Kotthoff S, Vielhaber H, et al. Infant methylenetetrahy-drofolate reductase 677TT genotype is a risk factor for congenital heart disease. Cardiovasc Res 2001;51:251–4.
182. Goyette P, Frosst P, Rosenblatt DS, Rozen R. Seven novel mutations in the methylenetetrahydrofolate reductase gene and genotype/ phenotype correlations in severe methylenetetrahydrofolate reduc-tase deficiency. Am J Hum Genet 1995;56:1052–9.
183. Rosenblatt DS, Erbe RW. Methylenetetrahydrofolate reductase in cul-tured human cells. II. Genetic and biochemical studies of methyl-enetetrahydrofolate reductase deficiency. Pediatr Res 1977;11:1141–3.
184. Jacques PF, Bostom AG, Williams RR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996;93:7–9.
185. Ma J, Stampfer MJ, Hennekens CH, et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation 1996;94:2410–6.
186. Ross D, Kepa JK, Winski SL, Beall HD, Anwar A, Siegel D. NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bio-activation, gene regulation and genetic polymorphisms. Chem Biol Interact 2000;129:77–97.
187. Chen H, Lum A, Seifried A, Wilkens LR, Le Marchand L. Association of the NAD(P)H:quinone oxidoreductase 609C→T polymorphism with a decreased lung cancer risk. Cancer Res 1999;59:3045–8.
188. Wiencke JK, Spitz MR, McMillan A, Kelsey KT. Lung cancer in Mexican-Americans and African-Americans is associated with the

wild-type genotype of the NAD(P)H:quinone oxidoreductase poly-morphism. Cancer Epidemiol Biomarkers Prev 1997;6:87–92.
189. Rosvold EA, McGlynn KA, Lustbader ED, Buetow KH. Identifica-tion of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer and smoking. Pharmacogenetics 1995; 5:199–206.
190. Lewis SJ, Cherry NM, Niven RM, Barber PV, Povey AC. Polymor-phisms in the NAD(P)H:quinone oxidoreductase gene and small cell lung cancer risk in a UK population. Lung Cancer 2001;34:177–83.
191. Xu LL, Wain JC, Miller DP, et al. The NAD(P)H:quinone oxidore-ductase 1 gene polymorphism and lung cancer: differential suscep-tibility based on smoking behavior. Cancer Epidemiol Biomarkers Prev 2001;10:303–9.
192. Chen S, Wu K, Zhang D, Sherman M, Knox R, Yang CS. Molec-ular characterization of binding of substrates and inhibitors to DT-diaphorase: combined approach involving site-directed mutagenesis, inhibitor-binding analysis, and computer modeling. Mol Pharmacol 1999;56:272–8.
193. Wu K, Deng PSK, Chen S. Catalytic properties of a natural occur-ring mutant of human NAD(P)H:quinone acceptor oxidoreductase (DT-diaphorase), Pro 187 to Ser. In: Yagi K, ed. Pathophysiology of lipid peroxides and related free radicals. Tokyo: Japan Scientific Societies Press, 1998:135–48.
194. Dailey HA, Dailey TA. Characteristics of human protoporphyrino-gen oxidase in controls and variegate porphyrias. Cell Mol Biol 1997; 43:67–73.
195. Frank J, Jugert FK, Breitkopf C, Goerz G, Merk HF, Christiano AM. Recurrent missense mutation in the protoporphyrinogen oxidase gene underlies variegate porphyria. Am J Med Genet 1998;79:22–6.
196. Frerman FE, Goodman SI. Chapter 47. Nuclear-encoded defects of the mitochondrial respiratory chain, including glutaric acidemia type II. In: Scriver C, ed. The metabolic and molecular bases of inherited disease. 7th ed. New York: McGraw-Hill, Inc, 1995:1611–29.
197. Salazar D, Zhang L, deGala GD, Frerman FE. Expression and char-acterization of two pathogenic mutations in human electron transfer flavoprotein. J Biol Chem 1997;272:26425–33.
198. Roberts DL, Frerman FE, Kim JJ. Three-dimensional structure of human electron transfer flavoprotein to 2.1-Å resolution. Proc Natl Acad Sci U S A 1996;93:14355–60.
199. Triggs WJ, Roe CR, Rhead WJ, Hanson SK, Lin SN, Willmore LJ. Neuropsychiatric manifestations of defect in mitochondrial beta oxidation response to riboflavin. J Neurol Neurosurg Psychiatry 1992; 55:209–11.
200. Beard SE, Spector EB, Seltzer WK, Frerman FE, Goodman SI. Muta-tions in electron transfer flavoprotein:ubiquinone oxidoreductase (ETFO) in glutaric acidemia type II (GA2). Clin Res 1993;41:271A (abstr).
201. Amendt BA, Rhead WJ. The multiple acyl-coenzyme A dehydro-genation disorders, glutaric aciduria type II and ethylmalonic-adipic aciduria. Mitochondrial fatty acid oxidation, acyl-coenzyme A dehy-drogenase, and electron transfer flavoprotein activities in fibroblasts. J Clin Invest 1986;78:205–13.
202. Uziel G, Garavaglia B, Ciceri E, Moroni I, Rimoldi M. Riboflavin-responsive glutaric aciduria type II presenting as a leukodystrophy. Pediatr Neurol 1995;13:333–5.
203. Green A, Marshall TG, Bennett MJ, Gray RG, Pollitt RJ. Riboflavin-responsive ethylmalonic-adipic aciduria. J Inherit Metab Dis 1985; 8:67–70.
204. Elias E, Gray RG, Poulton K, Green A. Ethylmalonic adipic aciduria—a treatable hepatomuscular disorder in two adult brothers. J Hepatol 1997;26:433–6.
205. al-Essa MA, Rashed MS, Bakheet SM, Patay ZJ, Ozand PT. Glu-taric aciduria type II: observations in seven patients with neonatal-and late-onset disease. J Perinatol 2000;20:120–8.
206. Indo Y, Glassberg R, Yokota I, Tanaka K. Molecular characterization of variant alpha-subunit of electron transfer flavoprotein in three patients with glutaric acidemia type II and identification of glycine
substitution for valine-157 in the sequence of the precursor, produc-ing an unstable mature protein in a patient. Am J Hum Genet 1991; 49:575–80.
207. Yamaguchi S, Orii T, Maeda K, Oshima M, Hashimoto T. A new variant of glutaric aciduria type II: deficiency of beta-subunit of electron transfer flavoprotein. J Inherit Metab Dis 1990;13:783–6.
208. Bennett MJ, Pollitt RJ, Goodman SI, Hale DE, Vamecq J. Atypical riboflavin-responsive glutaric aciduria, and deficient peroxisomal glutaryl-CoA oxidase activity: a new peroxisomal disorder. J Inherit Metab Dis 1991;14:165–73.
209. Kmoch S, Zeman J, Hrebicek M, Ryba L, Kristensen MJ, Gregersen N. Riboflavin-responsive epilepsy in a patient with SER209 variant form of short-chain acyl-CoA dehydrogenase. J Inherit Metab Dis 1995;18:227–9.
210. DiDonato S, Gellera C, Peluchetti D, et al. Normalization of short-chain acylcoenzyme A dehydrogenase after riboflavin treatment in a girl with multiple acylcoenzyme A dehydrogenase-deficient myopa-thy. Ann Neurol 1989;25:479–84.
211. Gregersen N, Wintzensen H, Christensen SK, Christensen MF, Brandt NJ, Rasmussen K. C6-C10-dicarboxylic aciduria: investiga-tions of a patient with riboflavin responsive multiple acyl-CoA dehydrogenation defects. Pediatr Res 1982;16:861–8.
212. Sperl W, Geiger R, Lehnert W, Rhead W. Stridor as the major pre-senting symptom in riboflavin-responsive multiple acyl-CoA dehy-drogenation deficiency. Eur J Pediatr 1997;156:800–2.
213. Tojo M, Gunji T, Yamaguchi S, Shimizu N, Koga Y, Nonaka I. [A case of riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency (glutaric aciduria type II).] No To Hattatsu 2000;32:163–8 (in Japanese).
214. Bernsen PL, Gabreels FJ, Ruitenbeek W, Hamburger HL. Treatment of complex I deficiency with riboflavin. J Neurol Sci 1993;118: 181–7.
215. Bar-Meir M, Elpeleg ON, et al. Effect of various agents on adeno-sine triphosphate synthesis in mitochondrial complex I deficiency. J Pediatr 2001;139:868–70.
216. Bernsen PL, Gabreels FJ, Ruitenbeek W, Sengers RC, Stadhouders AM, Renier WO. Successful treatment of pure myopathy, associated with complex I deficiency, with riboflavin and carnitine. Arch Neurol 1991;48:334–8.
217. Griebel V, Krageloh-Mann I, Ruitenbeek W, Trijbels JM, Paulus W. A mitochondrial myopathy in an infant with lactic acidosis. Dev Med Child Neurol 1990;32:528–31.
218. Scholte HR, Busch HF, Bakker HD, Bogaard JM, Luyt-Houwen IE, Kuyt LP. Riboflavin-responsive complex I deficiency. Biochim Bio-phys Acta 1995;1271:75–83.
219. Ogle RF, Christodoulou J, Fagan E, et al. Mitochondrial myopathy with tRNA(Leu(UUR)) mutation and complex I deficiency respon-sive to riboflavin. J Pediatr 1997;130:138–45.
220. Penn AM, Lee JW, Thuillier P, et al. MELAS syndrome with mito-chondrial tRNA(Leu)(UUR) mutation: correlation of clinical state, nerve conduction, and muscle 31P magnetic resonance spectroscopy during treatment with nicotinamide and riboflavin. Neurology 1992; 42:2147–52.
221. Goto Y, Nonaka I, Horai S. A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature 1990;348:651–3.
222. Zempleni J, Galloway JR, McCormick DB. The metabolism of riboflavin in female patients with liver cirrhosis. Int J Vitam Nutr Res 1996;66:237–43.
223. Zempleni J, Galloway JR, McCormick DB. Pharmacokinetics of orally and intravenously administered riboflavin in healthy humans. Am J Clin Nutr 1996;63:54–66.
224. Steinmetz CG, Xie P, Weiner H, Hurley TD. Structure of mitochon-drial aldehyde dehydrogenase: the genetic component of ethanol aversion. Structure 1997;5:701–11.
225. Farres J, Wang X, Takahashi K, Cunningham SJ, Wang TT, Weiner H. Effects of changing glutamate 487 to lysine in rat and human liver
mitochondrial aldehyde dehydrogenase. A model to study human (Oriental type) class 2 aldehyde dehydrogenase. J Biol Chem 1994; 269:13854–60.
226. Nomura T, Noma H, Shibahara T, Yokoyama A, Muramatusu T, Ohmori T. Aldehyde dehydrogenase 2 and glutathione S-transferase M 1 polymorphisms in relation to the risk for oral cancer in Japan-ese drinkers. Oral Oncol 2000;36:42–6.
227. Yokoyama A, Muramatsu T, Omori T, et al. Alcohol and aldehyde dehydrogenase gene polymorphisms and oropharyngolaryngeal, esophageal and stomach cancers in Japanese alcoholics. Carcino-genesis 2001;22:433–9.
228. Kamino K, Nagasaka K, Imagawa M, et al. Deficiency in mito-chondrial aldehyde dehydrogenase increases the risk for late-onset Alzheimer’s disease in the Japanese population. Biochem Biophys Res Commun 2000;273:192–6.
229. Seki T, Okayama H, Isoyama S, et al. The role of alcohol dehydro-genase 2 and aldehyde dehydrogenase 2 genotypes in alcohol-induced vasospastic angina. Tohoku J Exp Med 1999;187:311–22.
230. Matsuoka K. Genetic and environmental interaction in Japanese type 2 diabetics. Diabetes Res Clin Pract 2000;50(suppl):S17–22.
231. Murata C, Suzuki Y, Muramatsu T, et al. Inactive aldehyde dehy-drogenase 2 worsens glycemic control in patients with type 2 dia-betes mellitus who drink low to moderate amounts of alcohol. Alcohol Clin Exp Res 2000;24(suppl):5S–11S.
232. Stevens VJ, Fantl WJ, Newman CB, Sims RV, Cerami A, Peterson CM. Acetaldehyde adducts with hemoglobin. J Clin Invest 1981;67:361–9. 233. Kimura S, Okabayashi Y, Inushima K, Kochi T, Yutsudo Y, Kasuga M. Alcohol and aldehyde dehydrogenase polymorphisms in Japanese patients with alcohol-induced chronic pancreatitis. Dig Dis Sci
234. Wang X, Sheikh S, Saigal D, Robinson L, Weiner H. Heterotetramers
of human liver mitochondrial (class 2) aldehyde dehydrogenase expressed in Escherichia coli. A model to study the heterotetramers expected to be found in Oriental people. J Biol Chem 1996;271: 31172–8.
235. Weitberg AB. Effect of nicotinic acid supplementation in vivo on oxy-gen radical-induced genetic damage in human lymphocytes. Mutat Res 1989;216:197–201.
236. Majamaa K, Rusanen H, Remes AM, Pyhtinen J, Hassinen IE. Increase of blood NAD+ and attenuation of lactacidemia during nic-otinamide treatment of a patient with the MELAS syndrome. Life Sci 1996;58:691–9.
237. Franceschi S, Bidoli E, Negri E, et al. Role of macronutrients, vita-mins and minerals in the aetiology of squamous-cell carcinoma of the oesophagus. Int J Cancer 2000;86:626–31.
238. Salvemini F, Franze A, Iervolino A, Filosa S, Salzano S, Ursini MV. Enhanced glutathione levels and oxidoresistance mediated by increased glucose-6-phosphate dehydrogenase expression. J Biol Chem 1999;274:2750–7.
239. Miwa S, Fujii H. Molecular basis of erythroenzymopathies associ-ated with hereditary hemolytic anemia: tabulation of mutant enzymes. Am J Hematol 1996;51:122–32.
240. Notaro R, Afolayan A, Luzzatto L. Human mutations in glucose 6-phosphate dehydrogenase reflect evolutionary history. FASEB J 2000;14:485–94.
241. Vulliamy T, Mason P, Luzzatto L. The molecular basis of glucose-6-phosphate dehydrogenase deficiency. Trends Genet 1992;8:138–43. 242. Lykkesfeldt J, Christen S, Wallock LM, Chang HH, Jacob RA, Ames BN. Ascorbate is depleted by smoking and repleted by mod-
erate supplementation: a study in male smokers and nonsmokers with
matched dietary antioxidant intakes. Am J Clin Nutr 2000;71:530–6. 243. Vulliamy TJ, D’Urso M, Battistuzzi G, et al. Diverse point muta-
tions in the human glucose-6-phosphate dehydrogenase gene cause enzyme deficiency and mild or severe hemolytic anemia. Proc Natl Acad Sci U S A 1988;85:5171–5.
244. Kaeda JS, Chhotray GP, Ranjit MR, et al. A new glucose-6-phosphate dehydrogenase variant, G6PD Orissa (44 Ala→Gly), is the major
245. polymorphic variant in tribal populations in India. Am J Hum Genet 1995;57:1335–41.
246. 245. Roos D, van Zwieten R, Wijnen JT, et al. Molecular basis and enzy-matic properties of glucose 6-phosphate dehydrogenase volendam, leading to chronic nonspherocytic anemia, granulocyte dysfunction, and increased susceptibility to infections. Blood 1999;94:2955–62.
247. 246. Hirono A, Kuhl W, Gelbart T, Forman L, Fairbanks VF, Beutler E. Identification of the binding domain for NADP+ of human glucose-6-phosphate dehydrogenase by sequence analysis of mutants. Proc Natl Acad Sci U S A 1989;86:10015–7.
248. 247. Beutler E, Kuhl W, Gelbart T, Forman L. DNA sequence abnormal-ities of human glucose-6-phosphate dehydrogenase variants. J Biol Chem 1991;266:4145–50.
249. 248. Au SW, Gover S, Lam VM, Adams MJ. Human glucose-6-phosphate dehydrogenase: the crystal structure reveals a structural NADP(+) molecule and provides insights into enzyme deficiency. Structure Fold Des 2000;8:293–303.
250. 249. National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health. NCBI BLAST home page. Version current 29 January 2001. Internet: http://www.ncbi.nlm.nih. gov/BLAST/ (accessed 2 February 2002).
251. 250. Blau N. Tetrahydrobiopterin home page. Version current 14 January 2002. Internet: http://www.bh4.org (accessed 2 February 2002).
252. 251. Smooker PM, Gough TJ, Cotton RG, Alliaudi C, de Sanctis L, Dianzani I. A series of mutations in the dihydropteridine reductase gene resulting in either abnormal RNA splicing or DHPR protein defects. Mutations in brief no. 244. Online. Hum Mutat 1999;13:503–4.
253. 252. Vrecko K, Storga D, Birkmayer JG, et al. NADH stimulates endoge-nous dopamine biosynthesis by enhancing the recycling of tetrahy-drobiopterin in rat phaeochromocytoma cells. Biochim Biophys Acta 1997;1361:59–65.
254. 253. Kure S, Hou DC, Ohura T, et al. Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. J Pediatr 1999;135:375–8.
255. 254. Acosta PB, Wenz E, Williamson M. Nutrient intake of treated infants with phenylketonuria. Am J Clin Nutr 1977;30:198–208.
256. 255. Sims HF, Brackett JC, Powell CK, et al. The molecular basis of pediatric long chain 3-hydroxyacyl-CoA dehydrogenase deficiency associated with maternal acute fatty liver of pregnancy. Proc Natl Acad Sci U S A 1995;92:841–5.
257. 256. IJlst L, Ruiter JP, Hoovers JM, Jakobs ME, Wanders RJ. Common missense mutation G1528C in long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. Characterization and expression of the mutant protein, mutation analysis on genomic DNA and chromoso-mal localization of the mitochondrial trifunctional protein alpha subunit gene. J Clin Invest 1996;98:1028–33.
258. 257. National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health. Conserved domain data-base. NCBI CD-search. Internet: http://www.ncbi.nlm.nih.gov/ Structure/cdd/wrpsb.cgi (accessed 2 February 2002).
259. 258. Birktoft JJ, Holden HM, Hamlin R, Xuong NH, Banaszak LJ. Struc-ture of L-3-hydroxyacyl-coenzyme A dehydrogenase: preliminary chain tracing at 2.8-Å resolution. Proc Natl Acad Sci U S A 1987; 84:8262–6.
260. 259. Brown BG, Zambon A, Poulin D, et al. Use of niacin, statins, and resins in patients with combined hyperlipidemia. Am J Cardiol 1998;81:52B–9B.
261. 260. Guyton JR, Capuzzi DM. Treatment of hyperlipidemia with com-bined niacin-statin regimens. Am J Cardiol 1998;82:82U–6U.
262. 261. Guyton JR. Effect of niacin on atherosclerotic cardiovascular dis-ease. Am J Cardiol 1998;82:18U–23U, 39U–41U.
263. 262. Keenan JM, Fontaine PL, Wenz JB, Myers S, Huang ZQ, Ripsin CM. Niacin revisited. A randomized, controlled trial of wax-matrix sus-tained-release niacin in hypercholesterolemia. Arch Intern Med 1991;151:1424–32.
264. 263. Parkhomets PK, Kuchmerovskaia TM, Donchenko GV, Chichkovskaia GV, Klimenko AP. [Role of nicotinic acid and its derivatives in disorders of nervous system function.] Ukr Biokhim Zh 1995;67:3–11 (in Russian).
264. Hoffer A. Megavitamin B-3 therapy for schizophrenia. Can Psychi-atr Assoc J 1971;16:499–504.
265. Pauling L. On the orthomolecular environment of the mind: ortho-molecular theory. Am J Psychiatry 1974;131:1251–7.
266. Wyatt RJ. Comment. Am J Psychiatry 1974;131:1258–62.
267. Forsyth LM, Preuss HG, MacDowell AL, Chiazze L, Birkmayer GD,
Bellanti JA. Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome. Ann Allergy Asthma Immunol 1999;82:185–91.
268. Handfield-Jones S, Jones S, Peachey R. High dose nicotinamide in the treatment of necrobiosis lipoidica. Br J Dermatol 1988;118:693–6.
269. Gensler HL, Williams T, Huang AC, Jacobson EL. Oral niacin pre-vents photocarcinogenesis and photoimmunosuppression in mice. Nutr Cancer 1999;34:36–41.
270. Jackson TM, Rawling JM, Roebuck BD, Kirkland JB. Large supple-ments of nicotinic acid and nicotinamide increase tissue NAD+ and poly(ADP-ribose) levels but do not affect diethylnitrosamine-induced altered hepatic foci in Fischer-344 rats. J Nutr 1995;125:1455–61.
271. Bechgaard H, Jespersen S. GI absorption of niacin in humans. J Pharm Sci 1977;66:871–2.
272. Morita J, Thuy LP, Sweetman L. Deficiency of biotinyl-AMP syn-thetase activity in fibroblasts of patients with holocarboxylase syn-thetase deficiency. Mol Genet Metab 1998;64:250–5.
273. Wolf B. Chapter 103. Disorders of biotin metabolism. In: Scriver C, ed. The metabolic and molecular bases of inherited disease. 7th ed. New York: McGraw-Hill, Inc, 1995:3151–77.
274. Cowan MJ, Wara DW, Packman S, et al. Multiple biotin-dependent carboxylase deficiencies associated with defects in T-cell and B-cell immunity. Lancet 1979;2:115–8.
275. Packman S, Cowan MJ, Golbus MS, et al. Prenatal treatment of biotin responsive multiple carboxylase deficiency. Lancet 1982;1:1435–8.
276. Suzuki Y, Aoki Y, Sakamoto O, et al. Enzymatic diagnosis of holo-carboxylase synthetase deficiency using apo-carboxyl carrier pro-tein as a substrate. Clin Chim Acta 1996;251:41–52.
277. Aoki Y, Suzuki Y, Li X, et al. Characterization of mutant holocar-boxylase synthetase (HCS): a Km for biotin was not elevated in a patient with HCS deficiency. Pediatr Res 1997;42:849–54.
278. Dupuis L, Leon-Del-Rio A, Leclerc D, et al. Clustering of mutations in the biotin-binding region of holocarboxylase synthetase in biotin-responsive multiple carboxylase deficiency. Hum Mol Genet 1996; 5:1011–6.
279. Sakamoto O, Suzuki Y, Li X, et al. Relationship between kinetic properties of mutant enzyme and biochemical and clinical respon-siveness to biotin in holocarboxylase synthetase deficiency. Pediatr Res 1999;46:671–6.
280. Thuy LP, Jurecki E, Nemzer L, Nyhan WL. Prenatal diagnosis of holocarboxylase synthetase deficiency by assay of the enzyme in chorionic villus material followed by prenatal treatment. Clin Chim Acta 1999;284:59–68.
281. Thuy LP, Belmont J, Nyhan WL. Prenatal diagnosis and treatment of holocarboxylase synthetase deficiency. Prenat Diagn 1999;19:108–12. 282. Suormala T, Fowler B, Duran M, et al. Five patients with a biotin-responsive defect in holocarboxylase formation: evaluation of respon-siveness to biotin therapy in vivo and comparative biochemical
studies in vitro. Pediatr Res 1997;41:666–73.
283. Aoki Y, Li X, Sakamoto O, et al. Identification and characterization
of mutations in patients with holocarboxylase synthetase deficiency. Hum Genet 1999;104:143–8.
284. Zempleni J, Mock DM. Bioavailability of biotin given orally to humans in pharmacologic doses. Am J Clin Nutr 1999;69:504–8.
285. Burri BJ, Sweetman L, Nyhan WL. Heterogeneity of holocarboxy-lase synthetase in patients with biotin-responsive multiple carboxy-lase deficiency. Am J Hum Genet 1985;37:326–37.
286. Zempleni J, Helm RM, Mock DM. In vivo biotin supplementation at a pharmacologic dose decreases proliferation rates of human peripheral blood mononuclear cells and cytokine release. J Nutr 2001;131:1479–84.

287. Ledley FD, Levy HL, Shih VE, Benjamin R, Mahoney MJ. Benign methylmalonic aciduria. N Engl J Med 1984;311:1015–8.
288. Willard HF, Rosenberg LE. Inherited deficiencies of human methyl-malonyl CoA mutase activity: reduced affinity of mutant apoen-zyme for adenosylcobalamin. Biochem Biophys Res Commun 1977;78:927–34.
289. Willard HF, Rosenberg LE. Inherited methylmalonyl CoA mutase apoenzyme deficiency in human fibroblasts: evidence for allelic het-erogeneity, genetic compounds, and codominant expression. J Clin Invest 1980;65:690–8.
290. Morrow GD, Revsin B, Clark R, Lebowitz J, Whelan DT. A new variant of methylmalonic acidemia-defective coenzyme-apoenzyme binding in cultured fibroblasts. Clin Chim Acta 1978;85:67–72.
291. Drennan CL, Matthews RG, Rosenblatt DS, Ledley FD, Fenton WA, Ludwig ML. Molecular basis for dysfunction of some mutant forms of methylmalonyl-CoA mutase: deductions from the structure of methionine synthase. Proc Natl Acad Sci U S A 1996;93:5550–5.
292. Crane AM, Ledley FD. Clustering of mutations in methylmalonyl CoA mutase associated with mut- methylmalonic acidemia. Am J Hum Genet 1994;55:42–50.
293. Crane AM, Jansen R, Andrews ER, Ledley FD. Cloning and expres-sion of a mutant methylmalonyl coenzyme A mutase with altered cobalamin affinity that causes mut-methylmalonic aciduria. J Clin Invest 1992;89:385–91.
294. Wilson A, Leclerc D, Rosenblatt DS, Gravel RA. Molecular basis for methionine synthase reductase deficiency in patients belonging to the cblE complementation group of disorders in folate/cobalamin metabolism. Hum Mol Genet 1999;8:2009–16.
295. Fenton WA, Rosenberg LE. Chapter 102. Inherited disorders of cobalamin transport and metabolism. In: Scriver C, ed. The meta-bolic and molecular bases of inherited disease. 7th ed. New York: McGraw-Hill, Inc, 1995:3129–49.
296. Rosenblatt DS, Cooper BA, Schmutz SM, Zaleski WA, Casey RE. Prenatal vitamin B12 therapy of a fetus with methylcobalamin defi-ciency (cobalamin E disease). Lancet 1985;1:1127–9.
297. Gulati S, Baker P, Li YN, et al. Defects in human methionine syn-thase in cblG patients. Hum Mol Genet 1996;5:1859–65.
298. Leclerc D, Campeau E, Goyette P, et al. Human methionine syn-thase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamin disorders. Hum Mol Genet 1996;5:1867–74.
299. Chen J, Stampfer MJ, Ma J, et al. Influence of a methionine syn-thase (D919G) polymorphism on plasma homocysteine and folate levels and relation to risk of myocardial infarction. Atherosclerosis 2001;154:667–72.
300. Harmon DL, Shields DC, Woodside JV, et al. Methionine synthase D919G polymorphism is a significant but modest determinant of circulating homocysteine concentrations. Genet Epidemiol 1999;17: 298–309.
301. Harding CO, Arnold G, Barness LA, Wolff JA, Rosenblatt DS. Func-tional methionine synthase deficiency due to cblG disorder: a report of two patients and a review. Am J Med Genet 1997;71:384–90.
302. Sillaots SL, Hall CA, Hurteloup V, Rosenblatt DS. Heterogeneity in cblG: differential retention of cobalamin on methionine synthase. Biochem Med Metab Biol 1992;47:242–9.
303. Fowler B, Schutgens RB, Rosenblatt DS, Smit GP, Lindemans J. Folate-responsive homocystinuria and megaloblastic anaemia in a female patient with functional methionine synthase deficiency cblE disease. J Inherit Metab Dis 1997;20:731–41.
304. Steen C, Rosenblatt DS, Scheying H, Braeuer HC, Kohlschutter A. Cobalamin E (cblE) disease: a severe neurological disorder with megaloblastic anaemia, homocystinuria and low serum methionine. J Inherit Metab Dis 1997;20:705–6.
305. Davies JF II, Delcamp TJ, Prendergast NJ, Ashford VA, Freisheim JH, Kraut J. Crystal structures of recombinant human dihydrofolate reductase complexed with folate and 5-deazafolate. Biochemistry 1990;29:9467–79.
306. Freeman JM, Finkelstein JD, Mudd SH. Folate-responsive homo-cystinuria and “schizophrenia.” A defect in methylation due to defi-cient 5,10-methylenetetrahydrofolate reductase activity. N Engl J Med 1975;292:491–6.
307. Folate-responsive homocystinuria and “schizophrenia.” Nutr Rev 1982;40:242–5.
308. Murphy JV, Thome LM, Michals K, Matalon R. Folic acid respon-sive rages, seizures and homocystinuria. J Inherit Metab Dis 1985; 8:109–10.
309. Stoney CM, Engebretson TO. Plasma homocysteine concentrations are positively associated with hostility and anger. Life Sci 2000;66: 2267–75.
310. Arinami T, Yamada N, Yamakawa-Kobayashi K, Hamaguchi H, Toru M. Methylenetetrahydrofolate reductase variant and schizo-phrenia/depression. Am J Med Genet 1997;74:526–8.
311. Joober R, Benkelfat C, Lal S, et al. Association between the meth-ylenetetrahydrofolate reductase 677C→T missense mutation and schizophrenia. Mol Psychiatry 2000;5:323–6.
312. Regland B, Johansson BV, Grenfeldt B, Hjelmgren LT, Medhus M. Homocysteinemia is a common feature of schizophrenia. J Neural Transm Gen Sect 1995;100:165–9.
313. Regland B, Germgard T, Gottfries CG, Grenfeldt B, Koch-Schmidt AC. Homozygous thermolabile methylenetetrahydrofolate reductase in schizophrenia-like psychosis. J Neural Transm 1997;104:931–41.
314. Susser E, Brown AS, Klonowski E, Allen RH, Lindenbaum J. Schiz-ophrenia and impaired homocysteine metabolism: a possible associ-ation. Biol Psychiatry 1998;44:141–3.
315. Kunugi H, Fukuda R, Hattori M, et al. C677T polymorphism in methylenetetrahydrofolate reductase gene and psychoses. Mol Psy-chiatry 1998;3:435–7.
316. Virgos C, Martorell L, Simo JM, et al. Plasma homocysteine and the methylenetetrahydrofolate reductase C677T gene variant: lack of association with schizophrenia. Neuroreport 1999;10:2035–8.
317. van der Put NM, van Straaten HW, Trijbels FJ, Blom HJ. Folate, homocysteine and neural tube defects: an overview. Exp Biol Med 2001;226:243–70.
318. Arakawa T, Narisawa K, Tanno K, Hirooka Y, Ono T. Megaloblastic anemia and mental retardation associated with hyperfolic-acidemia: probably due to N5 methyltetrahydrofolate transferase deficiency. Tohoku J Exp Med 1967;93:1–22.
319. Walters T. Congenital megaloblastic anemia responsive to N5-formyl tetrahydrofolic acid administration. J Pediatr 1967;70:686–7.
320. Zittoun J. Congenital errors of folate metabolism. Baillieres Clin Haematol 1995;8:603–16.
321. Arakawa T. Congenital defects in folate utilization. Am J Med 1970;48:594–8.
322. Erbe RW. Inborn errors of folate metabolism (second of two parts). N Engl J Med 1975;293:807–12.
323. Perry TL, Applegarth DA, Evans ME, Hansen S, Jellum E. Meta-bolic studies of a family with massive formiminoglutamic aciduria. Pediatr Res 1975;9:117–22.
324. Erbe R. Inborn errors of folate metabolism. In: Blakely R, Whitehead V, eds. Folates and pterins. New York: John Wiley, 1986:413–65.
325. Howe RB, Branda RF, Douglas SD, Brunning RD. Hereditary dyserythropoiesis with abnormal membrane folate transport. Blood 1979;54:1080–90.
326. Torres OA, Miller VS, Buist NM, Hyland K. Folinic acid-responsive neonatal seizures. J Child Neurol 1999;14:529–32.
327. Devlin AM, Ling EH, Peerson JM, et al. Glutamate carboxypepti-dase II: a polymorphism associated with lower levels of serum folate and hyperhomocysteinemia. Hum Mol Genet 2000;9:2837–44.
328. Kim YI, Baik HW, Fawaz K, et al. Effects of folate supplementation on two provisional molecular markers of colon cancer: a prospec-tive, randomized trial. Am J Gastroenterol 2001;96:184–95.
329. Silaste ML, Rantala M, Sampi M, Alfthan G, Aro A, Kesaniemi YA. Polymorphisms of key enzymes in homocysteine metabolism affect
diet responsiveness of plasma homocysteine in healthy women. J Nutr 2001;131:2643–7.
330. Santhosh-Kumar CR, Bisping JS, Kick SD, Deutsch JC, Kolhouse JF. Folate sufficient subjects do not accumulate additional folates dur-ing supplementation. Am J Hematol 2000;64:71–2.
331. Boneh A, Bar-Ziv J. Hereditary deficiency of vitamin K-dependent coagulation factors with skeletal abnormalities. Am J Med Genet 1996;65:241–3.
332. Furie BC, Furie B. Structure and mechanism of action of the vita-min K-dependent gamma-glutamyl carboxylase: recent advances from mutagenesis studies. Thromb Haemost 1997;78:595–8.
333. Mutucumarana VP, Stafford DW, Stanley TB, et al. Expression and characterization of the naturally occurring mutation L394R in human gamma-glutamyl carboxylase. J Biol Chem 2000;275:32572–7.
334. Spronk HM, Farah RA, Buchanan GR, Vermeer C, Soute BA. Novel mutation in the gamma-glutamyl carboxylase gene resulting in con-genital combined deficiency of all vitamin K-dependent blood coag-ulation factors. Blood 2000;96:3650–2.
335. Chung KS, Bezeaud A, Goldsmith JC, McMillan CW, Menache D, Roberts HR. Congenital deficiency of blood clotting factors II, VII, IX, and X. Blood 1979;53:776–87.
336. Chu K, Wu SM, Stanley T, Stafford DW, High KA. A mutation in the propeptide of factor IX leads to warfarin sensitivity by a novel mechanism. J Clin Invest 1996;98:1619–25.
337. Shinzawa T, Mura T, Tsunei M, Shiraki K. Vitamin K absorption capacity and its association with vitamin K deficiency. Am J Dis Child 1989;143:686–9.
338. Institute of Medicine. Dietary reference intakes for calcium, phospho-rus, magnesium, vitamin D, and fluoride. Washington, DC: National Academy Press, 1997.
339. Kristjansson K, Rut AR, Hewison M, O’Riordan JL, Hughes MR. Two mutations in the hormone binding domain of the vitamin D receptor cause tissue resistance to 1,25 dihydroxyvitamin D3. J Clin Invest 1993;92:12–6.
340. Malloy PJ, Eccleshall TR, Gross C, Van Maldergem L, Bouillon R, Feldman D. Hereditary vitamin D resistant rickets caused by a novel mutation in the vitamin D receptor that results in decreased affinity for hormone and cellular hyporesponsiveness. J Clin Invest 1997;99:297–304.
341. Whitfield GK, Selznick SH, Haussler CA, et al. Vitamin D receptors from patients with resistance to 1,25-dihydroxyvitamin D3: point mutations confer reduced transactivation in response to ligand and impaired interaction with the retinoid X receptor heterodimeric partner. Mol Endocrinol 1996;10:1617–31.
342. Castells S, Greig F, Fusi MA, et al. Severely deficient binding of 1,25-dihydroxyvitamin D to its receptors in a patient responsive to high doses of this hormone. J Clin Endocrinol Metab 1986;63:252–6.
343. Slattery ML, Yakumo K, Hoffman M, Neuhausen S. Variants of the VDR gene and risk of colon cancer (United States). Cancer Causes Control 2001;12:359–64.
344. Tuohimaa P, Lyakhovich A, Aksenov N, et al. Vitamin D and prostate cancer. J Steroid Biochem Mol Biol 2001;76:125–34.
345. Hewison M, O’Riordan JL. Vitamin D resistance. Baillieres Clin Endocrinol Metab 1994;8:305–15.
346.Wang JT, Lin CJ, Burridge SM, et al. Genetics of vitamin D 1-hydroxylase deficiency in 17 families. Am J Hum Genet 1998;63: 1694–702.
347. Caca-Biljanovska NG, Vlckova-Laskoska MT, Dervendi DV, Pesic NP, Laskoski DS. Treatment of generalized morphea with oral 1,25-dihydroxyvitamin D3. Adv Exp Med Biol 1999;455:299–304.
348. Institute of Medicine. Dietary reference intakes for vitamin C, vitamin E, selenium, and carotenoids. Washington, DC: National Academy Press, 2000.
349. Schuelke M, Finckh B, Sistermans EA, Ausems MG, Hubner C, von Moers A. Ataxia with vitamin E deficiency: biochemical effects of malcompliance with vitamin E therapy. Neurology 2000;55:1584–6
350. Gabsi S, Gouider-Khouja N, Belal S, et al. Effect of vitamin E sup-plementation in patients with ataxia with vitamin E deficiency. Eur J Neurol 2001;8:477–81.
351. Spaapen LJ, Bakker JA, Velter C, et al. Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency in Dutch neonates. J Inherit Metab Dis 2001;24:352–8.
352. Trefz F, Blau N, Aulehla-Scholz C, Korall H, Frauendienst-Egger G. Treatment of mild phenylketonuria (PKU) by tetrahydrobiopterin (BH4). J Inherit Metab Dis 2000;23:47 (abstr).
353. Leandro P, Rivera I, Lechner MC, de Almeida IT, Konecki D. The V388M mutation results in a kinetic variant form of phenylalanine hydroxylase. Mol Genet Metab 2000;69:204–12.
354. Erlandsen H, Stevens RC. A structural hypothesis for BH4 respon-siveness in patients with mild forms of hyperphenylalaninaemia and phenylketonuria. J Inherit Metab Dis 2001;24:213–30.
355. Spaapen LJM, Bakker JA, Velter C, et al. Tetrahydrobiopterin-responsive hyperphenylalaninemia (HPA) in Dutch neonates. J Inherit Metab Dis 2000;23:45 (abstr).
356. Scriver CR, Prevost L. Phenylalanine hydroxylase locus database. Internet: http://data.mch.mcgill.ca/pahdb_new (accessed 3 February 2002).
357. Leuzzi V, Bianchi MC, Tosetti M, et al. Brain creatine depletion: guanidinoacetate methyltransferase deficiency (improving with cre-atine supplementation). Neurology 2000;55:1407–9.
358. Ostman-Smith I, Brown G, Johnson A, Land JM. Dilated car-diomyopathy due to type II X-linked 3-methylglutaconic aciduria: successful treatment with pantothenic acid. Br Heart J 1994;72: 349–53.
359. de Koning T, Duran M, Dorland L, Berger R, Poll-The BT. Mater-nal 3-methylglutaconic aciduria associated with abnormalities in offspring. Lancet 1996;348:887–8 (letter).
360. Zhou B, Westaway SK, Levinson B, Johnson MA, Gitschier J, Hayflick SJ. A novel pantothenate kinase gene (PANK2) is defec-tive in Hallervorden-Spatz syndrome. Nat Genet 2001;28:345–9.
361. Matalon R, Stumpf DA, Michals K, Hart RD, Parks JK, Goodman SI. Lipoamide dehydrogenase deficiency with primary lactic acidosis: favorable response to treatment with oral lipoic acid. J Pediatr 1984;104:65–9.
362. Rodriguez-Budelli M, Kark P. Kinetic evidence for a structural abnor-mality of lipoamide dehydrogenase in two patients with Friedreich ataxia. Neurology 1978;28:1283–6.
363. Hong YS, Kerr DS, Liu TC, Lusk M, Powell BR, Patel MS. Defi-ciency of dihydrolipoamide dehydrogenase due to two mutant alle-les (E340K and G101del). Analysis of a family and prenatal testing. Biochim Biophys Acta 1997;1362:160–8.
364. Byrd DJ, Krohn HP, Winkler L, et al. Neonatal pyruvate dehydro-genase deficiency with lipoate responsive lactic acidaemia and hyperammonaemia. Eur J Pediatr 1989;148:543–7.
365. Chalmers RA, Stanley CA, English N, Wigglesworth JS. Mitochon-drial carnitine-acylcarnitine translocase deficiency presenting as sud-den neonatal death. J Pediatr 1997;131:220–5.
366. Lamhonwah AM, Tein I. Carnitine uptake defect: frameshift mutations in the human plasmalemmal carnitine transporter gene. Biochem Biophys Res Commun 1998;252:396–401.
367. Radetti G, Persani L, Molinaro G, et al. Clinical and hormonal out-come after two years of triiodothyroacetic acid treatment in a child with thyroid hormone resistance. Thyroid 1997;7:775–8.
368. Takeda T, Suzuki S, Liu RT, DeGroot LJ. Triiodothyroacetic acid has unique potential for therapy of resistance to thyroid hormone. J Clin Endocrinol Metab 1995;80:2033–40.
369. Chatterjee VK, Beck-Peccoz P. Hormone-nuclear receptor interac-tions in health and disease. Thyroid hormone resistance. Baillieres Clin Endocrinol Metab 1994;8:267–83.
370. Nagashima T, Yagi H, Nagashima K, et al. A novel point mutation of thyroid hormone receptor beta gene in a family with resistance to thyroid hormone. Thyroid 1997;7:771–3.
371. Reilmann R, Rolf LH, Lange HW. Decreased plasma alanine and isoleucine in Huntington’s disease. Acta Neurol Scand 1995;91:222–4. 372. Lyons TJ, Liu H, Goto JJ, et al. Mutations in copper-zinc superox-ide dismutase that cause amyotrophic lateral sclerosis alter the zinc binding site and the redox behavior of the protein. Proc Natl Acad
Sci U S A 1996;93:12240–4.
373. Goto JJ, Zhu H, Sanchez RJ, et al. Loss of in vitro metal ion bind-
ing specificity in mutant copper-zinc superoxide dismutases associ-ated with familial amyotrophic lateral sclerosis. J Biol Chem 2000;275:1007–14.
374. Crow JP, Sampson JB, Zhuang Y, Thompson JA, Beckman JS. Decreased zinc affinity of amyotrophic lateral sclerosis-associated superoxide dismutase mutants leads to enhanced catalysis of tyro-sine nitration by peroxynitrite. J Neurochem 1997;69:1936–44.
375. Estevez AG, Crow JP, Sampson JB, et al. Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase. Science 1999;286:2498–500.
376. Lammich S, Kojro E, Postina R, et al. Constitutive and regulated alpha-secretase cleavage of Alzheimer’s amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci U S A 1999;96: 3922–7.
377. Kerr KM, Cahoon M, Bosco DA, Hedstrom L. Monovalent cation activation in Escherichia coli inosine 5-monophosphate dehydro-genase. Arch Biochem Biophys 2000;375:131–7.


使用道具 举报

您需要登录后才可以回帖 登录 | 立即注册



GMT+8, 2020-10-21 13:00 , Processed in 0.181987 second(s), 31 queries .

Powered by discuz.net! X3.3

© 2014-2015 discuz.net.

快速回复 返回顶部 返回列表